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CLASSIC GALACTOSEMIA 
Though the first description of classic galactosemia dates back to 1908, patient care 
continues to present challenges that emphasize gaps in our knowledge on the patho-
physiological and clinical basis of this rare disease. Classic galactosemia is an autosomal 
recessive disorder, affecting 1:16.000-60.000 newborns worldwide, and is caused by a 
profound deficiency of galactose-1-phosphate uridylyltransferase (GALT) (1, 2). Togeth-
er with galactokinase (GALK) and UDP-galactose 4’-epimerase (GALE) the GALT enzyme 
constitutes the main route for galactose metabolism, the Leloir pathway. The net result 
of galactose breakdown is the formation of glucose-1-phosphate (Glc-1-P), which can be 
further metabolized to produce energy, and UDP-galactose (UDP-gal), which is involved 
in glycosylation processes.  
The severe GALT deficiency in patients with classic galactosemia derives from muta-
tions in the GALT gene. Thus far over 300 GALT variants have been reported, of which 
the most prevalent lead to protein misfolding with subsequent increased propensity for 
aggregation and degradation (3, 4).  
Affected newborns develop an acute and potentially lethal syndrome upon exposure 
to galactose in milk, including failure to thrive, feeding difficulties, liver failure, encepha-
lopathy, and regularly E. coli sepsis. The present standard of care consists of lifelong 
dietary galactose restriction, which, notwithstanding its irrefutable life-saving role in the 
acute neonatal toxicity, fails to prevent severe fertility (5-9), brain (10-19) and bone 
health impairments (20) later in life. These complications represent a heavy burden for 
patients and their families (21), as well as for health care and society in general. 
In order to improve patient outcome, the development of new therapeutic agents is 
pursued (4, 22, 23). Increased knowledge on the pathogenesis of the disease, as well as 
insight in the developmental stage at which lesions occur, are crucial for accurate ther-
apeutic strategy establishment. Toxic accumulation of galactose and its metabolites (24, 
25), aberrant glycosylation (26, 27), endoplasmic reticulum stress (28, 29), GALT mis-
folding (3, 4) and dysregulation of gene pathways (30), such as down-regulation of the 
PI3K-Akt growth signaling pathway (31), have been implicated as potential pathogenic 
mechanisms. Whether organ damage is established in utero or in early postnatal life, or 
whether the clinical impairments are the result of ongoing toxicity throughout devel-
opment, remains to be elucidated. 
The two disease models currently available for classic galactosemia, the mouse 
model (29) and the Drosophila melanogaster model (32), have both shown their im-
portance for pathogenesis studies. However, a disease model amenable for organ stud-
ies from embryo stage to adulthood and high throughput screening of pharmacological 
compounds is currently lacking, which hampers progress of galactosemia research.  
Furthermore, it has been shown that large discrepancies between countries exist re-
garding diagnosis, treatment, follow-up and counseling of patients (33). Evaluation of the 
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extent and implications of the long-term complications and elaboration of clinical recom-
mendations are essential for creating consensual and improved patient care worldwide.  
OVARIES 
With its prevalence of over 90%, primary ovarian insufficiency (POI) represents the most 
frequent long-term impairment of classic galactosemia (34). Female patients are already 
at an early age confronted with the struggles that reduced fertility presents, and it is 
thus not surprising that POI is considered a major issue by both patients and their fami-
lies (21).  
Though POI is commonly defined as the presence of amenorrhea for at least 4 
months in a woman less than 40 years old, accompanied by two serum FSH levels in the 
menopausal range, it rather reflects a continuum of impaired ovarian function, which is 
varying, unpredictable and does not exclude pregnancy (35). In general, POI may be due 
to establishment of a compromised initial pool of primordial follicles in utero or an 
accelerated follicle apoptosis or destruction after birth (36). 
In classic galactosemia there seems to be a rapid decline of ovarian reserve due to a 
reduction in the number of primordial follicles (6, 8). Pathogenic processes proposed to 
be involved include impaired primordial germ cell (PGC) development (37), direct toxici-
ty of galactose and its metabolites to oocytes and follicles (38-46), aberrant glycosyla-
tion of gene signaling pathways, hormones and receptors involved in ovarian function 
(26, 27, 30, 47), and dysregulation of the PI3K-Akt growth signaling pathway (31). Eluci-
dating the developmental stage at which ovarian damage occurs, either entirely pre- or 
postnatal, or an ongoing process throughout development, is essential for counseling 
and estimating the success rates of potential future interventions. The Drosophila mel-
anogaster and mouse models for classic galactosemia do not allow embryonic studies, 
and therefore novel animal models are needed to provide an answer to this crucial 
question. 
Though POI inherently brings along reduced fertility, pregnancies occur in women 
despite POI diagnosis with a reported prevalence of 5-10% (48). Also in women with POI 
due to galactosemia spontaneous pregnancies have been reported multiple times (2, 5, 
7, 19, 49-66). Thus far only one small study addressed pregnancy chance in this popula-
tion and found that most women, despite an active child wish, had not tried to conceive 
because they had been told this was impossible (7). As much as 44% of the few women 
who attempted pregnancy was successful, suggesting pregnancy chance might be high-
er in this population than in women with POI due to other causes.  
Gaining more knowledge on pregnancy chance despite POI in this disorder is needed 
to improve counseling and assess the value of fertility preservation techniques, such as 
cryopreservation of embryos, oocytes and ovarian tissue, and oocyte donation, in this 
specific population.  
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BRAIN 
The brain represents the other main target of damage in classic galactosemia. Early case 
reports demonstrated that severe brain damage occurs in patients when galactose-
restriction is not initiated timely. Extensive degeneration of neurons, white matter and 
cerebellar structures, resulting in microcephaly, mental retardation and gross neurolog-
ical and motor abnormalities, were reported in two boys with galactosemia and pro-
longed galactose exposure (67, 68). However, despite early initiation of the diet, nearly 
all patients encounter one or more of a diverse field of brain impairments. Complica-
tions include lower intelligence levels (55, 66, 69-71), speech- and language problems 
(11-13, 15, 16, 72), slower information processing and memory deficits (69, 73), social 
and psychiatric difficulties (10, 19, 74), and neurological sequelae (14). Reduced partici-
pation in society and impaired ability to build up strong partnerships are generally the 
result (55), though considerable variability in cognitive functioning exists (69).   
Previous imaging studies already demonstrated diffuse atrophy of the cerebrum and 
ventricle enlargement, cerebellar atrophy, abnormal white matter signal intensity 
throughout the cerebrum and cerebellum, and focal white matter lesions in a significant 
part of galactosemia patients (14, 17, 18, 67, 68, 70, 75-79). The pathogenic basis of 
these abnormalities remains puzzling, however. Recent studies point towards defective 
white matter microstructure (18), which might result from deficient galactocerebroside 
formation due to aberrant glycosylation (68, 79), as well as disturbed gray matter density 
(17). In addition, a functional magnetic resonance imaging study demonstrated signifi-
cant changes in the language network in patients as compared to healthy controls (16). 
The broad spectrum of cognitive and neurological problems encountered in this disorder 
warrants further exploration of functional brain networks that are involved in executive 
functions, social behavior and psychiatric disorders. Also, fundamental research address-
ing brain development, myelin composition and neuronal functioning in the galactosemia 
brain are needed. An adequate animal model that allows organ studies throughout de-
velopment would contribute to elucidating the fundamental question regarding the 
timing of damage. 
Improved knowledge on the brain networks affected by the disease, as well as on 
the molecular pathways involved in pathogenesis, would contribute to a better under-
standing of the neurocognitive profile encountered by patients and create opportuni-
ties for the creation of accurate therapeutic or supportive interventions.  
BONE 
An association between classic galactosemia and decreased bone mass was postulated 
first in 1993, but until now the extent and clinical relevance for patient care have been 
undefined.  
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A bone mineral density (BMD) Z-score of more than 2 standard deviations (SD) be-
low the mean was reported in 25-30% of adult patients (19, 80). Additionally, several 
studies in children with classic galactosemia support the hypothesis of mildly decreased 
bone mass from an early age on in these patients (20, 81, 82). Yet, extensive research 
evaluating the frequency and severity of impaired bone health in patients, as compared 
to the non-galactosemia population, is lacking. 
Acquiring an optimal peak bone mass by maintaining adequate bone health during 
childhood and adolescence is essential for preventing osteoporosis later in life (83). 
Patients with classic galactosemia could be at risk for reduced bone mass because of 
nutritional deficiencies that come along with their diet, POI in females, limited physical 
activity in some, and possibly intrinsic bone defects associated with the disease (2, 84). 
The latter is supported by the persistence of reduced bone mass despite adequate sup-
plementation of estrogen and nutrients (84-86). Fundamental studies addressing this 
potential disease-specific bone defect are, however, very limited. Results from a study 
in patients with congenital disorders of glycosylation, which demonstrated defective 
glycosylation of insulin-like growth factor binding protein-3 (87), could have important 
implications for galactosemia as well, since this disorder secondarily results in glycosyla-
tion abnormalities. Future in vitro and in vivo studies focusing on the pathogenesis of 
reduced bone mass in classic galactosemia are needed to improve our understanding 
and management of this complication.  
If larger studies indeed confirm an increased propensity for reduced bone mass, care-
ful monitoring and optimization of bone mass seems necessary in these patients from an 
early age on to prevent the development of osteoporosis and fractures later in life. Rec-
ommendations for bone health improvement in this specific population were proposed 
by our research group in 2007 (88). However, as a result of evolved knowledge on bone 
mass in classic galactosemia and bone health management in general, these guides war-
rant revision. 
AIMS AND OUTLINE OF THE THESIS 
This thesis aims to provide novel perspectives on the long-term complications of classic 
galactosemia using a combined strategy that encompasses both basic and clinical sci-
ence. We aim to develop an animal model that is the first to allow both innovative 
pathogenic studies and pharmacological compound testing. Additionally, we aim to 
further investigate the extent and clinical implications of the damage to ovaries, brain 
and bones, thereby providing recommendations for improvement of patient care.  
Chapter 2 describes the development of a galt knock-out zebrafish model for classic 
galactosemia. This model allows gaining novel insights in the pathogenesis of this dis-
ease, with special focus on the evolvement of organ damage throughout development, 
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and forms a valuable tool for therapeutic strategy testing. Here, we provide the first new 
perspectives on the pathogenesis of the long-term impairments of classic galactosemia.  
The next two chapters focus on POI and its clinical implications. In chapter 3 the re-
sults of an international, epidemiological study on pregnancy chance in women with 
classic galactosemia and POI are presented. Chance of spontaneous conception was 
estimated using semi-standardized interviews. Chapter 4 encompasses recommenda-
tions regarding the application of fertility preservation techniques in women with classic 
galactosemia, created with the support of a multidisciplinary team of experts in repro-
ductive medicine.  
In chapter 5 we explore functional brain networks of adolescents with classic galac-
tosemia at resting-state using functional magnetic resonance imaging in order to in-
crease our understanding of the puzzling cognitive and neurological impairments seen 
in these patients. 
The last target organ of damage in this disease, the skeletal system, is subject of the 
next chapters. The results of a systematic review and meta-analysis on bone health in 
patients with classic galactosemia are presented in chapter 6. The reduced bone mass 
that is generally present in this population warrants adequate bone health monitoring 
according to evidence-based strategies, which are proposed in chapter 7. 
Lastly, in chapter 8 the most important results of the studies outlined in this thesis 
are discussed. Furthermore, directions for future research are provided. 
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ABSTRACT 
Classic galactosemia is a genetic disorder of galactose metabolism, caused by severe 
deficiency of galactose-1-phosphate uridylyltransferase (GALT) enzyme activity due to 
mutations of the GALT gene. Its pathogenesis is still not fully elucidated, and a therapy 
that prevents chronic impairments is lacking. In order to move research forward, there 
is a high need for a novel animal model, which allows organ studies throughout devel-
opment and high-throughput screening of pharmacologic compounds. Here, we de-
scribe the generation of a galt knockout zebrafish model and present its phenotypical 
characterization. Using a TALEN approach, a galt knockout line was successfully created. 
Accordingly, biochemical assays confirm essentially undetectable galt enzyme activity in 
homozygotes. Analogous to humans, galt knockout fish accumulate elevated concentra-
tions of galactose-1-phosphate upon exposure to exogenous galactose. Furthermore, 
without prior exposure to exogenous galactose, they exhibit reduced motor activity and 
impaired fertility (lower egg quantity per mating, higher number of unsuccessful cross-
ings), resembling the human phenotype of neurological sequelae and subfertility. In 
conclusion, our galt knockout zebrafish model for classic galactosemia mimics the hu-
man phenotype at biochemical and clinical levels. Future studies in our model will con-
tribute to improved understanding and management of this enigmatic disorder.  
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INTRODUCTION 
Though its first description dates back to 1908 (1), the pathogenesis of classic galactose-
mia is still not fully elucidated, and a therapy that prevents chronic impairments is cur-
rently lacking. Classic galactosemia is a genetic disorder of galactose metabolism, in 
which mutations in the GALT gene cause a severe impairment of galactose-1-phosphate 
uridylyltransferase enzyme activity (GALT; EC 2.7.7.12). Patients present during the neo-
natal period with a toxic syndrome, after ingestion of galactose-containing milk. Though 
a galactose-restricted diet is life-saving during this phase, it fails to prevent the develop-
ment of chronic impairments. Target organs of damage are brain, gonads and, to a lesser 
extent bones, leading to cognitive impairments (2-4), speech and language problems (5-
8), neurological sequelae (9), psychosocial difficulties (10), primary ovarian insufficiency 
in females (11), and mildly decreased bone mass (12). To date, the pathogenic molecular 
pathways of these complications, as well as the developmental stage at which lesions 
occur, remain to be elucidated. Toxic accumulation of galactose metabolites, such as 
galactose-1-phosphate (Gal-1-P) and galactitol (13, 14), aberrant glycosylation (15, 16), 
endoplasmic reticulum (ER) stress (17, 18), GALT misfolding (19, 20) and dysregulation of 
the PI3K-Akt growth signaling pathway (21) have been implicated. Improved knowledge 
is crucial for the establishment of therapies that can prevent damaging effects on the 
long term. Currently new therapeutic strategies are being explored, including pharmaco-
logical/chemical chaperones and GALK inhibitors (20, 22, 23).  
Two disease models for classic galactosemia, a fruit fly model (24) and a mouse 
model (18) have been developed, and both have shown their value (17, 21, 25-28). We 
have created a zebrafish model for classic galactosemia that complements these exist-
ing models. The zebrafish model is an ideal intermediate between the invertebrate 
(high throughput, evolutionary more distantly related) and the mammalian model sys-
tem (low throughput, evolutionary closely related) since it is, as a vertebrate, evolution-
ary more closely related to humans while being a more high-throughput system (high 
amounts of offspring). Additionally, embryonic development is external and different 
organ systems are easy to study (transparency and amiability to genetic modification) 
using reporter lines. 
Here, we describe the development of a galt knockout zebrafish model and present 
its phenotypical characterization. This model is meant to improve knowledge on the 
pathophysiology of chronic impairments, in particular throughout development, and to 
be used for therapeutic strategy testing. 
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METHODS 
Ethics statement 
This study was approved by the Animal Ethics Committee of the University of Maas-
tricht (Dier Experimenten Commissie, Maastricht University, Maastricht, The Nether-
lands) and the Dutch national Central Authority for Scientific Procedures on Animals 
(Centrale Commissie Dierproeven) (AVD107002016545). In addition, approval was ob-
tained from the Animal Ethics Committee of the University of Liège (Commission 
d’Ethique de l’Utilisation des Animaux, Université de Liège, Liège, Belgium; dossier 1576) 
for the experiments we performed initially in the GIGA Zebrafish Facility and Transgen-
ics, Liège. At all times, the care and use of animals was in agreement with the national 
and local guidelines. Care of animals and animal experiments were conducted exclusive-
ly by licensed technicians and researchers. 
Husbandry  
Zebrafish were housed in recirculating systems (Fleuren & Nooijen) on a 14/10 day-
night regime. Husbandry was essentially performed as described in Lawrence et al. (35).  
Generation of galt-deficient zebrafish 
The design and assembly of the TALE nuclease (TALEN) construct targeting the galt gene 
(ENSDARG00000069543) to create a knockout was based on the protocol described by 
Cermak et al. (2011) (36). TALEN coding sequences were obtained from TAL Effector-
Nucleotide Targeter (Bogdanove Laboratory, Cornell University; (36, 37)). In order to 
ensure loss-of-function of the galt protein, TALEN sequences located within the first 
part of the gene were chosen. The DNA binding sites for the TALEN pair targeting galt 
were: left site 5’-TTTTGGTCTCGGCCCATCGG-3’, right site 5’-AAAGGACAGGTGGAGAAA-
3’. Constructs were assembled using the Golden Gate TALEN and Tal Effector Kit 2.0 
(Addgene) (36). The integrity of the final constructs was verified by Sanger sequencing. 
The final TALEN plasmids were linearized by digestion with SacI. Afterwards, the 
DNA was purified and used as template for in vitro mRNA synthesis using the Ambion 
mMESSAGE mMACHINE T3 Transcription Kit (Life Technologies). The resulting mRNAs 
were purified by Lithium Chloride precipitation and integrity was verified using agarose 
gel electrophoresis. 
Subsequently, the mRNA of both left and right TALEN constructs were injected in 
wildtype zebrafish embryos in one-cell stage. Injected fish were raised to adulthood and 
outcrossed, followed by confirmation of heterozygotes in the offspring. Heterozygous 
fish were incrossed in order to generate homozygous, galt knockout zebrafish (Figure 1; 
Supplementary Figures S1 and S2).  
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Figure 1: Galactose metabolism in humans and zebrafish.  
Genes encoding the enzymes involved in galactose metabolism (panel A) in humans show strong conservation
with their zebrafish counterparts (panel B). Strikingly, only the UGP2 gene is duplicated in zebrafish (ugp2a
and ugp2b). 
GALM: Galactose mutarotase, GALK1: galactokinase, GALT: Galactose-1-phosphate uridylyltransferase, GALE: 
UDP-galactose 4-epimerase,  UGP: UDP-glucose/UDP-galactose pyrophosphorylase, AR: aldose reductase. 
Panel B shows the percentage of amino acid similarity between the human and zebrafish homologues of the
enzymes involved in galactose metabolism. 
Genotyping 
Zebrafish embryos were euthanized with a lethal dose of tricaine (MS222). Biopsies 
from the caudal fin of adult fish were removed with a sharp blade after anesthesia with 
MS222. Single embryos or fin clip biopsies were lysed in the same manner.  
Embryos or fin clips were placed individually in 80 µl of lysis buffer, consisting of 1M 
KCl, 1M MgCl, 1M Tris pH 8.3, NP40, Tween-20 and gelatine, supplemented with Pro-
teinase K to a concentration of 100 µg/ml. Lysis was performed for 1 h at 60 °C, 15 
minutes at 95 °C and then held at 4°C. After adding 80 µl of ultrapure H2O (Milli-Q, 
Merck Millipore) lysates were used for PCR.  
PCRs encompassing the targeted region of galt were conducted using Phusion Hot 
Start II DNA Polymerase (Thermo Scientific) in 50 µl reactions with 5µl lysate per reac-
tion as template. The following primers were used (including M13 sequence): forward 
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primer 5’-TGTAAAACGACGGCCAGTATCGTTTGAAGCCAAAATCG-3’, reverse primer 5’- 
CAGGAAACAGCTATGACCTGCGTATTTCTCTGGATTTGC-3’. The PCR product was verified 
on a 1% agarose gel with ethidium bromide at a final concentration of 0.5 µg/ml. 
15 µl of the PCR product were combined with 0.5 µl NcoI restriction enzyme. Reac-
tion mixes were incubated at 37°C for three hours and then analyzed on a 3% agarose 
gel. Mismatches at the targeted region of galt were expected to result in loss of an NcoI 
restriction site, thereby generating two large fragments (526 and 345 bp) rather than 
three shorter fragments (408, 118 and 345 bp) (Figure 2). Presence of a mutation in 
only one galt allele will therefore lead to the presence of both wild type and mutant 
fragments (526, 408, 345 and 118 bp). 
Mutations positive by NcoI digestion were confirmed by Sanger sequencing. 
15 µl of PCR product were denatured and re-annealed in a thermocycler by incuba-
tion for 2 min at 95 °C, for 10 seconds at 85 °C, for 15 minutes at 25 °C and then held at 
16 °C. The re-annealed products were treated with 0.5 µl of T7 endonuclease I (New 
England Biolabs) upon addition of 3 µl of buffer and 11.5 µl of H2O (Milli-Q, Merck Milli-
pore) to a final volume of 30 µl. Reaction mixes were incubated for 20 minutes at 37°C 
and analyzed on a 3% agarose gel. Mismatches at the targeted region of galt were ex-
pected to result in cleavage of heteroduplexes, thereby generating additional frag-
ments.  
Mutations positive by T7 endonuclease I were confirmed by Sanger sequencing. 
To enable large-scaled genotyping, a High Resolution Melting (HRM) analysis was ap-
plied (38). Primers were designed using Primer3 software (39) (forward primer 5’-
TACAATCCTCTGCGGGACTC-3’; reverse primer 5’-CGTGGGATGTTGTCCTCTG-3’) and 
purified by high-performance liquid chromatography (HPLC). Amplification and HRM 
analysis were performed in the LightCycler ®480 (Roche Applied Science), using the High 
Resolution Melting Master kit (Roche Applied Science). Both genotype A and genotype 
B amplicons were analyzed according to the following conditions: 95°C for 10 minutes; 
45 cycles of 95°C for 10 seconds, 59°C for 15 seconds, 72°C for 15 seconds; one cycle of 
95°C for 60 seconds, 40°C for 60 seconds, and a melting from 60°C to 95°C rising at 
0.02°C per second. All samples were run in triplicate. HRM analysis was performed using 
the software LightCycler ® 480 Gene Scanning version 1.5.1.  
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Figure 2: Establishment of a galt knockout model.  
Panel A shows the genomic layout of the zebrafish galt gene. Injection of galt-specific TALEN constructs, 
targeting exon 2, resulted in two different mutations, both leading to a predicted frame-shift and a premature 
stop codon. The two genotypes of galt knockout zebrafish (genotype A and B) could be identified by NcoI, T7 
endonuclease I and HRM analysis. Panel B illustrates a representative pattern of NcoI analysis of genotype A.
Panel C illustrates a representative pattern for HRM analysis for genotype A or B (pink: wildtype, blue: hetero-
zygous, green: knockout). Panel D shows a severe impairment of the galt catalytic activity in larval wildtype 
and knockout zebrafish (5dpf) using a HPLC assay.   
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Gene expression analysis RT-PCR 
RNA was extracted from single adult organs using TRIzol (Life Technologies). A qScript 
cDNA Synthesis Kit (Quantabio) was used to generate cDNA. Quantitative real-time PCR 
(qPCR)-based quantification of galt, gale and akr1b1 expression was conducted, with 
ef1a as a reference gene (40) . Primer sequences are available on request.. SYBR 
green (Bioline) was used for all qPCR experiments. Samples, obtained from two inde-
pendent RNA extractions were measured 5 times in total.   
galt assay 
In order to measure galt activity in zebrafish lysate with HPLC, 30 zebrafish embryos 
were suspended in 300 µl lysis buffer containing 80mM Tris pH 8.0 and cOmplete mini 
EDTA-free Protease Inhibitor (Roche). The suspension was homogenated in a potter 
tube (10 strokes) and subsequently sonicated by the ultrasonic processor UP50H 
(Hielscher) with a 2 mm diameter tip, amplitude 175 µm, power density 480W/cm2. 
Lysates were centrifuged at 11.500 x g for 20 minutes at 4 °C. 50 µl of the supernatant, 
diluted to contain 30 µg of protein (assessed with BCA Protein Assay Kit [Thermo Scien-
tific]), were mixed with 0.4 mM dithiothreitol, 30 mM Gal-1-P, 125 mM glycine and 15 
mM UDP-glucose, and subsequently incubated for 60 minutes at 28 °C. The reaction mix 
was further processed and analyzed as described by Lindhout et al. (2010) (41). Moreo-
ver, two reaction mixes were used as controls, one containing 0.4 mM dithiothreitol, 
125 mM glycine and 15 mM UDP-Glc (no Gal-1-P), and the other containing 0.4 mM 
dithiothreitol, 30 mM Gal-1-P and 125 mM glycine (no UDP-Glc).  
Additionally, galt activity was confirmed through a liquid chromatography tandem 
mass spectrometry (LC-MS/MS) based assay by colleagues of Gerard T. Berry’s laborato-
ry, Boston Children’s Hospital, Boston, USA (42).  
Zebrafish gale activity 
Frozen tissues were added to a tube containing 0.5 mol/L glycine pH 8.5 (Sigma), 1% 
proteinase  inhibitor cocktail (Sigma) and lysed by sonication at 4°C. Protein measure-
ment, gale assay and LC-MS/MS settings were the same as previously described (43) 
except that 20µl of 4 mg/ml of brain and muscle lysate or 1mg/ml gonads lysate were 
added to the cocktail and incubated at 30°C for 30min. 13C3-UDP-Glc was added as in-
ternal standard.  
Zebrafish galt and ugp activity  
For galt activity, the incubation medium consisted of 16µl of 0.5M glycine buffer pH 8.7, 
8µl of 2mM UDP-Glc, 8µl of 2mM 13C6-Gal-1-P and 8µl of 4 mg/ml tissue lysate and 
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incubated at 30°C water bath for 30min. Other steps were similar as described  (42). 
The ugp activity was measured in a reaction mixture consisting of 4.35µl of 0.5M glycine 
buffer pH 8.7, 4.35µl of 0.66mM UTP, 4.35µl of 4mM 13C6 Glc-1-P, 1.96µl of 6mM MgCl2 
and 5µl of 1 mg/ml tissue lysate and incubated at 30°C for 3 min. The reaction was 
stopped by adding 45µl of mixture composing of 7.8µl of 20µM 13C3 UDP-Glc, 31.2µl of 
acetonitrile and 6µl of 0.6M formic acid. After mixing and centrifugation at 14000 x g 
for 10min, 30µl of the supernatant was used for LC-MS/MS analysis. Calibrator concen-
trations of UGP were 111, 37, 12.3, 4.1, 2.05 and 1.03 µmol/L.  
All the samples were prepared in duplicate and measured twice. 
Gal-1-P evaluation 
In order to measure Gal-1-P in zebrafish, 30 zebrafish embryos were suspended in 300 
µl lysis buffer containing 80mM Tris pH 8.0 and cOmplete mini EDTA-free Protease 
Inhibitor (Roche). The suspension was homogenized in a potter tube (10 strokes) and 
subsequently sonicated by the ultrasonic processor UP50H (Hielscher) with a 2 mm 
diameter tip, amplitude 175 µm, power density 480W/cm2. Lysates were centrifuged at 
11,500 x g for 20 minutes at 4 °C. Gal-1-P content was then determined in 70 µl of the 
supernatant, by a coupled-enzyme assay, as described in “Laboratory Guide to the 
Methods in Biochemical Genetics” (44). Briefly, in the first reaction, Gal-1-P is converted 
into galactose by alkaline phosphatase (AP), and in the second reaction, galactose is 
converted into galactone by galactose dehydrogenase (GDH). In the second reaction, 
NAD+ is used as a co-substrate by GDH, thus leading to the production of NADH, which 
is determined UV-spectrophotometrically(λ=340 nm). 
Accordingly, Gal-1-P quantification was carried out using two mixes: the first con-
taining 160 mM Tris pH 8.6, NAD+ 12.5 mM, 43,000 U/ml AP and 60 U/ml GDH (galac-
tose and Gal-1-P), and the second containing 160 mM Tris pH 8.6, NAD+ 12.5 mM and 
60 U/ml GDH (galactose). A mix containing no enzyme was also prepared and used as 
blank. Gal-1-P concentration was calculated by subtracting total galactose (determined 
from reaction 2) to total galactose and Gal-1-P (determined from reaction 1), and nor-
malized to protein content. Total protein was quantified using the BCA Protein Assay Kit 
(Thermo Scientific) (45). 
Development and survival evaluation 
Development and survival of all fish was compared between genotypes from 5 dpf on-
wards until adulthood, in absence of exposure to galactose. At the age of 5 dpf mor-
phology was studied with microscopy. Specific attention was paid to hatching and swim 
bladder development. Abnormal fish were genotyped to evaluate whether the three 
different genotypes (wildtype, heterozygous, knockout) were disproportionally present 
in these fish (i.e. whether the number of galt knockout fish was disproportionally high). 
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Assessment of survival rates, and comparison between genotypes, was conducted at a 
daily basis throughout the embryonic phase, and monthly thereafter. 
Galactose challenge 
Wildtype and knockout embryos (n = 30-50 per genotype) of 24 hpf were exposed to 
galactose-containing E3 medium (200 mM) in 100mm petri dishes. All animals were 
monitored daily for viability until they either died or reached 9 days of age.  
Fertility evaluation 
A selected pool of unchallenged, adult galt wildtype, heterozygous and knockout 
zebrafish (n = 60) was crossed periodically (once every 2-3 weeks, total of 9 crossings), 
to explore fertility in the different genotypes. The following crossings were conducted 
(six pairs per condition): wildtype incross, heterozygous incross, knockout incross, 
wildtype female crossed to knockout male, and knockout female crossed to wildtype 
male. The number of eggs and egg quality per spawning event per genotype were as-
sessed.  
Neurological assessment 
Zebrafish embryos (5 dpf) and juveniles (4 weeks old) were placed in 24- and 12-well 
plates, respectively. Motor activity was quantified using a ZebraBox (Viewpoint) device 
under exposure to light for a period of 60 minutes. Activity is expressed as an average 
number of changes in pixels (arbitrary units) throughout the experiment. Motor activity 
was evaluated and compared between genotypes. 
Statistical analyses 
If required and appropriate, differences between two groups were evaluated for statis-
tical significance using an independent t-test (normal distribution) or Mann-Whitney U 
test (no normality), both two-tailed, and differences between more than two groups 
were evaluated by an ANOVA test. For all tests a p value less than 0.05 was considered 
statistically significant.  
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RESULTS 
Zebrafish metabolize galactose via the Leloir pathway 
To explore the role of galactose metabolism in zebrafish, we first confirmed that the 
zebrafish genome encodes and expresses orthologues of the human genes encoding 
the Leloir pathway enzymes (GALK, GALT, GALE) and the enzymes involved in escape 
routes (AR, UGP) (Figure 1). A BLAST search identified a single zebrafish orthologue of 
human GALT on chromosome 10 of the zebrafish genome (ENSDARG00000069543). 
The zebrafish galt gene has two protein coding transcripts, of which the first (galt-001, 
ENSDART00000138161) encodes a protein of 364 amino acids and shows the strongest 
conservation with the human orthologue (73%) (Figure 1). Despite the fact that fish 
underwent a genome duplication throughout evolution (29), the UGP2-gene is the only 
duplicated gene related to galactose metabolism in zebrafish (Figure 1). 
galt TALEN-generated mutants are loss-of-function  
TALEN mRNA pairs targeting exon 2 of galt were injected in AB wildtype zebrafish em-
bryos in the one-cell stage. A concentration of 150 pg of both TALEN mRNAs were in-
jected after assessing toxicity and as a function of injection dose at 24 hpf. NcoI and T7 
endonuclease I genotyping, followed by Sanger sequencing confirmation, revealed the 
generation of two galt mutant genotypes (Figure 2A and 2B). Genotype A 
(c.106_112delCGTCCAT) represents a 7 bp deletion, leading to a frame-shift at position 
c.106 and a subsequent introduction of a premature stop codon 26 amino acids down-
stream; the mutation is positive by NcoI and T7 endonuclease I analyses (Figure 2B). 
Genotype B (c.[106_107delCG; 106_109insGACA]) consists of a 2 bp deletion and 4 bp 
insertion, leading to a frame-shift at position c.106 and introduction of a premature 
stop codon 29 amino acids downstream; the mutation is negative by NcoI digestion and 
positive by T7 endonuclease I analysis. Genotype A and B presented the same melting 
profile by High Resolution Melting (HRM) analysis (Figure 2C). 
A severe reduction of galt enzyme activity was measured in the knockout zebrafish 
embryos at 5dpf. (Figure 2D), confirming at the biochemical level that the knockout 
represents a loss-of-function allele.  
Normal development and growth 
The galt knockout fish undergo normal development and growth: hatching, swim blad-
der development or morphology are not affected throughout embryo, juvenile or adult 
stages. Thus, galt knockout zebrafish are morphologically indistinguishable from heter-
ozygotes and wildtype fish; growth and survival rates are similar (data not shown). 
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galt, gale and ugp activity 
The galt enzyme activity was undetectable in lysates of adult brain and gonads of galt 
knockout fish (Figure 3A and 3B). Catalytic activity of gale and ugp, two other enzymes 
of galactose metabolism, was also measured in lysates of adult brain and gonads, the 
target organs of long-term damage in classic galactosemia. The gale activity was mar-
ginally elevated in brain and slightly reduced in the gonads of knockout animals (not 
statistically significant). Overall, gale enzyme-activity was 6-7 fold higher in gonads as in 
brain, both in knockout and wildtype animals. Activity of ugp was also not significantly 
different in knockout versus wildtype tissues with no clear difference in activity in both 
tissues (Figure 3A and 3B). In addition, we assessed mRNA expression levels in adult 
brain and gonads of knockout animals vs. controls (Figure 3D).  
 
 
Figure 3: Biochemical phenotype of galt knockout zebrafish.  
Panel A and B: galt knockout fish demonstrated essentially null galt activity in adult brain (panel A) and gonads
(panel B) using an LC-MS/MS method. Enzyme activity of indicated enzymes is plotted per genotype as the
average activity +/- SD. ND: not detectable. 
When challenged with 200 mM of galactose for 8 days (1dpf-9dpf), knockout zebrafish accumulated high 
concentrations of Gal-1-P, whereas levels remained low in wildtype zebrafish (Figure 3C). ND: not detectable. 
Panel D: mRNA expression levels of 4 key enzymes of the Leloir pathway was evaluated by QPCR. Values are
expressed as fold change of expression of the knockout compared to the wildtype tissues.  
ND ND
ND
BA
C D
ND
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galt knockout embryos accumulate Gal-1-P after exposure to galactose 
To identify susceptibility to galactose, knockout embryos were challenged with different 
concentrations of galactose, of which a concentration of 200 mM galactose was chosen 
to proceed with the galactose challenge studies. In order to avoid inducing early devel-
opmental effects, embryos were exposed to galactose for 24 hpf onwards to the ages 
indicated.  
When exposed to 200 mM of exogenous galactose, knockout embryos (5 dpf) accu-
mulated significant amounts of Gal-1-P (259 nmol/mg protein) as compared to the 
unexposed situation (1.5 nmol/mg protein). In wildtype embryos, Gal-1-P levels did not 
differ between unexposed and exposed situations (0.29 and 0.28 nmol/mg protein, 
respectively). Comparable biochemical parameters were seen in embryos of 9 dpf. In 
absence of exogenous galactose, wildtype and galt knockout fish did not accumulate 
Gal-1-P (essentially null nmol/mg protein). In the challenged situation, galt knockout 
embryos accumulated much higher concentrations of Gal-1-P (129 nmol/mg protein) 
than wildtype embryos (46 nmol/mg protein). 
Neurological assessment 
Knockout embryos (5 dpf) showed similar activity as wildtype controls, both without (p 
= 0.472) and with (p = 0.114) prior exposure to exogenous galactose (data not shown). 
At a later stage, unchallenged 4 weeks’ old knockout juvenile fish showed a statistically 
significant less activity than age-matched wildtype control (p = 0.002; Mann-Whitney U 
test ) (Figure 4).  
Fertility evaluation 
Heterozygous pairs did not exhibit a statistically significant difference in egg quantity or 
quality as compared to wildtype pairs (p = 0.106 and p = 0.228, respectively). 
Knockout pairs, wildtype female/knockout male and knockout female/wildtype male 
exhibited a lower egg quantity per mating as compared to wildtype pairs (Figure 4B). 
The number of unsuccessful crossings revealed a higher frequency in the presence 
of a knockout female for knockout pairs and knockout female/wildtype male pairs, 
comparatively to wildtype pairs or to wildtype female/knockout male pairs (Figure 4C).  
Egg quality seemed to be not affected (Supplementary Figure S3). 
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Figure 4: Chronic impairments.  
Impairments of motor activity and fertility were observed in galt knockout zebrafish never exposed to exoge-
nous galactose. Reduced motor activity was observed in knockout juvenile fish (4 weeks old) as compared to 
matched controls (n=66 per genotype; motor activity expressed as mean ± SEM) (panel A). Adult knockout 
pairs, wildtype female/knockout male and knockout female/wildtype male exhibited a lower average egg
quantity per mating as compared to wildtype pairs (panel B; expressed as mean ± SEM). Knockout pairs
demonstrated a premature decline in egg quantity as compared to wildtype pairs (panel C). The number of 
unsuccessful crossings was higher in the presence of a knockout female (panel D).  
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DISCUSSION 
In the current study, we described the successful development and initial characteriza-
tion of a galt knockout zebrafish model for classic galactosemia. During the past years, 
two other disease models were generated, a fruit fly model and a mouse model (18, 
24). We created our zebrafish line complementary to these models, since the many 
advantageous features of the zebrafish allow novel investigations that can further im-
prove our understanding and management of this disorder.  
The galt knockout zebrafish mimics the human phenotype at the biochemical and 
clinical levels. Enzymatic assays confirmed successful loss-of-function, with essentially 
null galt activity.  
Knockout fish accumulated elevated concentrations of Gal-1-P upon exposure to ex-
ogenous galactose. At juvenile stage, without prior exposure to exogenous galactose, 
galt knockout fish showed a significantly decreased motor activity as compared to 
wildtype fish. Furthermore, a premature decline of reproductive capacity in adult 
knockout zebrafish without prior exposure to exogenous galactose as compared to 
wildtypes was demonstrated. Knockout female fish presented a higher frequency of 
unsuccessful crossings. The decrease in motor activity might influence mating behavior 
and indirectly affect the reproductive capacity. 
Catalytic activity of gale and ugp were also measured, and interestingly varied consid-
erably in the various tissues, which probably reflect specific needs of the given organ (30). 
These findings are in line with the biochemical and clinical phenotype of patients 
with classic galactosemia, who develop acute toxicity in the newborn phase when ex-
posed to galactose-containing milk (31). At a biochemical level, patients accumulate 
high levels of gal-1-P in the newborn phase upon exposure to galactose (13). Chronic 
impairments of brain, ovaries and, to a lesser extent, bones occur despite adequate 
compliance to the diet, and even those individuals who were never exposed to galac-
tose as a newborn are affected (32-34). The observation of impaired motor activity in 
unexposed galt knockout zebrafish at juvenile stage seems to be in line with the human 
phenotype of neurological sequelae (9). Furthermore, unexposed adult knockout fish 
presented a decreased reproductive capacity. Knockout females exhibited an increased 
frequency of unsuccessful crossings, and the presence of a mutant allele was associated 
with a lower egg quantity per mating. These findings are in line with the primary ovarian 
insufficiency (POI) seen in nearly all females with classic galactosemia (11) and with 
previous reports of a possible male fertility impairment. Moreover, the clinical findings 
in our zebrafish model are in line with observations in other animal models for classic 
galactosemia. GALT-deficient flies exhibited motor impairments (24), whereas GALT-
deficient mice exhibited brain abnormalities, and females showed a smaller litter size 
and longer time to achieve pregnancy (18). 
With the creation of our zebrafish line, we have generated a model to study organ 
development from embryo stage to adulthood, which can provide important new in-
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sights on when lesions of target organs occur in this disease. Hitherto, it remains to be 
elucidated whether organ toxicity has a prenatal or postnatal onset, or extends over 
multiple developmental stages. Though the Drosophila melanogaster model and mouse 
model already demonstrated great importance for pathogenesis studies, the zebrafish 
model is more amenable to organ studies throughout development, which are essential 
to answer the long-standing open question if, and to what extent, prenatal organ dam-
age occurs. The external development of the zebrafish, the availability of transgenic 
reporter lines and the accessibility to sophisticated imaging techniques make our model 
an outstanding tool for studies of folliculogenesis and myelogenesis from embryonic 
stage to adulthood. In addition, the high-throughput screening potential of our model 
facilitates rapid and efficient testing of pharmacologic compounds, thereby contributing 
to the development of new therapeutic approaches. 
In conclusion, we have successfully developed a galt knockout zebrafish model for 
classic galactosemia, which recapitulates the human phenotype at biochemical and 
clinical levels. We generated this model because of the unique features of the zebrafish 
that allow organ studies throughout development and high throughput screening of 
pharmacological compounds, thereby underlining the importance of this model as a 
complement to the existing models. Future studies in our model will contribute to im-
proved understanding and management of this enigmatic disorder.  
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Figure S1: Flowchart for the generation of a galt knockout zebrafish line.  
The steps involved in the establishment of a galt knockout zebrafish line are outlined.  
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Figure S2: Fragments generated after NcoI digestion in galt wildtype, heterozygous and knockout zebrafish.  
TALEN construct targeting exon 2 of the galt gene (red lightning bold) has two distinct modes of action,
thereby generating two different mutations. Genotype A: a TALEN-derived mutation (red asterisk) at the
position of an NcoI restriction site (black scissors), which results in loss of this restriction site and thus an 
aberrant digestion pattern. Genotype B: a TALEN-derived mutation before the NcoI restriction site, which
does not affect the digestion pattern and is thus only rapidly detectable through T7 endonuclease I analysis. 
Both genotypes result in a frame-shift and subsequently a premature stop codon. As a result, wildtype (WT), 
heterozygous (Het) and knockout (KO) fish demonstrate different digestion patterns. 
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Figure S3: Evaluation of egg-quality during subsequent mating events. 
Next to quantity of eggs in successive spawning events, also egg quality was assessed. This was performed by
quantifying the amount of viable and unviable eggs immediately after spawning (measure for bad egg quality)
and at 24hpf to evaluate fertilization problems. 
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ABSTRACT 
Objective: To study pregnancy chance in adult women with classic galactosemia and 
primary ovarian insufficiency. Despite dietary treatment, over 90% of females with 
classic galactosemia develop primary ovarian insufficiency, resulting in impaired fertility. 
For many years, chance of spontaneous conception has not been considered, leading to 
counseling for infertility. Yet, the increasing number of reports on pregnancies in this 
group questions whether current counseling approaches are correct. 
Design: Multicenter observational study. 
Setting: This study was conducted in fifteen metabolic centers in the Netherlands, Aus-
tria, Belgium, Estonia, France, Ireland, Spain, Switzerland, and the United States of 
America. 
Patients: Adult females (aged ≥18 years) with confirmed classic galactosemia and prima-
ry ovarian insufficiency were included. 
Intervention(s): Participants and medical records were consulted to obtain study data in 
a standardized manner using a questionnaire. 
Main Outcome Measure(s): Conception opportunities, time to pregnancy, pregnancy 
outcome, hormone replacement therapy use, fertility counseling, and the participants’ 
vision on fertility were evaluated. Potential predictive factors for increased pregnancy 
chance were explored. 
Results: 85 women with classic galactosemia and primary ovarian insufficiency partici-
pated. 21 women actively attempted to conceive or did not take adequate contracep-
tive precautions. Of these 21 women, nine became pregnant spontaneously (42.9%). 
This was significantly higher than reported in primary ovarian insufficiency due to other 
causes (p < 0.0001, 1-sided). After a period of 12 months, a cumulative proportion of 
27.8% of couples had conceived, which increased to 48.4% after 24 months and 61.3% 
after 27 months. Predictive factors could not be identified. A considerable miscarriage 
rate of 30% was observed (6/20 pregnancies). Though a substantial proportion of wom-
en expressed a child-wish (n=28/53, 52.8%), the vast majority of participants (n=43/57, 
75.4%) considered conceiving highly unlikely, due to negative counseling in the past. 
Conclusion: The pregnancy rate in women with classic galactosemia and primary ovarian 
insufficiency was higher than expected. This shifting paradigm carries significant impli-
cations for fertility counseling and potential application of fertility preservation tech-
niques.   
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INTRODUCTION  
Primary ovarian insufficiency (POI) comprises a continuum of impaired ovarian function 
and is an important cause of menstrual cycle disorders and fertility impairments in 
women (1). With its prevalence of over 90% in females with classic galactosemia (2), it 
represents the most frequent long-term complication of this inborn error of galactose 
metabolism. Galactose is a sugar highly important for energy delivery and glycosylation 
purposes, among other functions (3). The Leloir pathway constitutes the main route for 
galactose degradation, with one of the key enzymes being galactose-1-phosphate uri-
dylyltransferase (GALT). Severe deficiency of this enzyme, due to mutations of the GALT 
gene, results in the metabolic disorder known as classic galactosemia, affecting approx-
imately 1 in 16,000-50,000 newborns (4, 5). The disease is characterized by neonatal 
onset of a toxic syndrome that quickly resolves when galactose-restriction is initiated. 
However, despite strict dietary treatment, nearly all females develop POI with conse-
quent reduced fertility.  
The remarkably high prevalence of hypergonadotropic hypogonadism in women 
with classic galactosemia was first reported in 1979 (6). Meanwhile, evolved experience 
has shown that female patients exhibit a wide phenotypic spectrum of POI, varying from 
young adolescents with primary amenorrhea to individuals with normal pubertal devel-
opment but irregular or absent menstrual cycles at a later stage. There seems to be a 
more rapid decline in the number of primordial follicles in prenatal or early postnatal 
life (7). Several pathophysiological mechanisms have been postulated, including toxicity 
of galactose and its metabolites to primordial germ cells, oocytes, and follicles (8), sig-
naling pathway abnormalities (9), and aberrant glycosylation (10) resulting in, among 
others, leptin dysregulation (11). The hypothesis of a prenatal or early postnatal origin 
of the ovarian damage is supported by the consistently reduced concentrations of anti-
Müllerian hormone and elevated gonadotropin concentrations that can be found in 
these girls already at an early age (12, 13).  
Due to the varying and unpredictable course of impaired ovarian function that POI 
reflects, pregnancies are not excluded in women with this diagnosis (1), and in general 
5-10% of women with POI of any cause conceive spontaneously (14). Also in women 
with classic galactosemia spontaneous pregnancies have been reported regularly de-
spite the presence of POI (summarized in (15), (4, 5, 16-19)). Thus far only one study in 
a small number of patients (n=22) addressed pregnancy attempts in females with classic 
galactosemia and concluded that most females did not try to become pregnant because 
they had been told they could not have children (15). Interestingly, of the few women 
who attempted to conceive spontaneously (n=9), as much as 4 (4/9 = 44%) succeeded.  
These data lead to the question whether pregnancy chance for this population 
might be higher than for women with POI due to other causes. Further exploration of 
pregnancy chance in this specific group is crucial to improve counseling of young pa-
tients and their parents. Furthermore, increased insight is essential for accurate as-
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sessment of the potential value of fertility preservation techniques (20). This interna-
tional epidemiological study investigates fertility in a cohort of adult women with classic 
galactosemia and POI, in order to determine whether current reproduction counseling 
of patients and their families is accurate.  
METHODS 
Study design and participants 
This observational study was conducted in fifteen metabolic centers in the Netherlands, 
Austria, Belgium, Estonia, France, Ireland, Spain, Switzerland, and the United States of 
America (USA). Centers and patients were informed on this study through the interna-
tional Galactosemia Network (http://www.galactosemianetwork.org/) and patient 
associations, respectively. Patients’ participation and informed consent were solicited 
during gatherings of patient associations, at the outpatient clinic, or by phone in case a 
patient had participated in an earlier study and had given consent to be recontacted. 
Participants were enrolled between February 2014 and July 2016. We obtained ethics 
approval for this study from local research ethics committees in participating centers in 
the different countries. Informed consent was obtained. 
Adult females (≥18 years of age) with classic galactosemia and POI were invited to 
participate in the study. Classic galactosemia diagnosis was confirmed by GALT enzyme 
activity assay and/or GALT mutation analysis. POI was defined as impaired ovarian func-
tion (primary or secondary amenorrhea, menstrual interval of >90 days, or oligomenor-
rhea of <9 cycles/year (21)) before the age of 40 years, supported by two serum follicle-
stimulating hormone (FSH) concentrations (obtained at least 1 month apart) in the 
menopausal range (1).  
Study procedure and outcome measures 
Patients and medical records were consulted to collect study data in a standardized 
manner using a questionnaire, translated in different languages (see supplemental 
material for English version), developed, validated and used by our group in the past 
(15). Information on GALT enzyme activity, GALT mutation, age at diet initiation, esti-
mated galactose intake (<20, 20-200 or >200 mg/day (22)), educational level (classified 
according to International Standard Classification of Education [ISCED] 2011 guidelines 
(23)), puberty development, menstrual history, ovarian function (i.e. serum 
FSH/LH/estradiol concentrations, results of ovarian imaging), and hormone replacement 
therapy (HRT) use were obtained. Additionally, pregnancy opportunities in the past 
(defined as periods of regular sexual intercourse without adequate precautions to avoid 
conception), time to pregnancy, and the number of spontaneous conceptions and their 
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outcomes were assessed. Furthermore, fertility counseling and the patients’ own vi-
sions about fertility and future pregnancies were evaluated.  
Statistical analysis 
The quantitative variables were reported through means and standard deviations (or by 
medians and ranges if non-normally distributed, as assessed by Shapiro-Wilk test). The 
qualitative variables of the questionnaire were reported through frequency-analysis and 
percentages. Characteristics of patient subgroups were compared using either a Mann-
Whitney U test in case of numeric variables or a chi square test/Fisher’s exact test in 
case of categorical variables. Potential predictive factors were formulated prior to start 
of the study (genotype p.Q188R/p.Q188R, GALT enzyme activity <0.4%, spontaneous 
menarche, low educational level, and galactose intake of >20 mg/day), based on previ-
ous literature (13, 15, 22, 24, 25), and subsequently evaluated using Fisher’s exact test 
and odds ratios (OR). The proportion of females in our cohort that became pregnant 
was compared to the 5-10% in women with POI in general using a binomial test. Time to 
first pregnancy was evaluated using a survival analysis and presented in a Kaplan Meier 
curve. Based on a sample size calculation with a desired power of 80%, an estimated 
effect of 24-44% in the classic galactosemia group and an estimated effect of 7.5% in 
the reference group (14), inclusion of a minimum of 9-27 women that had tried to con-
ceive was aimed for (26). All data analyses were performed by SPSS version 23. A p-
value of less than 0.05 was considered statistically significant.  
RESULTS 
Descriptive characteristics of the total cohort (n=85) and the cohort stratified by preg-
nancy opportunities are presented in Table 1. Overall, the median age in the cohort was 
30 years (range 18-53 years). The most prevalent genotype was p.Q188R/p.Q188R 
(n=45/65, 69.2%) and median GALT enzyme activity was 0.3% (range 0.0-1.2%, n=25). 
Galactose-restriction was initiated at a median age of 10 days (range 0-2920 days, 
n=75). Current galactose intake was restricted in the vast majority of patients (estimat-
ed galactose intake <20 mg/day; n=72/84, 85.7%); only some adhered to a diet with 
small relaxations (estimated galactose intake 20-200 mg/day; n=7/84, 8.3%) or a more 
relaxed diet (estimated galactose intake >200 mg/day; n=5/84, 6.0%). The level of edu-
cation in most patients was low (ISCED 2011 level 0-2; n=26/67, 38.8%) or intermediate 
(ISCED 2011 level 3-4, n=31/67, 46.3%).  
Of the total cohort, 47 women (n=47/85, 55.3%) presented with primary amenor-
rhea (induced menarche) and 38 (n=38/85, 44.7%) had a spontaneous menarche. First 
menstruation (either spontaneously or after induction with exogenous estrogen) oc-
curred at a median age of 15 years (range 10-28 years, n=78). The majority of partici-
Chapter 3 
46 
pants were using some form of HRT (n=59/75, 78.7%); the birth control pill was the 
most commonly used type (n=32/75, 42.7%).  
Women who did not experience pregnancy opportunities (i.e. women who had tak-
en contraceptive precautions to avoid conception or had never been sexually active) 
were younger (p < 0.0001) and were more often on a strict diet (<20 mg/day) (p < 0.01) 
than those who had pregnancy opportunities (i.e. women who actively attempted to 
conceive or had regular unprotected sexual intercourse). Also, induced puberty and HRT 
use were more frequent in the group of women without pregnancy opportunities, 
which could partly reflect improved clinical awareness. Yet, these group differences 
might also result from a less severe phenotype in the group of women with pregnancy 
opportunities, despite high similarity in genotype, GALT activity, diet onset, and cogni-
tive functioning. 
 
Table 1: Patient characteristics.  
Demographics of the complete cohort (n=85) are presented. Furthermore, characteristics of participants 
stratified by information on pregnancy opportunities (yes/no, n=71) are shown. Variables that significantly 
differ between these two groups are marked with an asterisk. 
 Total group (n=85) Without conception 
opportunity (n=50) 
With conception 
opportunity (n=21) 
Age 1 30 (18 - 53; n=85) 24 (18 - 44; n=50) 33 (24 - 53; n=21) * 
Genotype p.Q188R/p.Q188R 69.2% (n=45/65) 65.7% (n=23/35) 62.5% (n=10/16) 
GALT activity 2 0.3 (0.0 - 1.2; n=25) 0.3 (0.0 - 1.2; n=20) 0.3 (0.0 - 1.0; n=5) 
Onset diet 3 10 (0 - 2920; n=75) 8 (0 - 2920; n=48) 13 (0 - 195; n=18) 
Strict diet 4 85.7% (n=72/84) 92.0% (n=46/50) 65.0% (n=13/20) ** 
Low education 5 38.8% (n=26/67) 43.2% (n=19/44) 35.3% (n=6/17) 
Spontaneous menarche  44.7% (n=38/85) 42.0% (n=21/50) 71.4% (n=15/21) *** 
Age at first menstruation 6 15 (10 – 28; n=78) 14.5 (10 – 20; n=48) 15 (12 – 20; n=20) 
HRT 7 78.7% (n=59/75) 83.3% (n=40/48) 55.6% (n=10/18) **** 
Child-wish  52.8% (n=28/53) 47.5% (n=19/40) 66.7% (n=8/12) 
Negative counseling 8 75.4% (n=43/57) 72.5% (n=29/40) 87.5% (n=14/16) 
1 Median and range of age at time of participation in years 
2 Median and range of residual galactose-1-phosphate uridylyltransferase (GALT) activity in percentage of 
control values 
3 Median and range of age at initiation of dietary management in days 
4 A strict diet is defined as a galactose intake of <20 mg/day (22) 
5 A low educational level is defined as International Standard Classification of Education 2011 level 0-2 (23) 
6 Median and range of age at first menstruation in years 
7 Hormone replacement therapy (HRT) at time of participation 
8 Patient thinks pregnancy is impossible, based on fertility counseling by healthcare professionals 
* p < 0.0001 
** p < 0.01 
*** p = 0.04 
**** p = 0.03 
 
3Fertility in classic galactosemia 
47 
Only 21 women (n=21/71, 29.6%) had actively attempted to conceive spontaneously or 
had experienced a period of regular unprotected sexual intercourse, and of these 21 
women nine became pregnant (n=9/21, 42.9%). A binomial test indicated that this pro-
portion of pregnancies of 42.9% was significantly higher than the expected proportion 
of 7.5% (14) (p < 0.0001, 1-sided). A Kaplan Meier curve (n=16 cases, of which seven 
conceptions) demonstrated that after a period of 12 months 27.8% of couples had con-
ceived (estimated cumulative proportion; n=4), which increased to 48.4% after 24 
months (n=6) and 61.3% after 27 months (n=7) (Figure 1). A total of 20 spontaneous 
pregnancies in nine women were reported in this cohort (three women conceived four 
times, two females conceived twice and the other four women conceived once), of 
which six ended in a miscarriage (in five individuals; n= 6/20, 30.0%)). Women who 
conceived did not differ from women who could not conceive with regard to character-
istics (Table 2). Also, age ≤25 years at first pregnancy opportunity (p = 0.34, OR: 3.50 
[0.43 - 28.45]), genotype p.Q188R/p.Q188R (p = 1.00, OR: 1.00 [0.13 - 7.57]), history of 
a spontaneous menarche (p = 0.66, OR: 1.75 [0.24 - 12.64]), estimated galactose intake 
of <20 mg/day (p = 1.00, OR: 0.83 [0.13 - 5.40]), and low educational level (p = 0.16, OR: 
5.33 [0.62 - 45.99]) did not demonstrate significant effects on the occurrence of spon-
taneous conception.   
 
Table 2: Characteristics of women who did not conceive despite pregnancy opportunities (n=12/21) and 
women who conceived (n=9/21).  
None of the variables was significantly different (p <0.05) between the two groups. 
 Did not conceive (n=12) Conceived (n=9) 
Age at first opportunity 1 30 (25 - 32; n=9) 24 (21 - 38; n=8) 
Genotype p.Q188R/p.Q188R 62.5% (n=5/8) 62.5% (n=5/8) 
Onset diet 2 13 (0 - 195; n=11) 13 (5 - 32; n=7) 
Strict diet 3 66.7% (n=8/12) 62.5% (n=5/8) 
Low education 4  20.0% (n=2/10) 57.1% (n=4/7) 
Spontaneous menarche 66.7% (n=8/12) 77.8% (n=7/9) 
Age at menarche 5 16 (12 - 20; n=11) 14 (13 - 17; n=9) 
Negative counseling 6 90.9% (n=10/11) 80.0% (n=4/5) 
1 Median age (range) in years at time of first pregnancy opportunity. 
2 Median and range of age at initiation of dietary management in days 
3 Strict diet is defined as a galactose intake of <20 mg/day (22) 
4 Low educational level is defined as International Standard Classification of Education (ISCED) 2011 (23) level 0-2 
5 Median and range of age at first menstruation in years 
6 Patient thinks pregnancy is impossible, based on fertility counseling by healthcare professionals 
Note: Residual galactose-1-phosphate uridylyltransferase (GALT) activity was discarded as a variable due to 
inadequate sample size (n=5). Data on women who conceived (n=3) and women who did not conceive (n=2) 
showed a residual GALT activity ≤1.0% in all females. 
 
Chapter 3 
48 
About half of the women expressed a child-wish, now or in the future (n=28/53, 52.8%) 
(Table 1). However, the majority of participants (n=43/57, 75.4%) reported healthcare 
professionals told them that pregnancy was not feasible, and that they therefore con-
sidered pregnancy highly unlikely. Interestingly, one participant did not even try to be-
come pregnant spontaneously, despite an active child-wish, because she believed she 
would not succeed. She and her partner decided to proceed to oocyte donation direct-
ly, and the woman is now carrying her second child (both pregnancies established with 
donor oocytes). The other half of participants had no intention of ever having children, 
and the most important reason for this was that many females considered themselves 
unable to bring up a child. Four out of nine women became pregnant unplanned, under 
the assumption contraceptives were not needed. 
 
 
Figure 1: Kaplan Meier curve of conception in study cohort. Function for conception is presented, with dura-
tion of pregnancy opportunity (i.e. time period wherein no precautions were taken to prevent conception) in
months on X-axis and cumulative pregnancy prevalence on Y-axis. Couples that did not conceive during their
period of pregnancy opportunities are censored (tick marks). Only outcomes of subjects’ first pregnancy
opportunities are included.  
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DISCUSSION 
In this observational study among women with classic galactosemia and POI, our data 
indicate that fertility is not as impaired as previously thought, which has significant 
implications for counseling of these patients and their families regarding reproduction 
and fertility preservation.  
Studies in the general population indicate that 70% of couples achieve pregnancy 
within a period of 6 months of unprotected sexual intercourse, which increases to a 
proportion of 80% after 12 months and 90% after 24 months (27). Our results indicate 
that chances for women with classic galactosemia and POI are substantially lower, 
namely 20%, 28% and 48% after 6, 12, and 24 months, respectively (Figure 1). This is 
not unexpected, given that these females have considerable ovarian damage and a 
severely compromised ovarian reserve. However, if these women attempt to conceive 
for a slightly longer period of time (27-30 months), over 60 percent of couples are esti-
mated to conceive. Previous studies reported that in general 5-10% of women conceive 
spontaneously after POI diagnosis (14). We observed a significantly higher spontaneous 
pregnancy prevalence of 43% in our study cohort (p < 0.0001).  
Albeit time to pregnancy is expected to be longer than for women with an unaffect-
ed ovarian reserve, many females with classic galactosemia do not try to conceive for as 
long as 1 year, let alone 2 years (Figure 1). An explanation for this premature abandon-
ment of trying to conceive given by many women is the discouraging nature of fertility 
counseling by healthcare professionals, which is reported by three quarters of partici-
pants. Since women consider pregnancy highly unlikely, several months of unsuccessful 
attempts might strengthen these thoughts and make them give up early.  
Our study emphasizes the importance of adequate precautions to avoid conception, 
in case pregnancy is not desired, despite POI diagnosis. We showed that half of patients 
do not have the intention of ever having children and that several women became 
pregnant unplanned. The need for contraception in those cases should be underlined in 
counseling. 
It remains unclear why some women conceive spontaneously and others fail to be-
come pregnant. We explored several characteristics with a potentially predictive value. 
Though the p.Q188R/p.Q188R genotype was reported to be a risk factor for POI devel-
opment (24), our data indicate that pregnancy chance of women with this genotype is 
not lower than for patients with other classic GALT mutations (OR: 1.00, 95% CI: 0.13 - 
7.57). Moreover, spontaneous menarche was suggested to result in increased chance of 
spontaneous pregnancy (15), yet our findings do not fully support this hypothesis. We 
observed a higher frequency of spontaneous menarche in women who had pregnancy 
opportunities as compared to women who did not have pregnancy opportunities, which 
might reflect a less severe phenotype in this group due to other factors than genotype, 
GALT activity, and diet onset. Within this subgroup, we did not observe differences with 
regard to menarche between women who became pregnant and women who could not 
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have children (OR: 1.75, 95% CI: 0.24 - 12.64). We were unable to evaluate the potential 
effect of residual GALT enzyme activity ≥0.4% on pregnancy chance due to the limited 
number of patients for whom this data was available (13). Also, low educational level 
and a strict diet did not show significant effects, though findings could result from the 
limited sample size.  
In this cohort, a total of 20 spontaneous pregnancies were observed, of which six 
ended in a clinically recognized miscarriage (30%). This is relatively high as compared to 
the general population, in which 10-15% of all pregnancies is estimated to end in a 
clinically recognized spontaneous abortion (28).  
Furthermore, the current data challenge the application of invasive fertility preser-
vation techniques at an early age. As reported previously, fertility preservation in this 
population is only likely to be successful in very young girls, due to the severely deplet-
ed follicle pool from an early age on (20), which is supported by the poor response to 
ovarian stimulation in the majority of adult patients (7). Cryopreservation of ovarian 
tissue is the only available technique at prepubertal age. Though experience with this 
method has evolved, tissue quality and pregnancy chances remain only limitedly known 
(29, 30). Thus far, there are no reports on transplantation of cryopreserved tissue in 
classic galactosemia, so the potential impact of the disease’s (ongoing) pathogenesis on 
the quality of the frozen tissue and its follicles is yet to be determined. Furthermore, 
application of this technique might reduce future chances of spontaneous pregnancy by 
removal of one entire ovary.  
This is the largest cohort hitherto studied to estimate pregnancy chance of women 
with classic galactosemia and POI. Despite our international multicenter study design 
and major efforts to include as many participants as possible, conclusions on pregnancy 
chance derive from a small subgroup (n=21), since only a limited number of participants 
had conception opportunities in the past. This could partly be related to the relatively 
low median age in the cohort (30 years). The limited subgroup size, as well as the po-
tential selection bias of women with successful pregnancy attempts (we experienced 
that women who did not succeed in conceiving sometimes do not want to participate 
because of painful memories), could influence the pregnancy prevalence that was ob-
served in our study.  
In conclusion, the pregnancy rate in women with classic galactosemia and POI was 
higher than expected, even though many women did not try to conceive because they 
were told they are infertile. If more women would attempt to conceive, and if they 
would try for a longer period of time than they generally do now (>2 years), potentially 
more pregnancies would occur in this group. Importantly, there was a substantial risk of 
miscarriage in this cohort. Our data corroborate the paradigm that women with classic 
galactosemia have a considerable chance of spontaneous pregnancy despite POI. These 
findings prompt revision of current fertility counseling and the potential application of 
fertility preservation.   
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SUPPLEMENTAL MATERIAL 
Questionnaire pregnancy chance in classic galactosemia 
Personal data 
 
1 What is your age?  ........ years 
2 In which country were you born?  ............................................................. 
 Where does your family come from?  ............................................................. 
3 What is your height?  ................. cm or feet/inches 
4 What is your current weight?  ................. kg or pounds 
5 What is/was your job?  ……….................................................. 
6 What is your highest level of education?  ............................................................ 
7 Do any diseases run in your family?  No / Yes,  ................................................................................................. 
8 Does any of your family members suffer from infertility?  No / Yes 
Which family member(s) suffer(s) from infertility and which disease causes his/her/their infertility? 
.............................................................. 
 
 
Medical history 
 
9 Are you currently under treatment of a doctor?  No / Yes, 
 Name:  ............................................................ 
 Specialty:  ............................................................ 
 Reason:  ............................................................ 
10 Have you ever undergone surgery?  No / Yes, for: ............................................................................................ 
Year:  ............................................................. 
11 Were you ever treated by a doctor for another reason?  No / Yes, for: 
 Name:  ............................................................ 
 Specialty:  ............................................................ 
 Reason:  ............................................................ 
Year:  ............................................................. 
12 Do you use any medication?  No / Yes, I use …........................................... 
13 Do you smoke?  No / Yes, .......................... cigarettes per day 
14 Do you drink alcohol?  No / Yes, .......................... glasses per week 
15 Do you drink coffee or tea?  No / Yes, ....................... cups coffee and …. cups tea per day 
 
 
Classic galactosemia 
 
16 How old were you when doctors found out that you have classic galactosemia? 
..........................................years 
17 Are you on a (ga)lactose restricted diet?  No / Yes 
 If you are not on a diet, have you ever been on a diet?  No / Yes, from 
 ....................................................... until ............................................................. 
 If you are on a diet, since when?  Since ................... 
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Gynecological history  
 
18 At what age did you experience your first period?  .................... years 
19 Did your need help to get your periods started?  No / Yes, it was started with medication called  
……………………………………………………. 
20 Are your periods regular?  Yes / No, cycle: …................... 
 Have your periods always been regular?  Yes / No, cycle: …................... 
21 Do/did you use oral contraceptives (the pill)?  No / Yes, name: …......................... 
 When?  From …................ until ……................ 
22 Do you have (biological) children?  No (continue to question 26) / Yes 
 How many?  …………… children 
23 Have you ever had a miscarriage?  No / Yes, …. miscarriages at …... weeks of pregnancy 
24 How long did it take you and your partner to become pregnant?  ………months 
25 Did you need help from a doctor (medical assistance, assisted reproductive techniques) in order to be-
come pregnant?  No / Yes, I needed…………….. ……………………………..………. Continue to question 29 
 
26 Have you ever tried to become pregnant?   No (continue to question 29) / Yes 
27 How long did you and your partner try to become pregnant?  
............ months 
Period: …..............until…...............  
Your partner’s age at the time: ….…years 
28 Have you had a miscarriage?  
No / Yes, ….. miscarriages at ……..… weeks of pregnancy 
 
29 Have you ever undergone examinations or tests to determine whether you are fertile?  No / Yes, the 
result was …………………………………………. 
Have you been diagnosed with primary ovarian insufficiency or premature ovarian failure?  No / Yes, 
based on:  Ultrasound / Hormone levels in blood / Other,………..……………………….. 
30 Has your partner ever undergone examinations or tests to determine whether he is fertile?  No / Yes, the 
result was…..………………………………………… 
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ABSTRACT 
Almost every female classic galactosemia patient develops primary ovarian insufficiency 
(POI) as a diet-independent complication of the disease. This is a major concern for 
patients and their parents, and physicians are often asked about possible options to 
preserve fertility. Unfortunately, there are no recommendations on fertility preserva-
tion in this group. The unique pathophysiology of classic galactosemia with a severely 
reduced follicle pool at an early age requires an adjusted approach. In this article rec-
ommendations for physicians based on current knowledge concerning galactosemia and 
fertility preservation are made. Fertility preservation is only likely to be successful in 
very young prepubertal patients. In this group, cryopreservation of ovarian tissue is 
currently the only available technique. However, this technique is not ready for clinical 
application, it is considered experimental and reduces the ovarian reserve. Fertility 
preservation at an early age also raises ethical questions that should be taken into ac-
count. In addition, spontaneous conception despite POI is well described in classic ga-
lactosemia. The uncertainty surrounding fertility preservation and the significant chance 
of spontaneous pregnancy warrant counseling towards conservative application of 
these techniques. We propose that fertility preservation should only be offered with 
appropriate institutional research ethics approval to classic galactosemia girls at a 
young prepubertal age.  
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INTRODUCTION 
Almost every female patient with classic galactosemia, an inborn error of galactose 
metabolism, has primary ovarian insufficiency (POI) and is confronted with the struggle 
that reduced chances of having children presents (1). Patients and/or their parents 
often approach physicians with questions regarding fertility preservation. Answering 
these questions, however, remains difficult, due to the unique and yet to be deter-
mined underlying pathophysiological mechanisms of POI as well as the lack of experi-
ence with fertility preservation techniques in general and in girls with classic galactose-
mia in particular.  
Classic galactosemia (ORPHA79239) is caused by deficient activity of galactose-1-
phosphate uridyl transferase (GALT), as a result of mutations in the GALT gene located 
on chromosome 9p13. GALT is the second of the three enzymes in the Leloir pathway, 
the main pathway of galactose metabolism. The incidence of classic galactosemia varies 
between 1:16.000 (2) and 1:60.000 (3) in Western countries. Galactose is needed for 
energy metabolism and glycosylation of complex molecules. It may be derived from 
exogenous (dietary) sources, most importantly lactose from dairy products, or endoge-
nous production. Deficiency of the GALT enzyme leads to accumulation of galactose and 
its metabolites and results in secondary glycosylation abnormalities. Patients usually 
present in the first weeks of life with signs of liver and renal disease, cataracts and an 
Escherichia coli sepsis. Diagnostic tests include elevated galactose and galactitol in body 
fluids, elevated Gal-1-P in erythrocytes, severely diminished enzyme activity in erythro-
cytes and mutations in the GALT gene. A galactose-restricted diet quickly resolves the 
early signs, but cannot prevent the development of later-onset complications, such as 
cognitive impairment, neurological sequelae, bone health abnormalities, and, in female 
patients, POI with subsequent infertility.  
Although POI in classic galactosemia represents a major concern for these patients 
and/or their parents (4), there are no published recommendations concerning fertility 
preservation in this group. The current guidelines in patients with cancer (5-10) may be 
useful in assessing the risk-benefit ratio for girls with galactosemia. However, unlike 
cancer patients, the mechanisms causing ovarian dysfunction are unknown and the 
timing of onset may begin as early as prenatally (1, 11-14).  Therefore, intervening when 
the patient reaches adulthood may be too late. As a consequence, applying fertility 
preservation options in very young girls raises medical, legal and ethical questions. Fur-
thermore, spontaneous pregnancies do occur in this disease, demonstrating that con-
ception is possible in some patients. 
The aim of this paper is to discuss the different aspects of fertility loss in female 
classic galactosemia patients from a multidisciplinary perspective, and to propose rec-
ommendations for fertility preservation, taking into account pathophysiology, chances 
of spontaneous pregnancies and ethical issues. These recommendations are based on 
our experiences with classic galactosemia patients and the currently available literature.  
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Pathophysiology  
Symptoms of POI differ between affected women, varying from subfertility, to early 
development of irregular menstrual cycles and infertility, to primary amenorrhea and 
absence of spontaneous puberty (15). The cause of POI in classic galactosemia is not yet 
understood. Several mechanisms have been postulated, including direct toxicity of me-
tabolites (i.e. galactose-1-phosphate), altered gene expression, or aberrant function of 
hormones and or receptors due to glycosylation abnormalities (1, 16-18). It is also pos-
sible that not one, but several mechanisms act in unison to cause POI in classic galacto-
semia.  
In general, POI can be caused by either the formation of a smaller primordial follicle 
pool or more rapid loss of primordial follicles (15) and there is evidence for both mech-
anisms in classic galactosemia. In classic galactosemia there is some evidence that the 
follicle pool at birth is as large as in girls without this disease. In two galactosemic neo-
nates, morphologically normal ovaries with abundant oocytes and normal folliculogene-
sis have been reported (19, 20). In another patient, ultrasound showed apparently nor-
mal ovaries at age 7 (21). These studies suggest that the primordial follicle complement 
is normal initially, but comprehensive evidence is lacking.  
Histological findings show that the ovaries contain a strongly reduced number of fol-
licles at older, but variable ages. Histological findings in adolescents (aged 16 or 17 
years) reveal a strongly reduced number of follicles, varying from far fewer follicles than 
expected for age (14) to almost complete absence (22-24). Data in younger adolescents 
or children are lacking.  Histological findings in two adults showed absence of ovarian 
parenchyma (25) and an extremely reduced number of follicles in one subject (26), and 
a follicle number within the normal range in the other (26). Ovarian size and volume in 
patients aged 9-21 years assessed with MRI were comparable to those found in post-
menopausal controls (27). Ultrasound or laparoscopy/laparotomy in patients during 
adolescence or adulthood often shows hypoplastic (24, 28, 29) or streak ovaries (22, 23, 
25, 30), consistent with the absence of follicles. Of note, streak ovaries were also found 
during adolescence in the girl with apparently normal ovaries at age 7 (21). Taken to-
gether, it is possible that a normal complement of primordial follicles forms, but under-
goes atresia more rapidly and that the ovaries can be severely damaged in girls at very 
young prepubertal age.  
There is also evidence for defective follicle maturation, which may result from a 
paucity of follicles able to respond to stimulation or inability of the follicle to respond to 
gonadotropins in galactosemia. The few follicles present in the ovaries of classic galac-
tosemia patients are mainly of the primordial type, and maturing follicles are rarely 
seen (14, 22, 23, 26, 28). Consistent with the absence of estrogen production due to 
absent ovarian activity (26, 27, 31), hypoplastic prepubertal uteri were observed in 
patients who did not receive estrogen supplementation (21-23, 29, 30). 
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Animal studies suggest that galactose might already have a direct toxic effect in fetal 
life. After feeding pregnant and lactating Sprague-Dawley rats a high galactose diet, the 
offspring had a significant and striking reduction in the number of small follicles, (11), a 
reduced number of primordial germ cells (PGCs) and a consequently smaller gonadal 
size (32) suggesting  impaired germ cell migration, and a deficient complement of folli-
cles in some of the exposed animals (33). 
An accelerated loss of follicles during life has also been suggested in several studies. 
Lai et al found that the number of apoptotic granulosa cells of maturing follicles was 
higher in Sprague-Dawley rats fed a high galactose diet than in animals receiving normal 
chow (34). The same has been concluded in a recent study by Banerjee et al (35). Their 
results in isolated granulosa cells suggest that galactose exposure leads to an increased 
expression of p53, a protein mediating intrinsic death pathways in cells (36), conse-
quently causing follicular atresia. The authors also suggest that attenuated FSH bioactiv-
ity is the underlying cause of the increased p53 expression. The latter is not consistent 
with failure of follicle response to exogenous FSH (27, 37). 
Some animal studies also point to a compromised maturation. A high galactose diet 
significantly decreased the number of healthy growing and antral follicles, whereas the 
number of primordial or total atretic follicles was not affected (38), although other 
studies suggested that the primordial follicle count was lower (11). Similarly, other stud-
ies using the same model demonstrated a decreased ovulatory response (33, 39, 40), 
evidenced by reduced numbers of corpora lutea.  
Both case reports of neonates compared to older girls and the animal studies sug-
gest that galactosemia results in increased follicle apoptosis with an accelerated follicle 
loss of either primordial follicles or maturing follicles as the cause of POI (34, 35, 38). It 
might be very difficult to determine whether the large follicle pool present at birth, 
consisting of millions of primordial follicles, is reduced in classic galactosemia patients 
unless the decrease is marked. Animal models indicate a prenatal toxic effect of galac-
tosemia but these animal studies, in which animals are fed a high galactose diet, might 
not represent human classic galactosemia completely. Although the histological and 
imaging data are very limited and call for a tedious conclusion, taken together, there 
seems to be a rapid decline in the number of primordial follicles either in fetal life or in 
early life in this disease, which has to be taken into account when discussing fertility 
preservation. 
Spontaneous pregnancies in women with classic galactosemia 
Over the past years it has become increasingly clear that spontaneous pregnancies in 
classic galactosemia occur, and occur more frequently than previously thought. In a 
cohort of 22 patients with classic galactosemia and POI, 9 patients tried to conceive, of 
which 4 succeeded (44 percent) (41). Although significant, the small sample size war-
rant further studies in a larger cohort. Many patients were told in the past that they had 
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no chance of conceiving and therefore may not have tried, which makes it difficult to 
determine the exact chance of spontaneous pregnancy in classic galactosemia. It is 
important that patients are aware of the occurrence of spontaneous pregnancies (2, 31, 
41-43), allowing them both to try to conceive spontaneously and to avoid unplanned 
pregnancies. The World Health Organization defines infertility as a failure to achieve 
spontaneous pregnancy within twelve months or more (44). Therefore we advise physi-
cians to encourage their patients to try to achieve spontaneous pregnancy for at least 
this period of one year. We also advise physicians to explain that pregnancy should not 
be postponed unnecessarily to increase chances of conception. Importantly, classic 
galactosemia women became pregnant despite postmenopausal FSH levels, extremely 
low estrogen concentrations, undetectable Müllerian Inhibitory Substance (MIS) or anti-
Müllerian hormone levels (31, 45) and the severe Q188R/Q188R genotype (2, 41, 43). 
Therefore, genotype, enzyme activity in erythrocytes, and measurement of markers of 
ovarian reserve do not appear accurate predictors of pregnancy chances in this patient 
population. Besides, the ovaries of prepubertal girls are very small, even in healthy girls, 
limiting the relevance of imaging techniques in these patients. Of note, most of the 
women that became pregnant spontaneously have gone through normal puberty and 
reached menarche spontaneously, indicating that these might be predictive factors for 
an increased chance of spontaneous conception (41).  
Fertility preservation in classic galactosemia patients 
Importantly, fertility preservation data are mainly derived from cancer patients. The 
ovaries of a girl affected with non-ovarian cancer are healthy when there is a need for 
fertility preservation. In contrast, the ovaries of classic galactosemia girls are probably 
already damaged at an early age. Therefore, the success rate of the procedures is prob-
ably lower in galactosemic girls. Perhaps the most important issue to discuss before 
choosing to apply fertility preservation techniques is the fact that fertility preservation 
does not guarantee future pregnancy. A thorough evaluation including the abovemen-
tioned chance of spontaneous pregnancy and the risks and benefits needs to be taken 
into account. Three fertility preservation procedures currently offered to girls and 
women in need of fertility preservation are: a. ovarian tissue cryopreservation, b. ma-
ture oocyte cryopreservation and/or c. embryo cryopreservation. The latter two tech-
niques require ovarian stimulation with FSH, whereas cryopreservation of ovarian tissue 
does not.  
a. Ovarian tissue cryopreservation 
In ovarian tissue cryopreservation, one ovary is harvested through laparoscopy and the 
cortex tissue is processed into cortical strips and frozen. When the patient is ready to 
conceive, the tissue is transplanted at either an orthotopic or a heterotopic location in 
the body. Currently, twenty healthy infants have been born worldwide as a result of 
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autotransplantation of the cryopreserved tissue (46). All mothers were women with no 
history of ovarian problems who were treated with chemotherapy after cancer diagno-
sis. However, the method is still experimental and consensus is lacking on the amount 
of tissue that needs to be harvested for cryopreservation (47, 48). The major risk of this 
technique is that the graft may not survive due to ischemic damage, which leads to 
massive follicular death (49, 50). As primordial follicles are more resistant to this dam-
age (49), the chance of restoring fertility is related to the number and quality of the 
primordial follicles in the transplanted cortical tissue (51). Therefore, it is possible that 
the quantity of ovarian tissue removed should be influenced by the expected probability 
of POI (47). Another disadvantage of cryopreservation of ovarian tissue is that this tech-
nique might lower the chance of spontaneous pregnancy, as a result of reduction of the 
remaining ovarian pool.  Moreover, it is also possible that the transplanted tissue is 
subject to the same detrimental factors that cause POI in this patient group. 
b. Mature oocyte cryopreservation 
In oocyte cryopreservation the patient’s ovaries are stimulated with exogenous FSH, the 
growing follicles are punctured transvaginally and the oocytes are extracted from the 
follicles. The metaphase II oocytes are frozen using vitrification, a technique in which 
high initial concentrations of cryoprotectant and ultra-rapid cooling are used to create a 
glass-like state in a cell without forming ice crystals. Once the patient desires to con-
ceive, the oocytes are warmed and consequently fertilized in a petri dish using a part-
ner’s or donor’s semen (intracytoplasmatic sperm injection, ICSI). The procedure of 
mature oocyte cryopreservation is no longer considered experimental by multiple in-
ternational reproduction societies, including the American Society for Reproductive 
Medicine (ASRM) (52). A recent review of the literature and meta-analysis suggested 
that fertilization and pregnancy rates were similar with vitrified/warmed oocytes and 
fresh oocytes (52). However, a limitation of this analysis is that the majority of data is 
derived from studies with oocytes obtained from healthy, young donors. The current 
recommendations by the ASRM state that oocyte cryopreservation is recommended for 
patients facing infertility due to chemotherapy or other gonadotoxic therapies, but that 
more widespread clinic-specific data on the safety and efficacy of oocyte cryopreserva-
tion in donor populations are needed before universal donor oocyte banking can be 
recommended. Therefore, its use in patients with galactosemia is as yet unclear. 
c. Embryo cryopreservation 
A third fertility preservation option is embryo cryopreservation, a well-established and 
successful technique. This procedure consists of ovarian stimulation, transvaginally 
harvesting cumulus oocyte complexes and extraction of oocytes. The oocytes are ferti-
lized in vitro using a partner’s or donor’s semen. The fertilized oocytes also develop in 
vitro to the embryo stage and are then cryopreserved by means of vitrification or slow 
freezing. Once the patient desires to conceive embryos are warmed and implanted in 
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the uterus. The embryo survival rate is approximately 90% when vitrification is used 
(53). Pregnancy rates in regular IVF programs are on average 30% (54).   
Since all fertility preservation techniques depend on the ovarian reserve (55), and 
considering the apparent rapid follicle pool decline in classic galactosemia, fertility 
preservation in these patients may need to take place during infancy or early childhood, 
seriously limiting the options. Techniques requiring ovarian stimulation are not suitable 
for prepubertal girls because of absence of maturation of the hypothalamic-
hypophyseal-ovarian axis (56), leaving cryopreservation of ovarian tissue the only avail-
able technique for this age group. Fertility preservation in older, postpubertal classic 
galactosemia patients is likely to be unsuccessful as the ovarian reserve may be poor. 
Embryo cryopreservation and oocyte cryopreservation are, in theory, the best options 
in these patients. However, both techniques require ovarian stimulation. Ovarian stimu-
lation in fifteen classic galactosemia patients, aged 15 to 36 years demonstrated poor 
estradiol production in all but one (27). Therefore, the severely reduced follicle pool 
limits the use of cryopreservation of embryos and mature oocytes (1). It might be an 
option for those young classic galactosemic women with a sufficient ovarian reserve, 
but these women probably are the women whose chances of spontaneous conception 
are highest.  
If fertility preservation is not a reasonable option, or if pregnancy does not occur de-
spite fertility preservation, another option is adoption or the use of donor oocytes to 
achieve pregnancy. The donor can be anonymous or can be a direct donor, such as a 
mother or sister. Mothers of galactosemic girls frequently propose to donate oocytes 
for their daughters. It may be necessary to cryopreserve the mother’s oocytes for the 
future if the patient is not ready for children at the time of donation. The ethical issues 
resulting from intra familial donation are discussed below.  
In the future, other fertility preservation techniques might become available. As an 
alternative for mature oocyte cryopreservation, cryopreservation of oocytes extracted 
from immature follicles has been evaluated (in vitro maturation, IVM). Another fertility 
preservation technique that is currently being evaluated and might be an option in the 
future is freezing and transplantation of the entire ovary including its vascular system 
(57, 58). Also the possible existence of oogonial stem cells (59) and induced pluripotent 
stem cells (60) might offer therapeutic options for the future. 
Ethical considerations in fertility preservation 
Ethical problems arise in all young patients in need of fertility preservation, regardless 
of the underlying etiology. Girls are often too young to decide about fertility preserva-
tion themselves and therefore their parents play a crucial role in this process. One 
probably cannot predict with certainty how she herself or, in case of the parents, their 
daughter will think about a pregnancy in the future. The parent’s decision may not ulti-
mately reflect the girl’s wishes when she becomes an adult (8).  In 2005, the American 
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Society for Reproductive Medicine stated that fertility preservation can be applied in 
minors if this is in the best interest of the child and if the girl gives her assent (6). If a girl 
is too young to give assent, parents may give consent if the procedure offers a net ben-
efit for the child. Review of this decision by the ethics committee of a hospital or anoth-
er independent body is in our opinion a must. The same criteria and advice hold true for 
fertility preservation techniques that are still considered experimental, though ap-
proved by the institutional ethics committee. Psychosocial guidance of the girl during 
the procedure and further discussion about fertility during adolescence and adulthood 
are very important. Moreover, legislation always plays a role in medical decision-
making, but laws often differ between countries and may not be specific. 
Cryopreservation of ovarian tissue, the most plausible fertility preservation option 
for this population, is still considered experimental and pregnancy rates resulting from 
this procedure are uncertain (9). Recommending methods that are not yet established 
may offer false hope (1). Therefore, the benefits and harms of every procedure should 
be discussed extensively, and chances of spontaneous pregnancy in this particular dis-
ease despite POI should be considered.  
Intrafamilial oocyte donation might lead to ethical issues including psychosocial 
pressure on the donor and recipient, over-attachment of the donor to the offspring, 
and role confusion for the persons involved, including the resulting offspring (61). The 
process of intrafamilial donation requires the help of multiple professionals, a thorough 
screening of the donor, psychological counseling of both the donor and the recipient 
and extensive informing about legal parenting relations (61, 62). 
DISCUSSION 
As a consequence of the severe depletion of the follicle pool that probably occurs pre-
natally or early in childhood in classic galactosemia patients, fertility preservation in this 
group is only likely to be successful in very young patients. Oocyte cryopreservation 
after ovarian stimulation will likely not be successful in most women with classic galac-
tosemia. It might be useful in women with a sufficient ovarian reserve who wish to 
postpone pregnancy. Ovarian tissue cryopreservation, the only available technique at a 
young age, has several important disadvantages, including the experimental character 
of the procedure and the reduced chances of spontaneous pregnancy. Therefore, the 
technique should probably not yet be offered in a clinical setting, but could be consid-
ered on research basis. 
In general, classic galactosemia patients may have below-average cognitive function-
ing (2, 63-65) and social-emotional problems (66, 67), which might affect the ability to 
raise children. However, the severity of these impairments will not be clear at the time 
of fertility preservation, since this can change over time (68). At the time of fertility 
preservation, physicians should explain to the patient’s parents that some patients 
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might not develop enough parental competency and that this might prevent the use of 
cryopreserved tissue. In adulthood, when the cognitive and ovarian phenotype of the 
patient is clear and when psychological tests have been performed, the adult patient 
can decide if she wishes to have children and if she wants to use the cryopreserved 
tissue in order to achieve this. At that time, physicians and the ethics committee of the 
hospital or another independent body should evaluate whether the patient has ade-
quate parental competency, in case this is doubtful. This is consistent with other fertility 
preservation procedures, for instance in pediatric cancer patients (10).  
Physicians confronted with questions regarding POI and fertility preservation in clas-
sic galactosemia, should emphasize that pregnancy has been repeatedly reported de-
spite POI and they should not discourage patients to try to conceive spontaneously.  
Noteworthy, girls with a spontaneous puberty are likely to have higher chances of spon-
taneous pregnancy. Furthermore the risk of postponing pregnancy needs to be dis-
cussed as well, since in galactosemic women, as in any woman, fertility declines with 
age, lowering the risk of spontaneous conception. However, due to the unknown course 
of ovarian function and the unknown pathophysiological mechanism of POI in classic 
galactosemia, decisions about fertility and fertility preservation remain difficult for pa-
tients, parents and physicians.    
CONCLUSIONS AND RECOMMENDATIONS 
Based on the current knowledge about classic galactosemia and its pathophysiology, we 
recommend that fertility preservation should not be offered to these patients as com-
mon practice (Figure 1). If it is part of institutional research ethics approved research it 
might be taken into careful consideration. Cryopreservation of ovarian tissue in young 
prepubertal girls is at this moment the procedure of choice. At a later age, estimated 
success rates are too low since the ovarian damage is probably already too prominent. 
Trying to achieve spontaneous pregnancy seems to be the best option for older girls 
and women. 
Another option for classic galactosemic girls and women might be oocyte donation, 
both anonymous donation and intrafamilial donation. We currently do not recommend 
intrafamilial donation by the mother, as mentioned above. If in a special situation oo-
cyte donation by the patient’s mother is considered, psychological screening and exten-
sive counselling are required, according to previously mentioned guidelines (61). 
Finally, we recommend engagement of an independent review board in the process 
of fertility preservation at minimum two points in the process: when the parental deci-
sion to preserve their daughter’s ovarian tissue is considered, but also when the patient 
wishes to use the preserved tissue, as the parental capacity of the patient should be 
reviewed.  
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● Physicians should emphasize that spontaneous pregnancies occur in 
women with classic galactosemia, even after POI diagnosis. 
● If fertility preservation is desired, cryopreservation at an early prepubertal 
age as a part of approved research currently seems to be the best option.   
● The ethics committee of the hospital or another independent body should 
review the parent’s decision before the fertility preservation procedure. 
● The ethics committee of the hospital or another independent body should 
be involved in the decision making surrounding the use of the 
cryopreserved material. 
● If a patient desires pregnancy, a one-year window for attempting 
spontaneous pregnancy is advised to avoid unnecessary use of assisted 
reproductive techniques. 
● Anonymous or intrafamilial oocyte donation might be another option for 
classic galactosemia patients if pregnancy does not occur. 
Figure 1: Our recommendations regarding fertility preservation in female classic galactosemia patients. 
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ABSTRACT 
Patients with classic galactosemia, a genetic metabolic disorder, encounter a variety of 
cognitive impairments, including motor (speech), language, and memory deficits. We 
used functional magnetic resonance imaging to evaluate spontaneous correlations in 
functional activity during rest to investigate potential abnormalities in neural networks. 
We characterized resting-state networks using seed-based correlation analysis in 13 
adolescent patients and 13 matched controls. Patients showed alterations in networks 
encompassing the medial prefrontal cortex, pre- and postcentral gyrus, and inferior 
parietal lobule, involved in sensory-motor integration and spatial orientation. Further-
more, altered connectivity of networks including the insula, inferior frontal gyrus, pre-
supplementary motor area, pre- and postcentral gyrus and superior parietal lobule - 
important for language production and motor (speech) planning - was demonstrated. 
Lastly, abnormalities were found in networks involving the occipital region, (pre)cuneus 
and lingual gyrus, possibly linked to visuospatial processing abnormalities. Importantly, 
across several seeds, altered functional connectivity to the lingual gyrus, precentral 
gyrus, insula and cuneus was observed in patients, suggesting special importance of 
these brain regions. Moreover, these alterations correlated with clinical test results, 
supporting a relation with the clinical phenotype. Our findings contribute to improved 
characterization of brain impairments in classic galactosemia and provide directions for 
further future investigations. 
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INTRODUCTION 
The brain represents one of the target organs of damage in classic galactosemia, an 
inborn error of galactose metabolism, resulting in chronic impairments with significant 
impact on quality of life and general performance (1-3). Patients with classic galactose-
mia suffer from a profound deficiency of galactose-1-phosphate uridylyltransferase 
(GALT) due to mutations in the GALT gene, and affected newborns present with a se-
vere toxicity syndrome upon exposure to galactose in milk. Immediate initiation of ga-
lactose-restriction is life-saving, but fails to prevent the development of burdensome 
brain impairments, including lower intelligence (4-8), language production and speech 
(motor) problems (9-13), slower information processing and memory deficits (4, 14), 
social difficulties (15), psychiatric conditions (16) and neurological sequelae (17).  
The pathogenic basis of these debilitations is puzzling and there is an increasing 
number of studies providing evidence for structural changes in white and grey matter, 
as well as alterations at a functional level (17-28). Using innovative diffusion-weighted 
magnetic resonance imaging (MRI) analysis techniques, evidence for abnormal white 
matter microstructure in bilateral anterior tracts (reduced neurite density) and the left 
hemisphere (increased dispersion of neurites) was provided (27), which strengthens the 
hypothesis of aberrant myelin composition, possibly resulting from deficient galacto-
cerebroside formation due to aberrant glycosylation (21, 25). Additionally, several stud-
ies demonstrated cerebral or cerebellar atrophy and decreased tissue density of grey 
matter (17-19, 21, 22, 24, 25, 28). This neuronal loss has been speculated to result from 
direct toxicity of galactose and its metabolites or aberrant glycosylation (25). In addition 
to reduced grey matter density, Timmers et al. (2016) also observed increased grey 
matter density in the inferior frontal and medial prefrontal cortex, which could reflect 
compensation for problematic motor and cognitive functions (memory, language) or 
abnormal maturation (28). 
At a functional level, Dubroff et al. (2008) used [18F]fluorodeoxyglucose (FDG) posi-
tron emission tomography (PET) to evaluate glucose metabolism in patients (20). De-
creased metabolism was found in the occipital region, orbital frontal lobes, sensorimo-
tor areas, cerebellum, superior temporal lobes, and the mid and superior parietal re-
gions. Increased metabolism was demonstrated in bilateral anterior cingulate cortex 
(ACC) and temporal poles, as well as in basal ganglia. The findings in ACC and basal gan-
glia were interpreted as showing potential compensation for problematic motor func-
tions.  
Recently, a task-based functional MRI (fMRI) study by our group, wherein patients 
carried out a language production task, was the first to point towards abnormal lan-
guage-related brain networks in this disorder (26). Evaluation of neural activity demon-
strated that patients recruited different and more extensive brain regions during lan-
guage production as compared to controls. The left inferior frontal gyrus (IFG), the right 
insula and the left pre-supplementary motor area (pre-SMA) were subsequently select-
Chapter 5 
74 
ed as seeds for a seed-based functional connectivity analysis, which revealed variations 
in functional connectivity in comparison to controls.  
Resting-state fMRI studies, in which neuronal connectivity in absence of a specific 
stimulus or task is assessed, are increasingly conducted within multiple fields of neuro-
science to study the organization of core processing systems of the brain. The rationale 
behind these studies is that the brain is always active and shows spontaneous neuronal 
activity even during rest. Brain regions that show synchronous neuronal activity are 
considered to be functionally connected, thereby constituting a functional network (29-
32). A commonly used approach to study functional connectivity is the seed-based cor-
relation analysis (SCA). This method is hypothesis-driven and correlates the resting-state 
time courses of an a priori selected region of interest (ROI; i.e. seed) to the time series 
of the rest of the brain (29, 31, 33, 34), wherein the seed is selected from a task-
dependent activation map or anatomically based on previous literature (35). Despite 
differences in data acquisition and analysis methods, multiple resting-state networks 
have been consistently found across functional connectivity studies (30, 36, 37). Addi-
tionally, altered functioning of these networks has been demonstrated in participants 
suffering from a variety of brain disorders (38), including neurodegenerative diseases 
such as Alzheimer’s disease (39-41), as well as attention deficit hyperactivity disorder 
(ADHD) (42-44) and other psychiatric conditions.  
In our previous study, we focused on functional networks that are involved in an ac-
tive task (26). However, resting-state fMRI allows us to investigate the overall functional 
organization of brain networks, which has not been studied before in classic galactose-
mia. The current study therefore characterized functional networks in resting-state in 
patients with classic galactosemia as compared to healthy controls using a seed-based 
approach. Seeds were selected based on previous neuroimaging studies in this popula-
tion, namely the left IFG, right insula, left pre-SMA, right and left putamen, right and left 
medial prefrontal cortex (mPFC), and the medial occipital region (20, 26, 28). Findings 
were correlated to available behavioral outcome measures as well, in order to confirm 
potential relations between functional networks and behavior (45). For this, measures 
of functional connectivity of brain regions of interest were correlated to neurocognitive 
test results. Our aim was to elucidate affected brain networks in patients with this dis-
ease to improve the characterization of brain impairments encountered by these pa-
tients. 
MATERIAL AND METHODS 
Participants 
Thirteen adolescent patients with classic galactosemia and thirteen age- and gender-
matched healthy controls participated in this study. Participants were recruited as de-
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scribed by Timmers et al. (2015) (26). Briefly, patients who participated in an earlier 
study of our group and aged 14 years or older were invited to participate in the current 
study. Classic galactosemia diagnosis was confirmed by GALT enzyme activity measure-
ment and/or GALT mutation analysis. One patient and one control subject were exclud-
ed because of extensive motion during scanning and a current health condition, respec-
tively. Characteristics of included patients and controls are presented in Table 1. Partic-
ipants had no other relevant health conditions, had normal or corrected to normal vi-
sion, were native Dutch speakers, and were eligible for MRI assessment. All gave written 
informed consent, and in case of minors informed consent was obtained from the par-
ents/caregivers as well. The Medical Ethical Committee of the University Hospital Maas-
tricht/University of Maastricht (azM/UM) gave ethical approval for this study. The study 
was conducted in accordance with the Declaration of Helsinki. 
 
Table 1: Participant characteristics for both patient and control group.  
 Patients (n=12) Controls (n=12) 
 Value (range) Value (range) 
Gender Males: 3 
Females: 9 
Males: 3 
Females: 9 
Age (years) 1 17.4 (14.6 - 21.1) 17.1 (14.0 - 20.0) 
Age at initiation of galactose-restricted diet (days) 11.0 (0 - 35)  
GALT activity (% of reference value) 2 0.55 (0 - 1.52)  
GALT mutation 5x p.Q188R/p.Q188R (42%) 
1x p.Q188R/p.L195P (8%) 
3x p.L195P/p.K229N (25%) 
2x p.W134fs/unknown (17%) 
1x Unknown (8%) 
 
Special education (% of group) 3 75  
Speech therapy (% of group) 3 92  
Motor therapy (% of group) 3 42  
Visuospatial working memory 4 30 (<20-51)  
Verbal working memory 5 4.25 (2-7)  
Sustained attention 6 14.9 (11.3-20.3)  
1: Median age was not significantly different between groups (F1,22 = 0.12, p = 0.73) 
2: GALT enzyme activity measured at diagnosis 
3: Special education, speech therapy or motor therapy at some point in life 
4: Immediate Recall subtest of Rey Osterreith Complex Figure T-score (Meyers and Meyers 1995) 
5: Digit Span (Forward and Backward) score (Van Haasen et al. 1986) 
6: Bourdon-Vos mean reaction time (Vos 1988) 
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Procedure 
To prevent excessive motion during scanning, participants practiced lying in a dummy 
scanner. After this practice session, participants received explicit instructions and were 
placed comfortably in the MRI scanner. Resting-state data were acquired, followed by a 
language task. The task-evoked functional connectivity pattern analyses were described 
elsewhere (26). During the resting-state scan (duration: 6 minutes) a fixation point was 
presented and participants were instructed to relax, not to think of something in partic-
ular and to keep their eyes open. Total duration of the experiment, including the acqui-
sition of other data, was approximately 90 minutes. Afterwards, participants completed 
a short questionnaire addressing the difficulty of the session (not significantly different 
between patients and controls; t = 0.562, df = 24, p = 0.58).  
Data acquisition 
Data were obtained on a 3T Siemens MAGNETOM® Allegra head scanner using an 8-
channel head coil, and a 3T Siemens MAGNETOM® Trio whole body scanner using a 32-
channel head coil (Siemens Medical System, Erlangen, Germany). Data acquisition on 
two different scanners was necessary as a result of irresolvable technical issues with the 
Allegra scanner. Four patients and four controls were scanned on this MRI scanner. 
Parameters of the Allegra scanner and Trio scanner were identical unless otherwise 
specified. 
T1-weighted anatomical images were acquired using an ADNI MPRAGE sequence 
with 192 slices and 1mm iso-voxel resolution covering the whole brain (repetition time 
[TR] = 2250 ms; echo time [TE] = 2.6 ms). Functional T2*-weighted resting-state images 
were obtained using a standard echo-planar imaging (EPI) sequence covering the whole 
brain, except for cerebellum (TR = 2000 ms, TE = 30 ms, 32 slices, 180 volumes, 3.5 mm 
iso-voxel).  
Data pre-processing 
Data were analyzed using BrainVoyager QX version 2.8.4.2645 (Brain Innovation, Maas-
tricht, the Netherlands). For functional datasets, the first four volumes of each com-
plete time series were discarded because of saturation effects. Pre-processing of the 
functional data included correction for slice time differences, 3D head motion correc-
tion (none of the six parameters differed significantly between patients and controls, p 
> 0.05 for all parameters), linear trend removal and spatial smoothing (Gaussian filter 
FWHM of 4 mm). Functional datasets were co-registered with anatomical data and 
normalized in Talairach space (3.5 mm iso-voxel). Anatomical data of all participants 
were averaged to create a group-based dataset. 
5Resting-state fMRI abnormalities in galactosemia 
77 
Statistical analyses 
We conducted a SCA with the left IFG, right insula, left pre-SMA, right and left putamen, 
right and left mPFC, and the medial occipital region as seeds (a sphere was created 
surrounding the peak voxel and taken as region of interest [ROI], 257 voxels; Table 2). 
The six detrended 3D head motion parameters and their derivatives, head motion 
spikes (not significantly different between patients and controls, t = -0.974, df = 22, p = 
0.34), the extracted mean signal from the cerebral spinal fluid (CSF) and white matter 
(WM), and the global signal were Z-normalized and added as variables of no interest. 
Though the approach remains a subject of debate (73, 74), we decided to regress out 
the global signal since we are interested in localized network-specific neuronal activity, 
which could be obscured by unspecific global blood oxygenation level dependent 
(BOLD) fluctuations. Furthermore, signal oscillations at a frequency of 0.1 – 0.25 Hz 
(sine-cosine pairs) were added as confounders for low-pass filtering of the time series. 
The BOLD time courses of the seeds were extracted, normalized and correlated with 
the time series from all other brain voxels using a random-effects (RFX) group analysis. 
We first estimated functional connectivity for each participant separately in a multi-
study RFX General Linear Model analysis (first level), which then served as input for a 
second-level analysis of variance (ANOVA), allowing group contrasts. Functional connec-
tivity per group was inspected at the level of the whole cerebrum on maps corrected at 
q(FDR) < 0.05. Statistical contrasts between patients and controls were inspected at the 
level of the whole cerebrum on maps corrected at a statistical threshold of p < 0.005. 
The significant group differences were converted to volumes of interest (VOIs) with a 
cluster threshold of 150. 
 
Table 2: Regions of interest (ROIs) used as seeds in seed-based correlation analysis 
 Mean X Talairach 
coordinate 
Mean Y Talairach 
coordinate 
Mean Z Talairach 
coordinate 
Left IFG -49 13 22 
Left pre-SMA -6 -2 62 
Right insula 32 14 6 
Right mPFC 3 45 34 
Left mPFC -8 48 28 
Right putamen 21 15 1 
Left putamen -17 9 4 
Occipital region 2 -81 2 
Mean Talairach coordinates (center of gravity) for seeds used in seed-based correlation analysis are present-
ed. Abbreviations: IFG = inferior frontal gyrus, pre-SMA = pre-supplementary motor area, mPFC = medial 
prefrontal cortex. 
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Correlations with neurocognitive tests 
From clusters in which group differences were observed, beta values were extracted. In 
the patient group, the beta values per cluster (representing the functional connectivity 
of that region with the seed region) were correlated with results of neurocognitive tests 
using a Pearson correlation analysis. The Immediate Recall subtest of the Rey Osterreith 
Complex Figure (expressed as T-score) was used to evaluate visual working memory 
(75). The Digit Span (Forward and Backward) measured verbal working memory (76). 
The Bourdon-Vos test was used to assess sustained attention (mean reaction time [RT]) 
(77). Correlations with a p value < 0.05 were considered statistically significant (no mul-
tiple comparison correction was performed due to the limited sample size, but only 
strong correlations > |0.6| were reported (78)).  
RESULTS 
Group differences in seed-based correlation analysis  
Medial prefrontal cortex 
In controls, activity in the right mPFC seed region correlated with left and right middle 
temporal gyrus (MTG) and the bilateral posterior cingulate cortex (PCC) and precuneus 
(Pc) (Figure 1A). Furthermore, the bilateral ACC, left IFG and bilateral inferior temporal 
gyrus were correlated. In patients a generally similar, yet more extensive network was 
revealed on a q(FDR) corrected map (Figure 1A). More extensive regions of the frontal 
lobe, right precuneus, PCC, right MTG and ACC were correlated with the right medial 
frontal seed, and in addition the right parietal region was correlated. Statistical compar-
ison between the two groups confirmed increased connectivity with the right superior 
frontal gyrus (SFG), right IFG, right inferior parietal lobule (IPL), right PCC, left mid cingu-
late cortex (MCC), right precuneus and right MTG in patients, as well as with right lin-
gual gyrus, left cuneus and left insula (Figure 1A, Table 3). Decreased connectivity was 
demonstrated in left medial frontal gyrus (MeFG), right parahippocampal gyrus, bilat-
eral precentral gyrus (PrG), left postcentral gyrus (PoG), left pre-SMA, left IFG, left 
precuneus and left MTG.     
Connectivity maps showed that the left mPFC seed was functionally connected with 
the surrounding medial and superior frontal area, as well as with the dorsal ACC (bilat-
erally) in the control group (Figure 1B). In patients, activity of the seed correlated with 
more extensive parts of the left and right frontal regions, as well as with the left middle 
temporal lobe and both parietal lobes (right > left) (Figure 1B). Statistical tests corrobo-
rated increased functional connectivity in patients between the seed and bilateral SFG, 
left MeFG, left IPL, left MTG, left superior temporal gyrus (STG), right ACC and left PCC 
(Figure 1B, Table 3). Decreased functional connectivity was found with right MeFG, left 
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MTG, bilateral PoG, right PrG, bilateral IFG, right IPL, right STG, bilateral (pre)cuneus and 
left insula. 
 
 
Figure 1: Functional connectivity (Fc) maps for the medial prefrontal cortex (mPFC) as seed; panel a: right 
mPFC seed, panel b: left mPFC seed.  
Upper and middle row: Statistical maps resulting from the seed-based correlation analysis separate per group
(red indicates positive correlation, blue indicates negative correlation). Seeds are overlaid in purple (right 
mPFC seed) or blue (left mPFC seed). Maps are thresholded at q(FDR) < 0.05. Lower row: Group differences in
functional connectivity per seed region (red indicates patients show increased connectivity as compared to
controls, blue indicates patients show decreased connectivity as compared to controls). Maps are corrected at
p < 0.005 with a cluster threshold of 150.  
 
Putamen  
The seed in the right putamen showed temporal correlation with the head of the right 
nucleus caudatus and right thalamus, as well as with a small region of the right IFG 
(Figure 2A). In the patient group, a more extensive region of the right IFG was correlat-
ed. Furthermore, additional correlations were seen with right insula, right ACC and right 
MCC (Figure 2A). Statistical comparisons between patients and controls demonstrated 
increased functional connectivity with right PoG, right IFG, left superior parietal lobule 
(SPL) and left temporal lobe in the patient group (Figure 2A, Table 3). Decreased func-
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tional connectivity was found in right MTG, right thalamus, bilateral PCC and left cere-
bellum. 
In controls, activity in the left putamen seed correlated with activity in the left nu-
cleus caudatus, left thalamus, right nucleus caudatus and right putamen (Figure 2B). A 
similar network was shown in patients. However, additional correlations with the left 
ACC and right thalamus were seen on the q(FDR) corrected map (Figure 2B). The statis-
tical comparison revealed decreased connectivity with left SPL and left lingual gyrus in 
patients (Figure 2B, Table 3). 
 
Table 3: Group differences per seed and significant correlations with neurocognitive tests 
 Group 
difference 
Nr of 
voxels 
Peak Talairach 
coordinate 
Significant correlation (patients only) 
X Y Z 
Lef IFG – Cl. 1 c>p 300 9 26 22  
Left IFG – Cl. 2 p>c 170 -9 11 52  
Left IFG – Cl. 3 c>p 164 -39 -61 49  
Right Insula – Cl. 1 c>p 227 48 -4 10 Verbal working memory (r = 0.60; p = 0.04) 
Right Insula – Cl. 2 p>c 241 33 17 7  
Right Insula – Cl. 3 p>c 921 24 50 16  
Right Insula – Cl. 4 p>c 305 -6 8 49  
Right Insula – Cl. 5 c>p 168 -30 -16 34  
Right Insula – Cl. 6 c>p 158 -60 -19 19  
Left pre-SMA – Cl. 1 p>c 182 -21 -52 70  
Occipital region – Cl. 1 c>p 182 22 -88 22  
Occipital region – Cl. 2 c>p 2460 -12 -97 7 Verbal working memory (r = -0.60;  
p = 0.04) 
Occipital region – Cl. 3 c>p 412 -33 -73 -11 Sustained attention (r = -0.60; p = 0.04) 
Occipital region – Cl. 4 c>p 196 -42 -13 55 Verbal working memory (r = -0.62;  
p = 0.03) 
Left putamen – Cl. 1 c>p 448 -22 -67 61  
Left putamen – Cl. 2 c>p 195 -30 -82 -5 Visuospatial working memory (r = -0.62;  
p = 0.03) 
Right putamen – Cl. 1 c>p 445 51 5 -14  
Right putamen – Cl. 2 p>c 187 51 -22 43  
Right putamen – Cl. 3 c>p 211 51 -13 -14  
Right putamen – Cl. 4 c>p 2167 12 -25 10  
Right putamen – Cl. 5 p>c 724 21 17 -2  
Right putamen – Cl. 6 c>p 995 -9 -37 7  
Right putamen – Cl. 7 c>p 150 -3 -52 -14  
Right putamen – Cl. 8 p>c 192 -24 -49 46  
Right putamen – Cl. 9 p>c 246 -39 -49 -2  
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 Group 
difference 
Nr of 
voxels 
Peak Talairach 
coordinate 
Significant correlation (patients only) 
X Y Z 
Left mPFC – Cl. 1 p>c 173 63 -7 22  
Left mPFC – Cl. 2 p>c 1040 67 14 10  
Left mPFC – Cl. 3 c>p 257 57 -40 19  
Left mPFC – Cl. 4 c>p 169 57 -31 13  
Left mPFC – Cl. 5 c>p 162 54 5 34  
Left mPFC – Cl. 6 c>p 857 45 41 4  
Left mPFC – Cl. 7 c>p 285 39 -28 65  
Left mPFC – Cl. 8 c>p 1509 33 5 31  
Left mPFC – Cl. 9 c>p 3119 30 -46 46  
Left mPFC – Cl. 10 c>p 160 39 2 -14  
Left mPFC – Cl. 11 c>p 344 36 -31 34  
Left mPFC – Cl. 12 p>c 208 30 38 4  
Left mPFC – Cl. 13 c>p 1876 18 -52 40  
Left mPFC – Cl. 14 c>p 247 18 50 4  
Left mPFC – Cl. 15 p>c 1232 15 32 7  
Left mPFC – Cl. 16 c>p 224 15 -64 7  
Left mPFC – Cl. 17 p>c 2724 -3 50 28  
Left mPFC – Cl. 18 c>p 444 12 2 19  
Left mPFC – Cl. 19 c>p 579 -3 -91 13  
Left mPFC – Cl. 20 p>c 224 -9 41 43  
Left mPFC – Cl. 21 c>p 333 -9 -64 28  
Left mPFC – Cl. 22 p>c 246 -12 47 1  
Left mPFC – Cl. 23 p>c 585 -21 44 22  
Left mPFC – Cl. 24 p>c 307 -15 -40 19  
Left mPFC – Cl. 25 p>c 320 -27 20 49  
Left mPFC – Cl. 26 c>p 336 -24 -55 37  
Left mPFC – Cl. 27 c>p 158 -27 53 4  
Left mPFC – Cl. 28 c>p 301 -27 -49 49  
Left mPFC – Cl. 29 c>p 550 -27 23 4 Visuospatial working memory (r = -0.67;  
p = 0.02 
Left mPFC – Cl. 30 c>p 196 -36 -34 65  
Left mPFC – Cl. 31 c>p 258 -42 -7 -8  
Left mPFC – Cl. 32 p>c 188 -46 -67 46  
Left mPFC – Cl. 33 p>c 317 -51 18 -20  
Left mPFC – Cl. 34 p>c 308 -54 -64 19  
Left mPFC – Cl. 35 p>c 213 -57 -1 -17  
Left mPFC – Cl. 36 c>p 337 -54 8 31  
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 Group 
difference 
Nr of 
voxels 
Peak Talairach 
coordinate 
Significant correlation (patients only) 
X Y Z 
Right mPFC – Cl. 1 c>p 284 67 17 13  
Right mPFC – Cl. 2 p>c 8285 39 -40 37  
Right mPFC – Cl. 3 p>c 712 39 -7 -26  
Right mPFC – Cl. 4 c>p 208 45 8 37  
Right mPFC – Cl. 5 p>c 284 42 38 7  
Right mPFC – Cl. 6 c>p 1459 24 -67 59  
Right mPFC – Cl. 7 c>p 209 27 -31 -14  
Right mPFC – Cl. 8 p>c 506 15 -43 37  
Right mPFC – Cl. 9 p>c 211 15 20 49  
Right mPFC – Cl. 10 p>c 465 9 -88 -8  
Right mPFC – Cl. 11 p>c 309 -3 -91 13  
Right mPFC – Cl. 12 c>p 193 3 56 22  
Right mPFC – Cl. 13 p>c 188 0 -19 -20  
Right mPFC – Cl. 14 p>c 283 -6 -76 16  
Right mPFC – Cl. 15 c>p 209 -12 57 1  
Right mPFC – Cl. 16 c>p 189 -12 26 58  
Right mPFC – Cl. 17 c>p 313 -18 -52 52  
Right mPFC – Cl. 18 p>c 163 -15 -10 31  
Right mPFC – Cl. 19 p>c 232 -24 8 31  
Right mPFC – Cl. 20 p>c 449 -33 29 7 Visuospatial working memory (r = 0.70;  
p = 0.01) 
Right mPFC – Cl. 21 c>p 167 -36 -7 49 Visuospatial working memory (r = -0.61;  
p = 0.04) 
Right mPFC – Cl. 22 c>p 454 -48 5 -26  
Right mPFC – Cl. 23 c>p 306 -45 -22 43  
Right mPFC – Cl. 24 c>p 326 -48 -73 28  
Right mPFC – Cl. 25 c>p 317 -48 23 16  
Right mPFC – Cl. 26 c>p 511 -60 -7 -5  
Clusters (cl.) of difference in functional connectivity between controls (c) and patients (p) specified per seed 
(cluster threshold 150). Size and peak Talairach coordinates of each cluster are presented. Furthermore, 
significant correlations between clusters and neurocognitive test results are shown (for patient group only). 
Tests used: Rey Immediate T-score for visuospatial working memory (Meyers and Meyers 1995), Digit span for 
verbal working memory (Van Haasen et al. 1986), Bourdon-Vos mean Reaction Time for sustained attention 
(Vos 1988). 
Left inferior frontal gyrus 
The seed in the left IFG showed temporal correlation with the left MeFG, left PrG, bilat-
eral MTG, right IFG, left IPL and SPL, left supramarginal gyrus, left precuneus and left 
5Resting-state fMRI abnormalities in galactosemia 
83 
angular gyrus in controls (Figure 3A). The q(FDR) corrected map revealed a less exten-
sive network in patients, with less extensive correlation between the seed and its sur-
rounding area, the contralateral side, and the left parietal lobule (Figure 3A). Statistical 
tests indicated that functional connectivity in patients is increased in the left pre-SMA 
and decreased in right ACC and left SPL, as compared to controls (Figure 3A, Table 3).  
 
 
Figure 2: Functional connectivity (Fc) maps for the putamen seed; panel a: right putamen seed, panel b: left 
putamen seed.  
Upper and middle row: Statistical maps resulting from the seed-based correlation analysis separate per group. 
Seeds are overlaid in pink (right putamen seed) or light green (left putamen seed). Maps are thresholded at 
q(FDR) < 0.05. Lower row: Group differences in functional connectivity per seed region (red indicates patients 
show increased connectivity as compared to controls, blue indicates patients show decreased connectivity as 
compared to controls). Maps are corrected at p < 0.005 with a cluster threshold of 150.  
Right insula 
In controls, activity in the right insula seed showed correlation with activity in right pre-
SMA, bilateral PrG, bilateral PoG, bilateral ACC/MCC, right MFG, bilateral IFG, right nu-
cleus caudatus, right putamen, right thalamus, right IPL, left insula and left cuneus (Fig-
ure 3B). More extensive correlation with bilateral pre-SMA regions and the right MeFG 
was noticed in patients, as compared with controls (Figure 3B). Less extensive correlation 
was seen with right basal ganglia and thalamus, left insula, left IFG and left PoG. The 
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statistical comparison corroborated increased connectivity with right anterior insula, 
right SFG and left pre-SMA in patients, as compared to controls, as well as a decreased 
connectivity with right posterior insula, right PrG and left PoG (Figure 3B, Table 3). 
 
 
Figure 3: Functional connectivity (Fc) maps for the left inferior frontal gyrus (IFG) seed (panel a) and right
insula seed (panel b).  
Upper and middle row: Statistical maps resulting from the seed-based correlation analysis separate per group.
Seeds are overlaid in green (left IFG seed) or dark blue (right insula seed). Maps are thresholded at q(FDR) < 
0.05. Lower row: Group differences in functional connectivity per seed region (red indicates patients show
increased connectivity as compared to controls, blue indicates patients show decreased connectivity as com-
pared to controls). Maps are corrected at p < 0.005 with a cluster threshold of 150.  
Left pre-supplementary motor area 
Connectivity maps showed that the left pre-SMA seed was functionally connected with 
bilateral (pre-)SMA and premotor cortices and the left PrG in the control group (Figure 
4A). A similar network was seen in patients. However, several additional regions were 
correlated, including the right PrG, the left MeFG and left SFG (Figure 4A). Statistical 
comparison showed that patients have increased connectivity between the seed and 
left SPL, as compared to controls (Figure 4A, Table 3). 
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Occipital region 
Activity in the medial occipital region seed correlated with activity in bilateral middle 
occipital gyrus, bilateral lingual gyrus, extrastriate cortex, bilateral cuneus, the right 
precuneus, the right and left PrG in controls (Figure 4B). In the control group bilateral 
PrG, right pre-SMA and cerebellum were also correlated. In patients, less extensive 
correlation was seen with the occipital region surrounding the seed, especially bilateral 
middle occipital gyri, as well as with right precuneus, cerebellum and motor areas (Fig-
ure 4B). Statistical tests confirmed decreased functional connectivity in patients with 
regard to bilateral cuneus, left lingual gyrus and left PrG (Figure 4B, Table 3).  
 
 
Figure 4: Functional connectivity (Fc) maps for left pre-supplementary motor area (SMA) seed (panel a) and
occipital seed (panel b).  
Upper and middle row: Statistical maps resulting from the seed-based correlation analysis separate per group.
Seeds are overlaid in dark red (left pre-SMA seed) or red (occipital seed). Maps are thresholded at q(FDR) < 
0.05. Lower row: Group differences in functional connectivity per seed region (red indicates patients show
increased connectivity as compared to controls, blue indicates patients show decreased connectivity as com-
pared to controls). Maps are corrected at p < 0.005 with a cluster threshold of 150. 
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Correlations with neurocognitive tests 
A significant correlation between the patients’ beta values (representing the functional 
connectivity with the seed region) and results of neurocognitive tests was found for 
eight clusters (Table 3, Figure 5 (A)). Functional connectivity between the left putamen 
and the left lingual gyrus (cluster 2, which showed decreased functional connectivity in 
patients, as compared to controls) was negatively correlated with visuospatial working 
memory (r = -0.62, p = 0.03), i.e. increased connectivity was correlated with lower per-
formance in patients. The same holds true for connectivity between the right mPFC and 
left PrG (cluster 21, which showed decreased functional connectivity in patients, as 
compared to controls) (r = -0.61, p = 0.04), i.e. increased connectivity was correlated 
with lower performance on visuospatial working memory in patients. Correlations of 
functional connectivity patterns with the left anterior insula (left mPFC cluster 29 and 
right mPFC cluster 20) were two-sided. Functional connectivity between the left mPFC 
and left anterior insula (cluster 29, which showed decreased functional connectivity in 
patients, as compared to controls) was negatively correlated with visuospatial working 
memory (r = -0.67, p = 0.02) (i.e. increased connectivity was correlated with lower per-
formance in patients), whereas functional connectivity between the right mPFC and the 
left anterior insula (cluster 20, which showed increased functional connectivity in pa-
tients, as compared to controls) was positively correlated with visuospatial working 
memory (r = 0.70, p = 0.01) (i.e. increased connectivity was correlated with higher per-
formance in the patient group).  
Functional connectivity between the right insula seed and the right posterior insula 
(cluster 1, which demonstrated decreased functional connectivity in patients, as com-
pared to controls) was positively correlated to verbal working memory (r = 0.60, p = 
0.04), i.e. increased connectivity was correlated with higher performance in the patient 
group. Functional connectivity between the occipital region and left cuneus (cluster 2, 
which showed decreased connectivity in patients, as compared to controls), and be-
tween the occipital region and left PrG (cluster 4, which also showed decreased connec-
tivity in patients) as well, were both negatively correlated with verbal working memory 
(r = -0.61, p = 0.04 and r = -0.62, p = 0.03, respectively), i.e. higher functional connectivi-
ty was correlated with lower performance in patients.  
Finally, functional connectivity between the occipital region and left lingual gyrus 
(cluster 3, which showed decreased connectivity in patients, as compared to controls) 
was negatively correlated to sustained attention (r = -0.60, p = 0.04), i.e. increased con-
nectivity was correlated with lower performance in the patient group. 
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DISCUSSION  
In the current study, we explored intrinsic functional networks by investigating sponta-
neous correlations in functional activity during rest in patients with classic galactosemia. 
The right and left mPFC, right and left putamen, left IFG, right insula, left pre-SMA and 
occipital region were selected as seeds for a SCA, based on previous studies indicating 
altered structure, function and/or metabolic activity of these brain regions (20, 26, 28). 
Results from the SCA point towards several differences in these resting-state functional 
networks between patients with classic galactosemia and age- and gender-matched 
controls. Importantly, group differences per seed show substantial overlap. Independ-
ent of the seed region, differences in connectivity across groups were observed within 
the IPL and SPL, precuneus, cuneus, lingual gyrus, insula, IFG, PrG and PoG. These re-
sults indicate a special role of these brain regions within the altered brain connectivity 
in this patient group (Figure 5). 
The right and left mPFC seed analysis indicated decreased connectivity with the PrG 
and PoG, and increased connectivity with the IPL. Assuming that decreased connectivity 
relates to impaired cognition and behavior, impaired connectivity of prefrontal execu-
tive functions and sensory-motor integration may relate to problems in the patients 
motor sequence planning, including motor speech production and planning difficulties 
(46, 47). This would be in agreement with previously described motor (speech) disor-
ders in classic galactosemia (9, 11, 17, 48). Assuming that increased connectivity relates 
to compensatory functions, the observed increased connectivity of mPFC and IPL could 
be related to elevation of attention. Enhanced attention is needed to conduct a more 
difficult task (49), and the IPL is a relevant region in this attention network (50, 51). 
Increased connectivity might also relate to compensation of motor sequencing prob-
lems via recruitment of spatial information, as IPL has a relevant role in spatial orienta-
tion (52).  
For both frontal seed regions, alterations in connectivity with the precuneus and cu-
neus were seen, which might be related to visuospatial and working memory deficits as 
these areas have been reported involved in these tasks (53-55). This interpretation is in 
line with the below average scores on visuomotor/-perceptual/-spatial functioning tests 
and working memory assessments found in patients with classic galactosemia (4, 5, 7, 
14, 56, 57).  
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Figure 5: Clusters (VOI) of group differences.  
Panel a: Overview of clusters (VOI) of group differences, specified per seed (see Table 3). Clusters with signifi-
cant correlations to neurocognitive tests are marked. Color legend: purple = right mPFC seed, blue = left mPFC
seed, pink = right putamen seed, light green = left putamen seed, green = left IFG seed, dark blue = right 
insula seed, dark red = left pre-SMA seed, red = occipital seed. Panel b: Scatterplots of clusters with significant
correlations to visuospatial working memory (Rey Immediate Recall T-score; Meyers and Meyers 1995), verbal
working memory (Digit Span score; Van Haasen et al. 1986) or sustained attention (Bourdon-Vos mean reac-
tion time; Vos 1988). Note: though the right mPFC-left precentral gyrus with visuospatial working memory
correlation might seem driven by two outliers, the correlation remains intact when outliers are removed. 
5Resting-state fMRI abnormalities in galactosemia 
89 
The results from the right insula seed analysis support the claim of potentially disrupted 
sensory-motor integration in classic galactosemia patients too. We observed increased 
connectivity with the anterior insula and decreased connectivity with the posterior 
insula, as well as altered connectivity with other structures of the posterior insula net-
work (PrG, PoG, pre-SMA) in patients. Our interpretation is based on previous studies 
that describe the insula – among other functions – as relevant for sensory-motor inte-
gration. More specific, the anterior insula has been associated with motor sequencing 
and speech planning (46), and the posterior insula has been connected to skeleto-body 
orientation (58).  
The left IFG, which is known for its importance in language, demonstrated increased 
connectivity with left pre-SMA, and decreased connectivity with right ACC and left SPL. 
These findings might reflect aberrant communication between regions involved in lan-
guage planning (IFG) and sensory-motor areas important for speech- and language 
production (pre-SMA, ACC, SPL). Note also that these results are in line with our previ-
ous task-based data, where the left IFG was also found to show decreased connectivity 
with superior parietal regions (in addition to other alterations) (26). The right IFG was 
not selected as seed for the analyses in the current study, however its connectivity was 
frequently altered in relation to selected seeds. This might point towards altered re-
sponse inhibition or attentional control – representing important functions of the right 
IFG (59). 
Evaluation of the occipital seed analysis showed decreased connectivity with bilat-
eral cuneus, left lingual gyrus and left PrG in patients, and with the bilateral middle 
occipital gyrus as well (q(FDR) corrected maps). This further supports the description of 
altered visuospatial capacities in those patients, since these brain regions have been 
implicated in visuospatial attention/processing (cuneus, middle occipital gyrus (54, 60)) 
and motor output (PrG (61)). Findings from the right and left putamen analyses (altered 
connectivity with PrG, cerebellum) and the pre-SMA analysis (increased connectivity 
with SPL, which is involved in spatial orientation, locating objects and body parts in 
space, and visuospatial attention (50, 62)) are also in line with this hypothesis.  
In addition to the importance for working memory and identification of landmarks 
and faces (63, 64), the lingual gyrus has been associated with lexical/semantic pro-
cessing (65, 66). Abnormal connectivity of a seed to the lingual gyrus in patients was 
demonstrated across multiple analyses (right mPFC, left putamen and occipital seeds), 
which might point towards an important role for this structure in the pathogenesis of 
classic galactosemia in general, and specifically in the pathogenesis of language produc-
tion problems observed in this disorder. Additionally, the STG and MTG, which are im-
portant for perception and production of language and speech (67), as well as for social 
cognition (68, 69), showed abnormal connectivity in patients across several analyses. 
Previous studies from our group already demonstrated specific abnormalities in the 
language network leading to lexical and syntactic planning impairments, in addition to 
often observed motor speech planning problems (12, 26). 
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To further investigate the relation between brain networks and behavior, we corre-
lated the patients’ resting-state brain connectivity patterns with their performances on 
several neurocognitive tasks. For that we used the individual neurocognitive test scores 
and the individual beta values per region (cluster). These beta values represent the 
quantification of functional connectivity of that region with the seed region. We select-
ed only beta values from those clusters that were different between patients and con-
trols. Although correlations could only be explored for the patient group, we observed 
some strong and specific correlations for several clusters. These correlations should be 
interpreted with caution, but they might support the general functional interpretation 
of our resting-state analysis. The observed correlations seem to underline a brain net-
work-behavior relation, although this needs to be confirmed in task-based fMRI studies 
targeting these specific neurocognitive functions. Most importantly, brain-behavior 
correlations were detected especially for those clusters that come back across multiple 
seed analyses as being divergently connected (compared to controls), namely the lin-
gual gyrus, PrG, insula and cuneus (Figure 5), thereby supporting the suggested rele-
vance of certain connectivity problems in these patients.   
In general, these findings might shed new light on the brain impairments in classic 
galactosemia. Future studies are needed to investigate whether the alterations ob-
served in this study are the result of targeted damage to these specific re-
gions/networks, or whether these structures are equally affected as other regions of 
the brain but show a more prominent functional impairment. Alternatively, these dif-
ferences in functional connectivity might reflect compensation mechanisms to cope 
with cognitive difficulties. In order to provide more detailed hypotheses on this, investi-
gations of longitudinal data and a systematic comparison of results of structural and 
functional brain imaging studies are needed.    
The current findings are in line with earlier studies in the field of classic galactose-
mia. A previous tasked-evoked fMRI study from our group already demonstrated al-
tered functional connectivity in the language network, with specific alterations at the 
level of the IFG, insula and pre-SMA, suggesting impaired sensory-motor integration, 
motor (speech) planning deficits and suboptimal communication between frontal re-
gions and temporal/parietal regions (26). The connectivity patterns and network altera-
tions are in agreement with the current resting-state findings. The observed language 
network abnormalities are also in line with an earlier syntactic language planning study 
using event related potentials (ERPs), in which lexical and syntactic planning impair-
ments were seen (12). Results from an FDG-PET study pointed towards abnormalities of 
the superior temporal lobes, parietal regions, primary visual cortex, sensorimotor areas 
and frontal lobes (20), brain regions that had a repeatedly altered functional connectivi-
ty in the current study. Imaging studies exploring brain structure in patients with classic 
galactosemia provided evidence for both white and grey matter abnormalities in line 
with the neurocognitive profile of patients (27, 28) and with the here reported results. 
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One of the limitations of this study is its limited sample size, making this study of ex-
plorative nature. The small cohort size hampers solid conclusions on functional connec-
tivity and confirmation of results in a larger sample is thus warranted. Moreover, gen-
ders were not equally balanced in our test sample (females>males) and this cohort is 
therefore not fully representative for the classic galactosemia population. Though cog-
nitive performance does not seem to differ between male and female patients (16), 
future studies exploring potential gender variations in functional connectivity are de-
sired. Furthermore, the current study method is based on certain assumptions and 
focuses on a priori selected seeds, deriving from previous investigations. Future resting-
state fMRI studies could consider an independent component analysis approach, which 
analyzes the overall pattern of functional connectivity without focusing on specific re-
gions of interest (70-72). The current SCA approach with 8 seeds also brings along mul-
tiple testing. Due to the nature of the current study, aiming to provide a first insight in 
functional brain networks at rest in this rare disorder, multiple comparisons corrections 
were not performed for group differences, which could lead to overestimation of ef-
fects. In addition, we correlated functional connectivity to results on neurocognitive 
tests in order to evaluate potential brain-behavior relations. Since correlations could 
only be explored for the patient group and multiple comparisons were not corrected, 
conclusions should be drawn with caution. These findings provide the first conjectures 
on potential brain-behavior relationships and the hypotheses generated by the current 
study require further testing in more dedicated study designs. 
Taken together, robust differences in functional resting-state networks between pa-
tients with classic galactosemia and age- and gender-matched controls were found. 
Results point towards abnormalities in networks encompassing the mPFC, PrG, PoG and 
IPL, which are involved in sensory-motor integration and spatial orientation. Further-
more, altered connectivity of networks including the insula, IFG, pre-SMA, PrG, PoG and 
SPL, which are important for language production, sensory-motor integration and mo-
tor (speech) planning/sequencing, was demonstrated. Lastly, abnormalities were found 
in resting-state networks involving the occipital region, (pre)cuneus and lingual gyrus, 
which might be linked to the observed impairments in visuospatial capacities and work-
ing memory, and possibly lexical/semantic processing as well. Most importantly, across 
several seeds, altered functional connectivity to the lingual gyrus, the PrG, the insula 
and the cuneus was observed in patients, suggesting these brain regions might be of 
special importance and deserve more thorough investigations. In addition, these differ-
ences in network connectivity correlated with clinical test results in patients, supporting 
a relation between functional abnormalities and the clinical phenotype. Our findings 
contribute to the characterization of functional brain impairments in classic galactose-
mia, which is needed to create a better understanding of this enigmatic disease. 
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ABSTRACT 
Introduction Previous studies have reported an association between classic galacto-
semia (CG) and decreased bone mass. The primary objective of this systematic review 
with meta-analysis was to determine the extent of bone mineral density (BMD) Z-score 
reduction. Low BMD was defined as a Z-score ≤-2 standard deviations (SD). The second-
ary objective was to evaluate other indicators of bone status through a descriptive anal-
ysis. 
Methods Systematic search strategies were developed by an experienced clinical li-
brarian. Selection of relevant manuscripts, risk of bias assessment and data-extraction 
were performed independently by two investigators. 
Results Four studies were included in the meta-analysis. BMD Z-scores in children 
and adults with CG measured at the lumbar spine (LBMD; 4 studies; n = 112), total hip 
(HBMD; 2 studies; n = 58), and femoral neck (FBMD; 2 studies; n = 73) were assessed. 
Mean BMD Z-scores in the CG population were: LBMD -0.70 (95% CI: -0.88, -0.52); 
HBMD -0.89 (95% CI: -1.14, -0.64); FBMD -0.63 (95% CI -1.29, 0.02). Results from stud-
ies included in the descriptive analysis (n=7) show that vitamin D levels were frequently 
in the low reference range, whereas serum calcium levels were within reference range.  
Conclusion The mean BMD Z-score in the CG population is -0.7, which is lower than 
in the general population, though still within two SD of the reference mean of zero. This 
indicates that bone health is mildly affected in CG and that more patients, compared to 
the general population, are at risk for a BMD Z-score ≤-2 SD. In conclusion, clinicians 
should ensure appropriate preventive and therapeutic measures for CG patients. 
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INTRODUCTION 
Classic galactosemia (CG, MIM 230400), a genetic disorder of galactose metabolism due 
to deficiency of galactose-1-phosphate uridyltransferase (GALT; EC 2.7.7.12), is charac-
terized by the occurrence of late complications in spite of early diagnosis and lifelong 
dietary treatment. The first report of an association between CG and decreased bone 
mass dates back to 1993 (1) and a bone mineral density (BMD) Z-score more than two 
standard deviations (SD) below the mean was found in 25-30% of adult patients (2,3). 
Thorough evaluation of the frequency and severity of impaired bone health in CG pa-
tients, compared to the non-galactosemia population, is crucial for determining its ex-
tent and relevance for patient care. 
CG patients could be at risk for compromised bone health due to diet restrictions, 
ovarian insufficiency in women, limited physical activity in some cases, and possibly 
unknown intrinsic factors associated with the disease. Sufficient intake of calories, pro-
tein and micronutrients is essential for acquiring an optimal bone mass, and the life-
long galactose restriction may predispose patients to nutritional deficiencies (3–6). 
Furthermore, ovarian damage resulting in low estrogen concentrations is present in 
over 80% of female patients with CG (7), which increases their susceptibility to the de-
velopment of low bone mass. Remarkably, supplementation of calcium, vitamins and 
estrogen only seem to partially improve bone mass (1,8,9), which may point to the 
presence of an underlying intrinsic bone defect. Aberrant glycosylation of collagen and 
other glycoproteins related to bone metabolism, which is also seen in patients with 
other glycosylation defects such as phosphomannomutase 2 deficiency (PMM2-CDG) 
(10), has been suggested as a potential intrinsic abnormality (1,11) and the decreased 
IGF-I and IGFBP-3 concentrations that are found in patients might reflect this (12). Fur-
thermore, reduced physical activity due to motor abnormalities (13) and cognitive im-
pairment (14–17) may affect bone health as well. Clinical practice, focused on reducing 
the risk of impaired bone health in those with CG, includes routine monitoring of BMD, 
which is an important determinant of bone strength and has predictive value in as-
sessing fracture risk (18), and optimization of exogenous factors affecting bone mass 
(nutrition, estrogen concentrations, physical activity)(19).  
The primary aim of our study is to evaluate the extent of impaired bone health in 
patients with CG, and the need of monitoring and treatment. Few studies assessing 
bone health in CG are published. These studies have small patient sample sizes, and 
results vary from one study to another. As the current conjecture of low BMD in CG is 
based on single studies, further evaluation is needed to confirm the validity of this hy-
pothesis (20). Meta-analysis is the most commonly used statistical technique to pool 
results from two or more separate studies. The added value of a meta-analysis may 
include increased power and improved precision of the results. Therefore, we per-
formed a systematic review with meta-analysis of BMD in children and adults with CG. 
As recommended by the International Society for Clinical Densitometry (ISCD), low BMD 
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is defined here as a BMD Z-score ≤ -2.0 SD (21,22). We also explored the usefulness of 
other indicators of bone status as potential diagnostic or monitoring tools. 
METHODS 
Research question 
The primary outcome for our meta-analysis was bone mass reported as BMD (areal 
BMD), either as Z-score or as absolute measurement, assessed with dual energy X-ray 
absorptiometry (DXA) since this is the preferred tool for evaluating BMD/bone mass in 
both children and adults (21,22). BMD is a major determinant of bone strength and its 
assessment is considered the cornerstone in the diagnostics of low bone mass (23). 
Only areal BMD measurements were included in the analysis since these are most 
commonly used in clinical practice; results of estimated volumetric BMD were not in-
cluded.  
The secondary outcomes for our systematic review, reported in a descriptive way, 
were bone mineral content (BMC), parameters involved in bone metabolism such as 
vitamins, minerals, hormones, bone turnover markers (BTM), and fracture risk. 
Inclusion and exclusion criteria for study selection 
We included all original studies (cross-sectional study design, randomized controlled 
trial [RCT], cohort study, case-control study) as well as conference abstracts on bone 
health in children and adults with CG. If there was (potential) overlap between study 
cohorts, only the first/original article was included. Articles in a language other than 
English, and animal and cell studies were excluded.   
Search strategy  
A computerized literature search was conducted in MEDLINE, EMBASE and the 
Cochrane Library by one of the investigators (LW) and a trained clinical librarian from 
University of Amsterdam (see Supplementary data S1, Search strategies). Databases 
were searched initially in February 2015 and a final search was completed in July 2015 
to ensure the inclusion of recently published articles. No limits were used in these 
searches.  
Study selection 
Titles and abstracts generated by literature searches were screened by two separate 
researchers (BvE and LW) to select potentially eligible studies. Studies not relating to 
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the research question were excluded. Selected conference abstracts and full text arti-
cles of selected studies were independently reviewed by two authors (BvE and LW) for 
inclusion in the systematic review. In case of exclusion, the reason was reported. Addi-
tionally, reference lists from included trials and excluded narrative or systematic re-
views were hand-searched to identify additional relevant studies. Consensus was 
reached between the two authors regarding the eligibility assessments. 
Data extraction 
Data were extracted by two separate researchers (BvE and LW) according to predefined 
criteria (see Supplementary data S2a and S2b, Summary of evidence tables). Outcome 
measures of interest were BMD at any site measured with DXA; BMC; incidence of frac-
tures; BTM reflecting bone formation (bone-specific alkaline phosphatase, under-
carboxylated osteocalcin [ucOC], carboxylated osteocalcin [cOC]), bone resorption (N-
terminal telopeptide, C-terminal telopeptide) or bone modeling (insulin-like growth 
factor-1 [IGF-1]); and vitamins (vitamin D), minerals (calcium) and hormones (estradiol, 
parathormone) important for bone metabolism.  
Data collection processes 
If a mean BMD Z-score and/or standard deviation (SD) was not reported for the entire 
cohort in an article, the authors were requested to share either these variables together 
with mean age at testing and SD, or individual patient data (IPD). IPD included individual 
mean BMD Z-score with SD, age at testing and gender. The corresponding author was 
contacted first, and if there was no reply within four weeks, one of the other authors 
was contacted.  
Individual patient data integrity 
IPD were checked for integrity by reviewing completeness; in case of incompleteness 
the data were not included in the systematic review. If more data were received from 
the authors than originally published, these were only included if patient characteristics 
matched those from the original article. In case of any discrepancies, the authors were 
contacted.  
Assessment of quality and risk of bias in individual studies 
Quality appraisal and assessment of bias were performed with an appropriate checklist 
from the ‘Scottish Intercollegiate Guidelines Network’ (SIGN), if available (available for: 
RCT, non-RCT, cohort study, case-control study). Quality appraisal and risk of bias analy-
sis were performed and discussed by two independent investigators (BvE and LW). 
Chapter 6 
102 
Articles were appraised as low, acceptable or high quality; those assessed as low quality 
were excluded from the review.  
Data analysis 
We performed a meta-analysis of BMD to evaluate whether the mean BMD Z-score in the 
CG population differs from normative data (a mean BMD Z-score of zero in the general 
population). We used Review Manager 5.3 version 5.3.5 for the analysis. The inverse-
variance method was used to pool study data, and the individual effect sizes were 
weighted according to the reciprocal of their variance (24). I2 was used as a measure of 
heterogeneity (25). The p-value used to reject the null hypothesis of homogeneity was 0.1 
(p-value of Q; Q=chi squared statistic). In case of low heterogeneity (0-30%) a fixed effects 
model was used to pool data. In case of moderate to high heterogeneity (30-100%), both 
a fixed and random effects model were applied, resulting in a sensitivity analysis with 
description of differences between the fixed and random effects models and selection of 
the most appropriate model. Aggregate data and IPD were analyzed together using a two-
stage approach: for IPD, a mean BMD Z-score and SD were calculated first, and were then 
included in the next step as aggregate data. BMD Z-scores were pooled based on the 
measurement site (lumbar spine, total hip, femoral neck and total body). For the overall 
effect size, a p-value of 0.05 was considered statistically significant. Yet, in case of multiple 
testing, adjustment for Bonferroni correction was applied. 
In order to assess clinical relevance of the mean BMD Z-score of the CG population, 
the normal distribution was used to find the percentiles of Z-scores, and thus the esti-
mated proportion of patients with a BMD Z-score ≤-2 SD (low bone mass) using SPSS 
version 23. For this, two approaches were used, one with the SD of normative data 
(mean of zero, SD 1), another with the SD of the mean calculated in our meta-analysis.  
The secondary outcome measures (BMC, minerals, vitamins, hormones and BTM) 
were presented in a descriptive manner.  
RESULTS 
Study selection 
The literature search identified 138 potential publications of which 94 remained after 
removing duplicates (n=44). After screening the titles and abstracts of the unique publi-
cations, 71 were excluded because they did not relate to the research question. De-
tailed evaluation of the 23 selected publications led to the exclusion of 10 studies for 
various reasons (see Figure 1: Flow diagram selection process). 
For the meta-analysis, eight studies were selected because they encompassed BMD 
measurements. Only one of these studies reported all data required for inclusion (26); 
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the authors of the other 7 studies were contacted for additional information. Three 
authors provided the required data at request (3,27,28)(Supplementary data S3, Data 
collection process). Accordingly, a total of four articles were included in our meta-
analysis on BMD. 
A total of seven studies reported on our secondary outcome measures and were 
therefore included in the descriptive analysis. 
The complete study selection process is presented as a flow diagram, separately for 
the meta-analysis and the descriptive analysis (Figures 1a and 1b). 
 
 
Figure 1a: Flow diagram selection process meta-analysis. 
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Figure 1b: Flow diagram selection process descriptive analysis. 
Included studies 
Characteristics of the studies included in the meta-analysis or descriptive analysis are 
presented in Supplementary data S2a and S2b, Summary of evidence tables. Age of the 
patients in the included studies ranged from 2.5-59 years. 
Individual patient data integrity 
No issues with IPD integrity were detected.  
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Assessment of quality and risk of bias in individual studies 
A quality appraisal with the standardized checklist was applicable for only one study, a 
randomized controlled trial (8). The paper was graded high quality as defined by the risk 
of bias checklist for randomized-controlled trial of SIGN. 
Meta-analysis on BMD in classic galactosemia patients 
Four studies (three cross sectional studies and one retrospective case series) were in-
cluded in this meta-analysis of BMD Z-score (3,26–28). Panis et al. (2004) assessed 40 
patients with a mean age of 8.9 years (range 3.0-17.3). Waisbren et al. (2012) evaluated 
BMD in 33 patients with a mean age of 32.6 years (range 18-59). Doulgeraki et al. 
(2014) reported BMD Z-scores of 14 patients with a mean age of 13.16 years (range 
6.17-16.58 years). Tan et al. (2014) provided the individual patient data reported in 
their conference abstract as well as additional new data (n=5). The mean age in these 
25 patients was 13.5 years (range 5-41 years). Mean BMD Z-scores were calculated and 
are presented in Supplementary Data S2a. 
Complete cohort (children and adults) 
A total of 112 CG patients assessed in 4 studies were included in this part of the meta-
analysis. At the site of the lumbar spine, a mean BMD Z-score of -0.70 (95% CI: -0.88, -
0.52) was found (3,26–28). Heterogeneity was zero (I2 = 0%); a fixed effects model was 
used. The overall effect was statistically significant (p < 0.00001) when compared to the 
mean of normative data (BMD Z-score of zero). One of the studies crossed the line of no 
effect (Figure 2).  
 
Figure 2: Forest plot of lumbar spine BMD Z-score in complete CG cohort. 
 
In 58 pooled patients included in 2 studies, mean total hip BMD Z-score was -0.89 (95% 
CI: -1.14, -0.64)(3,27). Heterogeneity was zero (I2 = 0%); a fixed effects model was used. 
The overall effect was significantly different from the mean of normative data (p < 
0.00001) and none of the studies crossed the line of no effect (Figure 3).  
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Figure 3: Forest plot of total hip BMD Z-score of the complete CG cohort. 
 
At the site of the femoral neck, 73 CG patients from 2 studies were pooled (3,26). The 
heterogeneity was high (I2 = 91%), leading to determination of the mean BMD Z-score 
with both a fixed as well as a random effects model (Figures 4 and 5, respectively). A 
mean BMD Z-score of -0.63 was found with both models, with a difference in 95% con-
fidence interval (95% CI fixed effects model: -0.83, 0.44; 95% CI random effects model: -
1.29, 0.02). As heterogeneity was very high and both studies are of adequate quality 
with comparable cohort sizes, it was chosen to base conclusions on the results of the 
random effects model. Even though both studies did not cross the line of no effect, the 
overall effect was not significantly different from the mean of normative data when 
using the random effects model (p = 0.06) (Figure 5).  
 
Figure 4: Forest plot of femoral neck BMD Z-score in complete CG cohort (fixed effects model). 
 
 
Figure 5: Forest plot of femoral neck BMD Z-score in complete CG cohort (random effects model). 
 
Children with CG 
In pooled data from 76 children from 3 studies, mean lumbar spine BMD Z-score was -
0.64 (95% CI: -0.84, -0.43)(26–28). Heterogeneity was zero (I2 = 0%); a fixed effects 
model was used. This was overall significantly different from the mean of normative 
data (p < 0.00001). One study crossed the line of no effect (same study as in lumbar 
spine BMD Z-score analysis of the entire patient group) (Figure 6).  
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Figure 6: Forest plot of lumbar spine BMD Z-score in children with CG. 
Adults with CG 
In pooled data from 36 adults with CG included in 2 studies, mean lumbar spine BMD Z-
score was -0.94 (95% CI: -1.30, -0.57)(3,27). Heterogeneity was zero (I2 = 0%); a fixed 
effects model was used. The overall effect was statistically significant from the mean of 
normative data (p < 0.00001), and none of the studies crossed the line of no effect 
(Figure 7). 
 
Figure 7: Forest plot of lumbar spine BMD Z-score in adults with CG. 
 
Mean BMD Z-score at the total hip in this group of adults was -0.91 (95% CI: -1.20, -
0.63)(3,27). Heterogeneity was zero (I2 = 0%); a fixed effects model was used. One study 
crossed the no effect line, but the overall effect was significantly different from the 
mean of normative data (p < 0.00001) (Figure 8).  
 
Figure 8: Forest plot of total hip BMD Z-score in adults with CG. 
 
We could not perform a subgroup analysis on BMD Z-scores for adult males and adult 
females separately since one study included data on only one or two patients.  
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Clinical relevance 
The normal distribution was used to find the  percentiles of Z-scores, and thus the esti-
mated proportion of patients with a BMD Z-score ≤-2 SD (low bone mass). Two ap-
proaches were used: one with an SD of 1.9 (resulting from the 95% CI of the calculated 
mean lumbar spine BMD Z-score of -0.7 in the complete CG group) and one with an SD 
of 1.0 (according to the normal distribution curve of BMD in the general population). 
Accordingly, 10-25% of CG patients are estimated to be at risk for a BMD Z-score ≤ -2 
SD, and thus a low bone mass, whereas this is only 2.3% in the general population 
(normally distributed parameter).  
Descriptive analysis 
Other indicators of bone status in classic galactosemia 
Bone mineral content 
Another indicator of bone health is BMC, which reflects other aspects of bone mass 
acquirement than BMD and might therefore be of additional value in children (29). BMC 
of femoral neck, lumbar spine and total body was assessed in a single study by Panis et 
al. (2006) (40 patients, age range 3-17 years)(8). In this randomized-controlled trial, in 
which the effect of supplementation of calcium, vitamin K1 and vitamin D3 on bone 
health was studied, baseline measurements of BMC Z-scores in 40 children with CG (age 
3-17 years) were conducted. Mean BMC Z-scores (varying between -0.3 and -1.1 for 
different subgroups) were lower than in controls.  
Vitamins, minerals and hormones 
Six studies evaluated vitamin D status in CG patients (n=197)(3,26,30–33). One study 
assessed 1,25-OH-D concentrations only (26), four measured 25-OH-D only, and one 
evaluated both (32). The studies varied with regard to vitamin D reference ranges and 
units, and in some the specified range of desired vitamin D concentrations was not 
stated. Two studies in adults with CG reported that most patients had levels in the low 
reference range (3,33). Compliance to vitamin D supplements differed between the two 
cohorts. The remaining four studies, performed in children with CG, found vitamin D 
levels to be within reference range.  
Four studies with a total of 148 patients assessed serum calcium levels (26,30–32). 
In all studies calcium levels were found to be within reference range. Rubio-Gozalbo et 
al. (2002) found no correlation between BMD results and calcium intake in their cohort 
of children with CG (32).  
Parathormone was also measured in the studies by Rubio-Gozalbo et al. (2002) and 
Panis et al. (2004) and revealed values within reference range. Only one study meas-
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ured 17-beta estradiol levels in a cohort of 40 children aged 3-17.3 years (mean age 8.9 
years)(26). Mean levels did not differ from reference values.  
Bone turnover markers 
Four cross-sectional studies examined BTM in CG patients (26,30–32), three studies 
included children only (<18 years) and one study included patients up to 20 years. A 
total of 148 patients were included in these studies (range 11-62 patients/study). There 
were no studies reporting on markers of bone status in adult patients.  
Carboxy-terminal telopeptide of type 1 collagen, measured in all four studies, was 
found to be significantly reduced in children but not in adolescents when compared to 
controls. Panis et al. (2004) found it to be inversely correlated with BMD Z-score of the 
femoral neck and lumbar spine (26). Amino terminal telopeptide of type I collagen lev-
els were measured in two study cohorts and levels were found to be significantly low in 
both cohorts of CG children (26,32). Gajewska et al. (2008) reported about 30% higher 
values of bone-specific alkaline phosphatase in adolescents than in controls (31), 
whereas normal values were found in children. In addition, Gajewska et al. found in-
creased osteocalcin (OC; sum of carboxylated [cOC] and under-carboxylated osteocalcin 
[ucOC]) levels in adolescents with CG (31), whereas Panis et al. (2004) reported signifi-
cantly decreased cOC levels with normal ucOC levels in children (26). Normal values of 
OC (30,31) and cOC and ucOC (32) in children were reported in three studies. Further-
more, Panis et al. (2004), the only study measuring IGF-1 levels, reported reduced IGF-1 
Z-scores in children (26) and found that IGF-1 Z-score was a strong positive predictor of 
femoral neck and lumbar spine BMD. 
Fracture history 
Waisbren et al. (2012) reported that 45% of 33 patients (mean age 32.6 years, range 18-
59) had broken a bone, six during childhood and the others at ages 20 to 46 years (3). 
DISCUSSION 
In this systematic review we evaluated bone mass in patients with CG through a meta-
analysis of BMD. The results of our meta-analysis indicate that mean bone mass in the 
CG population, reflected by mean BMD Z-score, is more than a half-standard deviation 
lower than in the general population.  While this is still within two SD of the normative 
mean, this result indicates that an increased proportion of individuals with CG will have 
a BMD Z-score ≤ -2 SD, and thus a low bone mass for age, as compared to individuals in 
the general population. Based on the meta-analysis, estimated prevalence of BMD Z-
score ≤-2 SD in patients with CG is 10% to 25%, which is higher than in the general pop-
ulation (2.3%). Mean BMD Z-scores in pooled data of adults and children with CG were 
reduced at all sites (lumbar spine -0.70, total hip -0.89, femoral neck -0.63), of which 
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only the latter was not statistically significant, probably due to heterogeneity between 
included study cohorts. Findings from our descriptive analysis support the need for 
improved evaluation and optimization of vitamin D concentrations. Though serum calci-
um levels were within reference range in all studies that addressed calcium status, en-
suring sufficient intake of calcium remains a point of attention in this population. Data 
on the role of BMC and BTM as other indicators of bone status are very limited and, in 
the case of BTM, highly ambiguous. Therefore, routine screening of these indicators in 
CG patients does not seem of additional value at present. Literature on bone mass in CG 
is scarce and study cohorts are small as a result of the rarity of the disease. This limits 
the number of studies and patients included in our meta-analysis, which hampers ex-
tensive subgroup analyses and solid conclusions. However, this systematic review is 
currently the most comprehensive study evaluating bone health in CG patients, thereby 
providing results that are more representative for the whole population of CG patients.  
This study was limited in that not all original patient data could be obtained. In addi-
tion, data used in this study were all cross-sectional, and conclusions about progression 
over time must therefore be interpreted with caution. Longitudinal studies following 
patients in time are needed to enable firm conclusions on this. Moreover, ISCD recom-
mendations for pediatric DXA (34) were not unanimously followed by the researchers, 
as they used different sites of measurement and did not take into account the presence 
of short stature or growth delay, with the exception of only one study (28). Further-
more, data on fracture history were obtained in only one study (3), though this is re-
quired to establish a diagnosis of osteoporosis. Future studies should consider the ISCD 
recommendations to further improve insights on bone health in CG. 
CONCLUSIONS 
BMD Z-scores in individual CG patients are within two SD of the normative mean in the 
majority of patients with CG. However, results from our meta-analysis demonstrate that 
the mean BMD Z-score in the CG population is lower than the mean BMD Z-score in the 
general population. These results suggest that bone health in general is mildly affected, 
and that an estimated proportion of 10-25% of patients with CG could be at risk for a 
low bone mass (BMD Z-score ≤-2) as compared to the general population. With the 
currently available literature, which lacks data on fracture prevalence, it is impossible to 
draw conclusions about osteoporosis risk. Vitamin D levels are low in many patients, 
emphasizing the need for monitoring of 25(OH)D levels and vitamin D supplementation. 
Optimization of calcium intake remains important. Evaluation of the importance of 
other parameters of bone health (BCM, BTM, hormones) was inconclusive due to a 
limited number of studies with inconsistent results. Concluding, it is important that 
treating physicians are aware that patients with CG are at risk for having or developing 
low bone mass, so that patients will be screened and treated appropriately. 
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SUPPLEMENTARY DATA S1: SEARCH STRATEGIES 
Searches in all databases were performed in February 2015.  
Search strategy MEDLINE 
1  galactosemias/ 
2  (galactosem* or ((galt utp hexose 1 phosphate uridyltransferase or gale or galk or galactokinase) adj3 
deficien*)).tw. 
3  1 or 2 
4  Bone Density/ 
5  Bone Diseases, Metabolic/ 
6  exp bone resorption/ 
7  exp "Bone and Bones"/ 
8  (Calcium/ or vitamin d/ or vitamin k/) and (me or bl).fs. 
9  Absorptiometry, Photon/ 
10 Osteocalcin/ 
11 ((bone adj3 density) or bone mass or fractures or fracture or bone metabolism or bone resorption or 
osteolysis or bone loss or bone mineral* or osteoporosis or osteolysis or skeletal health or bone turn 
over or dxa or dual energy x ray).mp,kf. 
12 exp Fractures, Bone/ 
13 or/4-12 
14 3 and 13 
 
Search strategy EMBASE 
1 galactosemias/ 
2 (galactosem* or ((galt utp hexose 1 phosphate uridyltransferase or gale or galk or galactokinase) adj3 
deficien*)).tw. 
3 1 or 2 
4 Bone Density/ 
5 Bone Diseases, Metabolic/ 
6 exp bone metabolism/ 
7 exp "Bone and Bones"/ 
8 Calcium/ec or vitamin d/ec or vitamin k/ec 
9 Absorptiometry, Photon/ 
10 Osteocalcin/ 
11 ((bone adj3 density) or fracture or fractures or bone mass or bone resorption or bone metabolism or 
bone loss or bone mineral* or osteoporosis or osteolysis or skeletal health or bone turn over or dxa 
or dual energy x ray).mp,kw. 
12 exp Fractures, Bone/ 
13 calcium blood level/ 
14 or/4-13 
15 3 and 14 
Cochrane Library 
Search in Title, Abstract, Keywords: galactosemias (MeSH term)  
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ABSTRACT 
Decreased bone mass is frequently encountered in classic galactosemia, an inborn error 
of galactose metabolism. This decrease is most prominent in adults, but is already seen 
in prepubertal children with increased risk of osteoporosis and fractures later in life. 
Therefore, bone health in patients with classic galactosemia is increasingly monitored. 
Although the pathophysiological mechanism is still not fully understood, several factors 
could negatively affect bone metabolism in this disease. Patients are at risk of nutrition-
al deficiencies due to the galactose-restricted diet. Primary ovarian insufficiency (POI) in 
female patients also contributes to decreased bone mass. Furthermore, patients with 
classic galactosemia might be less physically active due to motor or neurological im-
pairments. A disease specific intrinsic abnormality has been suggested as well. This 
revised proposal is an update of the 2007 recommendations. In this current approach 
we advise comprehensive dietary evaluation, optimization of calcium intake if needed, 
monitoring and if necessary supplementation of vitamin D, hormonal status evaluation 
and hormone replacement therapy (HRT) consideration, as well as a regular exercise 
and assessment of skeletal deformities and clinically significant fractures. We propose 
bone mineral density (BMD) assessment by serial DXA scans of lumbar spine, femoral 
neck and total hip in adults and lumbar spine and total body less head (TBLH) in chil-
dren.  
  
7Revised proposal for the prevention of low bone mass in classic galactosemia 
123 
INTRODUCTION 
Decreased bone mass is frequently encountered in classic galactosemia (OMIM 
230400), an inborn error of galactose metabolism (1-7). This decrease in bone mass is 
most prominent in adults, but is already seen in prepubertal children (4-6). Since bone 
mass increases quickly during puberty and reaches its peak at the end of adolescence or 
early adulthood, a low bone mass at an early age predisposes to osteoporosis and an 
increased risk of fractures later in life (8). Therefore, bone health in patients with classic 
galactosemia is increasingly monitored. 
Scarce data are available with regard to reduced bone mass and its clinical relevance 
in this patient population. The average reported bone mineral density (BMD) as as-
sessed by dual-energy X-ray absorptiometry (DXA) in adults with galactosemia is more 
than one standard deviation (SD) below the mean, even about 25 to 30 percent of pa-
tients has a BMD more than 2 SD below the mean (1, 7), whereas in pediatric patients 
with galactosemia the average is between 0 and -1 SD (5, 6). Fracture rates in adult 
patients with classic galactosemia have been reported between 31 and 63 percent (1, 
7), which is slightly higher than in the general population in which rates between 21 and 
53 percent have been reported for this age category (9). Only one study addresses the 
fracture rates in pediatric patients (7), and the reported prevalence of 18 percent is not 
higher than in the healthy pediatric population (10).  
Although the pathophysiological mechanism is still not fully understood, several fac-
tors could negatively affect bone metabolism in this disease. Due to the galactose-
restricted diet, patients are at risk of developing nutritional deficiencies. The primary 
ovarian insufficiency (POI) with low estradiol levels in females with galactosemia predis-
poses affected females to decreased bone mass. A disease specific intrinsic abnormality 
such as abnormal glycosylation of collagen or other glycoproteins involved in bone me-
tabolism has also been suggested (4). Furthermore, the decreased IGF-I and IGFBP-3 
concentrations that are found in galactosemia patients might be involved (11).  
For classic galactosemia, optimization of exogenous factors influencing the bone 
mass is considered the most important intervention. The latest recommendations re-
garding follow-up and treatment of reduced bone mass in this disease date from 2007 
(12). Since then, insights regarding different aspects of bone health have increased and 
there is a need to update and expand the previous recommendations based on our 
experience and the current literature. This proposal shortly reviews the diagnostic pro-
cedure and recommendations for follow-up including DXA, dietary evaluation, biochem-
ical markers, physical activity, and in females supplementation of estrogen.  
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DIAGNOSTIC PROCEDURES 
Dietary evaluation and bone metabolism markers 
A balanced diet sufficient in energy, protein and micronutrients is a criterion for achiev-
ing and maintaining a high bone mass. Recently, it has been shown that body weight 
and Body Mass Index (BMI) correlate with bone mass in patients with classic galactose-
mia, emphasizing the need for monitoring caloric intake in this group (1). Evaluation of 
food records or food frequency questionnaires, preferably by a nutritionist, can be used 
to determine a patient’s general nutrition status and to assess the completeness of a 
patient’s diet.  
The galactose-restricted diet predisposes patients to nutritional deficiencies, includ-
ing a calcium deficiency. Dietary calcium intake therefore needs to be monitored, as is 
also recommended for other metabolic diseases in which the bone health is often af-
fected. The recommended daily dietary calcium intake, which varies slightly per coun-
try, can be used as reference (table 1). 
Adequate vitamin D status, assessed by dietary and laboratory evaluation, is also re-
quired for optimal bone health. The preferred marker for vitamin D status is the total 
25-hydroxyvitamin D (25(OH)D) serum concentration. Measurement of 1,25(OH)2D is 
not recommended, since these concentrations do not reflect vitamin D reserves and 
can even be normal or elevated in patients with vitamin D deficiency due to secondary 
hyperparathyroidism (13). It is advised to aim for a total 25(OH)D serum concentration 
higher than 30 ng/mL (75 nmol/L) in patients at risk of developing osteoporosis and this 
requires a vitamin D intake of at least 400-1000 IU per day (13) (Table 1).  
 
Table 1: Recommended dietary allowances of calcium (Institute of Medicine 2011) and vitamin D (Holick et al 
2011) for different age groups in case of risk for low bone mass. 
Age  Calcium  Vitamin D  
<1 year 200-260 * 400-1000 IU/day 
1-3 years 700   mg/day 600-1000 IU/day 
4-8 years 1000 mg/day 600-1000 IU/day 
9-13 years 1300 mg/day 600-1000 IU/day 
14-18 years 1300 mg/day 600-1000 IU/day 
19-70 years 1000 (M) or 1200 (F) mg/day 1500-2000 IU/day 
>70 years 1200 mg/day 1500-2000 IU/day 
* Reflects adequate intake value, since a recommended dietary allowance value has not been established for 
this group 
M = value for males; F = value for females. 
 
The importance of vitamin K in acquiring adequate bone mass remains controversial. 
Several studies, including one study in patients with classic galactosemia, have reported 
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that supplementation positively affects bone mass when combined with calcium and 
vitamin D. Panis et al (2006) showed that supplementation of vitamin K increased the 
concentration of carboxylated osteocalcin, which is required for the incorporation of 
calcium and hydroxyapatite in the bone (14). Braam et al (2003) found a slower bone 
loss in post-menopausal women receiving vitamin K in combination with calcium and 
vitamin D (15). However, there is also evidence that vitamin K does not increase bone 
mass (16). 
Other nutrients that might be important for bone metabolism include zinc, phos-
phorus and magnesium. There have been concerns that soy formula might have a nega-
tive effect on bone metabolism and growth due to its high phytate content, which caus-
es reduced absorption of zinc. However, in a recent meta-analysis, zinc serum concen-
trations were found to be similar in children who were fed soy infant formula during 
infancy compared to children fed human milk or cows’ milk-based formula during infan-
cy (17). Therefore, soy feeding related zinc deficiency is unlikely and measuring zinc 
concentrations is not recommended. Deficiencies of phosphorus and magnesium are 
unlikely in a balanced diet, and therefore routine monitoring is not advised for patients 
at risk of developing low bone mass. However, serum phosphate and serum magnesium 
require special attention when dietary assessment indicates an insufficient diet. Fur-
thermore, there is some evidence that a high phosphorus intake, resulting from food 
additives, combined with a low or normal calcium intake may have adverse effects on 
bone metabolism due to a disturbed ratio of calcium-to-phosphorus intake (18). How-
ever, further research in this field is required to define adequate phosphate concentra-
tions.  
Other biochemical markers for bone metabolism, including carboxylated and uncar-
boxylated osteocalcin (cOC, ucOC), bone specific alkaline phosphatase (BAP), amino 
terminal telopeptide (NTX) and carboxy terminal telopeptide (CTX) are at this point only 
recommended in research settings.  
Estrogen supplementation 
In females, hypergonadotropic hypogonadism needs to be assessed by measuring FSH, 
LH and beta-estradiol concentrations. Estrogen is a powerful inhibitor of bone resorp-
tion via the alpha and beta estrogen receptors on osteoblasts and osteoclasts, and low 
levels negatively influence bone metabolism. Evaluation of these hormones and referral 
to a pediatric endocrinologist should start from the age of 10-12 years (19).  
Physical activity evaluation 
Sufficient physical activity is required to achieve optimal bone mass. The World Health 
Organization (WHO) recommends 60 minutes of moderate- to vigorous-intensity physi-
cal activity per day for children and 150 minutes per week for adults. However, this is 
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often not achieved. Furthermore, patients with classic galactosemia might be less phys-
ically active due to motor dysfunction (20) and less participation in social activities (21). 
Regular evaluation of physical activity in patients with this disease is therefore im-
portant and a standardized questionnaire, for instance the Physical Activity Question-
naire for Children and Adolescents (PAQ-C/A), can be used for this (22). 
Assessment of spinal deformities 
Scoliosis and hyperkyphosis are seen in 1-5 percent of all children in the general popula-
tion and seem to be partly related to reduced bone mass and neurological abnormali-
ties (23). Scoliosis is defined as a lateral curvature of the spine that is more than 10 
degrees on a conventional X-ray in standing position. A hyperkyphosis is defined as a 
kyphosis of more than 45 degrees. We observed a prevalence of 29 percent of these 
spinal deformities in a cohort of patients with classic galactosemia (n=24, 14 females 
and 10 males, age range 13-48 years with a mean of 22 years), which is surprisingly 
higher than reported in the general population (unpublished results). A relationship 
between galactosemia and deformities of the spine has not been reported. It is ques-
tionable whether the observation in our cohort represents a real phenotypical charac-
teristic or whether it is a coincidental finding. Yet, we advise to perform physical exami-
nation of the spine.  
Dual energy X-ray absorptiometry 
The method of choice to evaluate the bone mass is with dual energy X-ray absorptiome-
try (DXA) scans, since this is a safe and relatively easy method with low exposure to radi-
ation and low costs. Recently, the 2013 recommendations of the International Society for 
Clinical Densitometry have been published (24, 25). For postmenopausal women and 
men aged 50 years or older DXA scans of the lumbar spine, femoral neck and total hip 
are advised and T-scores are preferred to express the decrease in BMD. However, in 
premenopausal women and men younger than 50 years of age Z-scores taking into ac-
count age, gender and ethnicity are preferred. Also for children Z-scores are preferred 
and the results should be adjusted in children with short stature or growth delay. Meas-
urements of the BMD of the lumbar spine and the total body less head (TBLH) are rec-
ommended in children, since they yield the most reliable results. DXA scans of the femur 
have been proven to be unreliable in children and total body scans with head might give 
false positive outcomes due to the relative large size of the head during childhood.  
In postmenopausal women and men aged 50 years or older, a BMD T-score ≤ -1.0 
standard deviation (SD) is diagnostic of low bone mass (formerly called osteopenia), 
while a T-score ≤ -2.5 SD is diagnostic of osteoporosis. A BMD Z-score ≤ -2.0 SD in 
premenopausal women or males younger than 50 years of age is defined as a BMD 
below the expected range for age, whereas a Z-score > -2.0 SD represents a BMD within 
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the expected range for age (25). In children the diagnosis of osteoporosis requires ei-
ther the finding of one or more vertebral compression fractures or the presence of both 
a BMD Z-score ≤ -2.0 SD and a clinically significant fracture history, meaning two or 
more long bone fractures by age 10 years, or three or more long bone fractures at any 
age up to 19 years. A Z-score < -2.0 SD without a clinically significant fracture is classi-
fied as a low BMD (24).  
FOLLOW-UP AND THERAPEUTIC INTERVENTIONS 
Dietary evaluation and bone metabolism markere 
Batey et al (2013) found that most adults with galactosemia do not routinely visit a 
nutritionist, which might have implications for their bone health (1). Since a balanced 
diet is important for maximizing bone accrual during adolescence as well as for main-
taining bone mass during adulthood, regular dietary evaluation throughout life is desir-
able. We recommend yearly dietary assessment, preferably by a nutritionist, with spe-
cial focus on energy, protein, and micronutrient requirements. In case a patient’s diet is 
suboptimal, enhanced nutritional counseling is essential to optimize a patient’s general 
diet taking into account limitations deriving from galactose-restriction. Special focus on 
vitamin D and calcium intake is suggested, including yearly evaluation of total 25(OH)D 
serum concentrations. We recommend supplementation of calcium and vitamin D when 
intake is lower than the recommended daily intake and does not normalize despite 
dietary optimization. When vitamin D supplementation has been initiated, more fre-
quent monitoring of 25(OH)D serum concentrations might be helpful in determining the 
optimal dosage. Supplementation of vitamin K might be beneficial when combined with 
an adequate intake of calcium and vitamin D, but currently there is not enough evi-
dence to recommend the routine use of vitamin K supplements. 
Estrogen supplementation: 
If evaluation of hormone status indicates hypergonadotropic hypogonadism, initiation 
of hormonal replacement therapy (HRT) needs to be considered. The decision to start 
supplementation during adolescence will have to take into consideration growth, psy-
chological factors and bone measurements. Duration of HRT throughout adult life will 
depend on an individual assessment of the possible risks and benefits.    
Physical activity evaluation 
We advise physicians to assess a patient’s physical activity and to encourage exercise 
when evaluation suggests that the patient does not meet the recommendations. Im-
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plementation of a regular routine of weight bearing exercise is recommended, taking 
into consideration possible physical limitations. 
Assessment of spinal deformities 
For now, we recommend physicians to evaluate for possible spinal deformities during 
routine physical examination. In case of clinical suspicion, an X-ray of the entire spine 
with a Cobb angle is recommended and subsequent referral to an orthopedist for ex-
tensive evaluation may be considered (26). 
Dual energy x-ray absorptiometry 
It is advised to assess BMD from an early age to ensure that optimal bone mass is 
reached in early adolescence. We recommend the first DXA to be performed at the age 
of 4 years, or as soon as the child is able to lie still, since a decreased bone mass can 
already be present at this early age. In children the minimum time interval between 
subsequent DXA scans is 6-12 months (ISCD 2013). We suggest yearly DXA scanning 
when BMD is ≤ -2.0 SD and one DXA scan per two years when BMD is higher. In adults it 
is advised to repeat a DXA scan one year after initiation or change of therapy (25). The 
interval can be increasingly elongated once the BMD is stable.  
Furthermore, we recommend regular assessment of fracture history in order to de-
termine whether a pediatric patient meets osteoporosis criteria and to evaluate the 
clinical relevance of a patient’s reduced bone mass. In patients with frequent clinically 
relevant fractures additional pharmacological therapy needs to be considered. 
CONCLUSION 
Our recommendations regarding assessment and follow-up of decreased bone mass in 
patients with classic galactosemia (Figure 1): 
- Dietary evaluation to assess adequacy of a patient’s diet. 
- Optimization of calcium intake, either improvement of dietary intake (preferably) or 
supplements.    
- Monitoring of vitamin D status by dietary assessment and laboratory measurement 
of total 25(OH)D concentrations. If total 25(OH)D serum concentrations are < 30 
ng/mL (< 75 nmol/L) intake should be improved through diet or supplements. 
- Hormonal status evaluation in females, in case of hypergonadotropic hypogonadism 
HRT should be considered. Initiation and duration of treatment should take into 
consideration potential harms and benefits.  
- Assessment of physical activity using standardized questionnaires. In case the WHO 
recommendations are not met, exercise needs to be encouraged. 
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- Evaluate for spinal deformities, since these might be more prevalent in this patient 
group, and fracture rate estimation. 
- DXA as the tool to monitor BMD. DXA scans of the lumbar spine and TBLH are ad-
vised in children, whereas for adults DXA scans of the lumbar spine, femoral neck 
and total hip are preferred.  
 
 
Figure 1: Flow chart for the follow-up of bone health in patients with classic galactosemia. 
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The work presented in this dissertation aims to further investigate the chronic compli-
cations of classic galactosemia. The research builds up on previous work presented in 
other theses brought forth by the Galactosemia Research Group Maastricht. Objectives 
included the development of a new disease model, as well as improved understanding 
and patient care with regard to fertility, brain and bone impairments in this disorder.  
DEVELOPMENT OF A ZEBRAFISH MODEL 
In order to move classic galactosemia research forward, there was a high need for a 
novel disease model. The existing models, the Drosophila melanogaster model (1) and 
the mouse model (2), showed their importance for disease pathogenesis studies (3-8), 
yet do not meet the features demanded to fulfill two key investigations for the field: 1) 
organ studies throughout development in order to answer the long-standing open 
question if, and to what extent, prenatal organ damage occurs; 2)  rapid and efficient 
testing of pharmacological compounds in order to establish new therapeutic approach-
es. The external development of the zebrafish, the availability of transgenic reporter 
lines and the accessibility to sophisticated imaging techniques make it an outstanding 
tool for organ studies from embryonic stage to adulthood. Furthermore, zebrafish mod-
els are amenable to high-throughput screening due to the large numbers of offspring, 
and are therefore increasingly used in pharmacological studies (9). 
In chapter 2 we describe the generation of a galt knockout zebrafish model and 
demonstrate that our transgenic line recapitulates the human phenotype. At a bio-
chemical level, an essentially complete lack of detectable galt enzyme activity and, upon 
exposure to exogenous galactose, accumulation of high concentrations of Gal-1-P were 
confirmed. The galt knockout fish develop reduced physical activity and a premature 
decline of egg production, which resembles the neurological sequelae and primary 
ovarian insufficiency found in humans with classic galactosemia. 
Future investigations will encompass in-depth evaluation of damage to gonads and 
brain. Transgenic zebrafish lines that carry tissue-specific promoters driving green fluores-
cent protein (GFP) expression provide rapid, real-time in vivo developmental systems for 
analyzing tissue and organ development (9). Accordingly, to study gonads and brain, we 
crossed our galt knock-out transgenic zebrafish line to two reporter lines: a reporter line 
with fluorescent primordial germ cells (PGCs) (vasa:GFP) (10), and a reporter line with 
fluorescent myelin (mbp:GFP) (11). By generating a galt knockout line with labeled PGCs 
and a galt knock-out line with fluorescent myelin, we established two models to study the 
damage to gonads and brain from embryonic stage to adulthood. Future studies in these 
models (by Dr. Ana I. Coelho, Marie Curie postdoctoral fellow) will provide important 
information on when and to what extent damage to these target organs occurs.   
Future investigations also encompass the exploration of glycosylation patterns and 
the implications of aberrant glycosylation for molecular pathways and organ function-
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ing. Additionally, in-depth microscopic evaluation of the eye lens of galt knockout 
zebrafish is considered in order to evaluate the potential development of cataracts 
upon exposure to exogenous galactose (12). 
Furthermore, a p.Q188R galt knock-in zebrafish will be developed to support the es-
tablishment of alternative therapeutic approaches such as pharmacological chaperones. 
Previous studies have demonstrated that enzymatic impairment of the most frequent 
GALT variants, including p.Q188R which affects about 60% of patients at a worldwide 
scale (13), results from altered protein folding, followed by aggregation and rapid de-
struction of the misfolded GALT protein (14-16). Pharmacological chaperones - mole-
cules that have the ability to stabilize (misfolded) proteins (17-19) - have therefore been 
suggested as potential therapeutic agents for this disorder (14, 15). By changing protein 
conformation, the stability and activity of the protein is increased. Since individuals with 
a GALT activity of >10% are generally not considered patients (20), only a slight eleva-
tion of residual enzyme activity might be sufficient to prevent chronic impairments. As a 
result of the high prevalence of p.Q188R within the galactosemia population, many 
patients could potentially benefit from a chaperone treatment. The p.Q188R galt knock-
in zebrafish model is designed to evaluate the effect of pharmacological chaperones 
using a high-throughput screening approach. One of the compounds of interest is argi-
nine, an amino acid with high therapeutic potential as a pharmacological chaperone and 
outstanding in vitro results (21).  
OVARIES 
The second aim of this dissertation was to further investigate the clinical implications of 
primary ovarian insufficiency (POI), which is present in nearly all females with classic 
galactosemia from an early age on and entails the struggle of having reduced pregnancy 
chance. Though POI reflects a continuum of impaired ovarian function, which is varying, 
unpredictable and does not exclude pregnancy (22, 23), fertility counseling of women 
with classic galactosemia and POI has remained of discouraging nature throughout the 
past years. In chapter 3 we present the first international, large-scaled epidemiological 
study on fertility in these patients. Our findings suggest that pregnancy rate is higher 
than expected, with a prevalence of 42.9% in our cohort, even though many women did 
not try to conceive due to negative counseling. If women with classic galactosemia and 
POI try to conceive for a longer period of time (>2 years) as compared to couples in 
general, it is estimated that >60% conceive within 2.5 years. These data fortify the re-
sults of earlier work from our group (24, 25) and underline the paradigm that these 
women have a significant chance of spontaneous conception. Accurate fertility counsel-
ing is thus important to encourage pregnancy attempts in those with an active child-
wish and to prevent unplanned pregnancies in those who have no intention of ever 
having children.  
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We evaluated several characteristics that could potentially affect an individual’s 
chance of spontaneous conception, including a history of a spontaneous menarche and 
the p.Q188R/p.Q188R mutation. However, our data did not confirm a statistically signif-
icant effect of any of these features. Furthermore, anti-Müllerian hormone (AMH) con-
centrations and ovarian imaging results (MRI, ultrasound) do not accurately predict 
fertility outcome in this population (26, 27). Taken together, adequate markers of fu-
ture pregnancy chance are lacking, which should be taken into account in reproduction 
counseling. 
POI and the consequent chance of reduced fertility are considered a major burden 
by both patients and their parents (28). As a result, many questions exist regarding the 
option to preserve fertility. Consensus on the application of fertility preservation tech-
niques in this population was lacking, and therefore we felt there was a need to develop 
recommendations, elaborated with the support of an international multidisciplinary 
expert team (chapter 4). We proposed that the uncertainty surrounding the success of 
fertility preservation in this group and the significant chance of spontaneous pregnancy 
warrant counseling towards conservative application of these techniques. In case fertili-
ty preservation is deeply wished for, cryopreservation of ovarian tissue in young pre-
pubertal girls in a research setting currently could be considered. In order to improve 
knowledge on long-term outcome and establish revised recommendations in the future, 
reports of longitudinal follow-up of patients after ovarian tissue cryopreservation in a 
research setting is important. 
As briefly discussed in chapter 4, another potential approach for galactosemic wom-
en to preserve their fertility is oocyte donation, often by a family member or acquaint-
ance. Though adult patients can seek for donors when pregnancy is desired, there is a 
tendency of intrafamilial egg donation at a very early stage, i.e. a mother donating oo-
cytes to her (newborn) girl with classic galactosemia. Though from a medical perspec-
tive this early intervention is needed to secure high quality of the donated oocytes, the 
procedure of a mother donating to her young daughter can be considered concerning. 
Ethical dilemmas that may arise include psychosocial pressure on the mother (to donate 
oocytes) and the recipient (to use the donated eggs), over-attachment of the donor to 
the offspring, and role confusion for all persons involved, including the resulting off-
spring (29, 30). In addition, galactosemia-specific issues require consideration, including 
the daughter’s unpredictable chance of developing cognitive impairments and psycho-
social difficulties later in life (31-40). Thorough evaluation of the potential benefits and 
risks by a multidisciplinary group is currently ongoing. 
BRAIN 
The third objective of this thesis was to further improve our understanding of the pallet 
of brain impairments encountered by patients with classic galactosemia. Chapter 5 is 
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dedicated to a study within the field of cognitive neuroscience that builds up on previ-
ous work by our group (41).  These earlier investigations used innovative magnetic res-
onance imaging (MRI) techniques to demonstrate structural abnormalities of white and 
grey matter in this disorder. Also, alterations in functional brain networks involved in 
speech and language production were revealed during a language task. In addition to 
task-based functional MRI (fMRI) studies, resting-state fMRI investigations, in which 
neuronal connectivity in absence of a specific stimulus or task is assessed, are increas-
ingly conducted within multiple fields of neuroscience to study the organization of core 
processing systems of the brain. These investigations allow exploration of the overall 
functional organization of brain networks, which had not been studied before in classic 
galactosemia. Therefore, we conducted a resting-state fMRI study in 13 adolescent 
patients and 13 healthy age- and gender-matched controls. A seed-based correlation 
analysis (SCA) was used to evaluate intrinsic functional brain networks during rest. Re-
sults showed robust group differences in resting-state functional networks involved in 
sensory-motor integration, (visuo)spatial orientation and capacities, motor (speech) 
planning, language production and working memory. Most importantly, across several 
seed analyses, altered functional connectivity to the lingual gyrus, the precentral gyrus, 
the insula and the cuneus was observed in patients, suggesting these brain regions 
might be of special relevance. In addition, these differences in network connectivity 
correlated with clinical test results in patients, supporting a relation between functional 
abnormalities and the clinical phenotype. In the future, more thorough investigations of 
these specific brain regions are needed to evaluate their potential role in pathogenesis. 
In the current study, eight brain regions were a priori selected as seeds for a SCA, 
based on previous studies indicating altered structure, function and/or metabolic activi-
ty of these regions (42-44). Future fMRI studies might consider an independent compo-
nent analysis (ICA) approach, which is data-driven and examines the general pattern of 
unique functional connectivity across the brain, without selection of a specific region of 
interest/seed (45-47). As a result, this approach might yield a more extensive evaluation 
of resting-state networks. Additionally, future studies are required to thoroughly inves-
tigate functional connectivity of the cerebellum at rest, since this brain structure was 
not entirely included in the functional coverage of the current study. Though functional 
connectivity of the cerebellum was not particularly affected in our study, cerebellar 
involvement is often suggested to be involved in the pathogenesis of neurological se-
quelae, motor problems and potentially language and speech disorders (48, 49).  
Our findings contribute to the characterization of the functional brain impairments 
in this enigmatic disease. However, in order to provide more detailed hypotheses on 
the pathogenesis of these deficits, investigations of longitudinal data and a systematic 
comparison of results of structural and functional brain imaging studies are needed. 
Longitudinal MRI data could provide information on the general disease process and 
progression over time. As a result, these data may give insight in whether future per-
formance and disease outcome at an individual level can be predicted, which is espe-
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cially important for the development of tailored treatment approaches. By combining 
data on white and grey matter structure with functional network assessments, it might 
become more clear whether the fMRI alterations represent specific targeted damage, 
or whether brain regions/networks with aberrant functional connectivity are equally 
affected as other regions but show a more prominent functional impairment. Alterna-
tively, these differences in functional connectivity might reflect compensation mecha-
nisms to cope with cognitive difficulties. 
BONE 
With this dissertation we also aimed to gain more insight in the extent and clinical im-
plications of impaired bone health in this disease. The first report of an association 
between classic galactosemia and decreased bone mass dates back to 1993 (50), and 
the Galactosemia Research Group Maastricht extensively studied this long-term compli-
cation in the past (51). However, its extent and relevance for patient care remained 
undefined due to limited sample sizes of previous investigations. Therefore, we con-
ducted a systematic review and meta-analysis on bone mineral density (BMD) in adults 
and children with classic galactosemia, which is presented in chapter 6. Results indicate 
that bone health in general is mildly affected, and that an estimated proportion of 10-
25% of patients could be at risk for a low bone mass (BMD Z-score ≤-2). As a result, it is 
important that treating physicians are aware that patients are at risk for having or de-
veloping low bone mass, warranting appropriate screening and treatment.  
Thus far, the pathogenesis of bone mass reduction in this disorder remains poorly 
understood. Since nutritional deficiencies and decreased estrogen concentrations alone 
do not seem to fully explain the low bone mass in this population (50, 52, 53), an intrin-
sic bone defect due to aberrant glycosylation has been suggested (50, 54-56). Evalua-
tion of glycosylation patterns of proteins and hormones involved in bone metabolism 
could shed new light on the pathogenesis, thereby providing relevant information for 
bone health management.  
As a result of evolved experience with classic galactosemia and improved knowledge 
on bone mass in general, we felt the 2007 recommendations on bone health monitoring 
in this group required an update (57). A revised strategy for diagnosis, treatment and 
follow-up of reduced bone mass in this population is outlined in chapter 7. Frequent 
evaluation of nutritional status, vitamin D levels, calcium intake, estrogen concentra-
tions and physical activity, as well as regular monitoring of BMD using dual-energy X-ray 
absorptiometry (DXA) scans, were suggested. We advised yearly DXA scanning in case of 
low bone mass and one scan per two years in case of adequate bone mass, with elonga-
tion of the intervals once BMD is considered stable. Evolved insights on the estimated 
proportion of patients at risk for low bone mass suggest that the DXA monitoring fre-
quency could be reduced, particularly in those patients with accurate bone mass. Fu-
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ture scientific investigations and improved clinical experience will have to define an 
optimal DXA monitoring rate. 
In chapter 7 we suggest a possible association between classic galactosemia and spi-
nal deformities, such as scoliosis and hyperkyphosis. We observed that 29% of patients 
from our cohort suffered from spinal deformities, whereas a prevalence of 1-5 % is re-
ported in the general population (58). Development of these deformities has been asso-
ciated with, among others, impaired strength of connective tissue, (paraspinal) muscle 
abnormalities, reduced bone mass of the lumbar spine and epigenetic factors (59-61), 
which could have a role in the increased prevalence observed in our cohort. Systematic 
evaluation of the prevalence of spine deformities in a large cohort, and comparison to a 
matched control group or the general population, is needed to explore this potential 
deficit. It is expected that the patient registry of the Galactosemia Network (GalNet), an 
international network of galactosemia treatment centers from 18 European countries, 
the United States of America (USA) and Australia (www.galactosemianetwork.org), will 
provide large-scaled, cross-sectional insights in this matter, as well as in many other 
aspects of the clinical phenotype of patients with this metabolic disorder.    
CONCLUSIONS 
The studies presented in this dissertation provide new perspectives on the chronic im-
pairments of ovaries, brain and bone in classic galactosemia through a combination of 
basic and clinical research. We successfully developed a galt knockout zebrafish line, 
which recapitulates the human phenotype. With this model we generated an outstand-
ing tool for studies of organ damage throughout development and high-throughput 
screening of pharmacological compounds. Furthermore, we demonstrated that pregnan-
cy rate in adult women with classic galactosemia and POI is higher than expected, which 
has significant implications for counseling of these patients and their families regarding 
reproduction and fertility preservation. We also evaluated the application of fertility 
preservation techniques in this patient group and recommended conservative applica-
tion, based on the significant chance of spontaneous conception and the unknown suc-
cess rates of preservation methods. Additionally, we further characterized the pallet of 
brain impairments encountered by patients with classic galactosemia through a resting-
state fMRI study. We demonstrated robust differences as compared to controls that are 
in line with the neurocognitive profile of patients, thereby providing directions for future, 
in-depth investigations. Previous small studies suggested an association between classic 
galactosemia and low bone mass, but evaluation of the extent and clinical implications in 
a large cohort was lacking. Findings from our systematic review and meta-analysis fortify 
the earlier conjecture of a mildly decreased bone mass in this population, which warrants 
clinical awareness. In order to prevent low bone mass in these patients, recommenda-
tions on bone health monitoring and optimization were proposed.   
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Classic galactosemia is a genetic disorder of galactose metabolism due to profound 
deficiency of the enzyme galactose-1-phosphate uridylyltransferase (GALT). The current 
standard of treatment - a galactose-restricted diet - fails to prevent the development of 
burdensome impairments of fertility, brain and bone health. In chapter 1 we further 
elaborate on this disorder and its complications, and introduce the objectives of this 
thesis. Our objective was to develop an animal model that allows organ studies 
throughout development and pharmacologic compound testing. Furthermore, the work 
presented in this dissertation aimed to expand clinical insights on fertility, brain and 
bone health complications, to improve patient care and counseling. 
In order to move classic galactosemia research forward, there was a high need for a 
novel disease model, since the existing models are less amenable to organ studies 
throughout development and high-throughput screening of pharmacologic compounds. 
Chapter 2 describes the generation of a galt knockout zebrafish model and its pheno-
typical characterization. Using a TALEN approach, knockout of the galt gene was suc-
cessfully established. Analogous to humans, biochemical assays confirmed essentially 
undetectable galt enzyme activity and, upon exposure to exogenous galactose, accumu-
lation of galactose-1-phosphate in knockout fish. Moreover, galt knockouts exhibited 
reduced motor activity and a premature decline of egg production, resembling the 
human phenotype of neurological sequelae and ovarian damage. In conclusion, this 
model mimics the human phenotype at biochemical and clinical levels and will contrib-
ute to improved understanding and management of this disorder.  
The next two chapters of this dissertation focus on fertility impairments in female 
patients. Primary ovarian insufficiency (POI) comprises a continuum of impaired ovarian 
function and represents the most frequent long-term complication of classic galacto-
semia. For years, chance of spontaneous conception was assumed to be marginal for 
these women, yet spontaneous pregnancies have been reported regularly in this group. 
In chapter 3 we present the results of an international, epidemiological study on fertility 
in a cohort of 85 women with classic galactosemia and POI. Many women did not try to 
conceive, because they were told they could not have children. In those women that 
attempted to conceive, pregnancy rate was higher than expected (9/21 = 42.9%). This 
shifting paradigm carries significant implications for reproduction counseling and the 
application of fertility preservation techniques in this group. 
Physicians are often asked about possible options to preserve fertility in female pa-
tients. However, due to the lack of guidelines on fertility preservation in this population, 
there is a great diversity of approaches around the world. Chapter 4 addresses recom-
mendations on fertility preservation in girls and women with classic galactosemia, de-
veloped with the support of an international multidisciplinary expert team. We propose 
that the uncertainty surrounding success rates of fertility preservation and the likely 
significant chance of spontaneous pregnancy warrant counseling towards conservative 
application of these techniques. If preservation of fertility is truly wished for, cryopres-
ervation of ovarian tissue in young prepubertal girls in a research setting currently 
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seems the best option, since cryopreservation of oocytes at a later age is likely unsuc-
cessful.  
The brain represents the other main target of organ damage in classic galactosemia. 
Despite decades of research, only little is known about the neural correlates of the 
pallet of cognitive impairments encountered by these patients. Chapter 5 encompasses 
an explorative functional magnetic resonance imaging (fMRI) study on resting-state 
neural networks. With this study, we are the first to investigate functional connectivity 
during rest in this population, using a seed-based approach. Resting-state networks 
were characterized in 13 adolescent patients and 13 healthy controls, and results point 
towards several substantial group differences. Alterations were observed in resting-
state functional networks involved in sensory-motor integration, (visuo)spatial capaci-
ties, motor (speech) planning, language production, and working memory, which is in 
line with the neurocognitive profile of patients. Most importantly, across several anal-
yses, repeatedly altered connectivity of some brain regions was observed (lingual gyrus, 
precentral gyrus, insula and cuneus), suggesting these brain regions might be of special 
relevance. These findings provide directions for future in-depth studies, aiming to fur-
ther elucidate the role of these key brain regions in disease pathogenesis. Also, our 
results shed light on new potential targets for clinical interventions, including 
(visuo)spatial capacities, which require further exploration in clinical studies.   
Additionally, previous investigations indicate an association between classic galacto-
semia and decreased bone mass. However, these studies were of limited sample size 
and results varied, leaving the extent of bone health impairment and its relevance for 
patient care undefined. We conducted a systematic review and meta-analysis on bone 
mineral density (BMD) in adults and children with classic galactosemia to evaluate bone 
health in this population and the need of monitoring and treatment (chapter 6). We 
demonstrate that bone health in general is mildly affected (mean BMD Z-score = -0.7) 
and that an estimated proportion of 10-25% of patients with classic galactosemia could 
be at risk for a low bone mass (BMD Z-score ≤-2). Therefore, follow-up and treatment 
are warranted. 
A revised strategy for diagnosis, treatment and follow-up of reduced bone mass in 
this population is presented in chapter 7. We recommend regular evaluation of nutri-
tional status and diet, physical activity, and, in females, ovarian function. Serial dual-
energy X-ray absorptiometry (DXA) scans are advised to accurately monitor BMD. 
Finally, in chapter 8, results are discussed and directions for future research are sug-
gested.  
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Klassieke galactosemie is een aangeboren aandoening van de galactosestofwisseling, 
veroorzaakt door ernstige deficiëntie van het enzym galactose-1-fosfaat uridylyltransfe-
rase (GALT). De huidige behandelstandaard – een galactose-beperkt dieet – kan ernsti-
ge beperkingen van vruchtbaarheid, brein en botgezondheid niet voorkomen. In hoofd-
stuk 1 gaan we verder in op deze aandoening en haar complicaties en introduceren we 
de doeleinden van dit proefschrift. Doelstelling was een diermodel te ontwikkelen dat 
kan voorzien in orgaanstudies gedurende verschillende levensfasen en het testen van 
farmacologische stoffen. Bovendien beoogde dit proefschrift de klinische inzichten in de 
complicaties van eierstokken, brein en botten te vergroten om de patiëntenzorg en 
counseling te verbeteren.  
Om het onderzoek naar klassieke galactosemie een impuls te kunnen geven, was er 
grote behoefte aan een nieuw diermodel. De reeds beschikbare diermodellen (fruitvlieg 
en muis) zijn minder geschikt voor het bestuderen van organen gedurende verschillen-
de levensfasen en voor het snel en efficiënt screenen van farmacologische stoffen. 
Daarom besloten wij een zebravismodel voor klassieke galactosemie te creëren. 
Hoofdstuk 2 beschrijft de ontwikkeling van een galt knockout zebravismodel en de 
typering van het fenotype. Succesvolle uitschakeling van het galt gen (knockout) werd 
bereikt middels een TALEN methode. Net als mensen met klassieke galactosemie had-
den knock-out vissen een niet-detecteerbare galt enzymactiviteit. Tevens vond na 
blootstelling aan galactose forse stapeling van galactose-1-fosfaat plaats in het lichaam. 
Bovendien lieten galt knockout vissen een verminderde lichamelijke activiteit en een 
vroegtijdige afname van de eitjesproductie zien, overeenkomstig aan het beeld van 
neurologische afwijkingen en eierstokschade in mensen met klassieke galactosemie. 
Concluderend bootst dit model het menselijke fenotype na op zowel biochemische als 
klinische niveaus. Toekomstige studies in dit zebravismodel zullen onze kennis over de 
ziekte vergroten en zullen bijdragen aan een betere behandeling van de aandoening. 
De volgende twee hoofdstukken van dit proefschrift richten zich op de vruchtbaar-
heidsproblemen in vrouwelijke patiënten. Primaire ovariuminsufficiëntie (POI) omvat 
een breed scala aan symptomen van verminderde eierstokfunctie en is de meest fre-
quente lange termijn complicatie van klassieke galactosemie. Jarenlang werd gedacht 
dat de kans op spontane zwangerschap voor deze vrouwen nihil was. Echter, spontane 
zwangerschappen zijn wel degelijk regelmatig gerapporteerd in deze groep. In 
hoofdstuk 3 presenteren we de resultaten van een internationale, epidemiologische 
studie naar vruchtbaarheid in 85 vrouwen met klassieke galactosemie en POI. Veel van 
deze vrouwen hadden niet geprobeerd zwanger te worden, omdat hen was verteld dat 
ze geen kinderen konden krijgen. In de vrouwen die hadden gepoogd zwanger te 
worden, was het aantal zwangerschappen hoger dan verwacht (9/21 = 42,9%). Deze 
verschuivende opvatting over zwangerschapskans brengt aanzienlijke gevolgen met zich 
mee voor reproductiecounseling en de toepassing van fertiliteitspreservatie in deze 
groep. 
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Aan behandelend artsen wordt vaak gevraagd of er mogelijkheden bestaan om de 
vruchtbaarheid van vrouwelijke patiënten te waarborgen. Echter, door het gebrek aan 
richtlijnen over fertiliteitspreservatie in deze populatie bestaat er wereldwijd een grote 
diversiteit in aanpak. Hoofdstuk 4 beschrijft aanbevelingen voor fertiliteitspreservatie in 
meisjes en vrouwen met klassieke galactosemie, die tot stand zijn gekomen met de 
ondersteuning van een internationaal multidisciplinair expertteam. De onbekende slag-
ingskansen van fertiliteitspreservatie en de aanzienlijke kans op spontane zwangerschap 
vragen om counseling richting een terughoudende toepassing van deze technieken. Als 
de wens om preservatie van fertiliteit groot blijft, lijkt op dit moment het invriezen van 
eierstokweefsel in jonge, pre-puberale meisjes, in de setting van een wetenschappelijk 
onderzoek, de beste optie. Het invriezen van eicellen op latere leeftijd is waarschijnlijk 
niet succesvol als gevolg van de op dat moment reeds vergevorderde eierstokschade.  
Het andere hoofddoelwit van orgaanschade in klassieke galactosemie is het brein. 
Ondanks vele jaren van onderzoek is weinig bekend over de mechanismen onderliggend 
aan het scala aan cognitieve beperkingen die deze patiënten kunnen ontwikkelen. 
Hoofdstuk 5 omvat een exploratieve functionele MRI studie, waarbij voor de eerste keer 
de breinnetwerken in rust in deze populatie worden bestudeerd. Middels een seed-
based benadering werden functionele netwerken in rust gekarakteriseerd in 13 
jongvolwassen patiënten en 13 gezonde controles, waarbij enkele substantiële groeps-
verschillen werden gevonden. Veranderingen werden gezien in netwerken betrokken bij 
de integratie van het sensorische en motorische systeem, (visuo)spatiële functies, mo-
torische (spraak)planning, taalproductie en werkgeheugen. Dit is in lijn met het neu-
rocognitieve profiel van mensen met klassieke galactosemie. Enkele hersengebieden 
(gyrus lingualis, pre-centrale gyrus, insula en cuneus) toonden herhaaldelijk abnormale 
functionele verbindingen in patiënten, wat erop kan duiden dat deze gebieden van 
bijzondere relevantie zijn. De huidige bevindingen bieden aanknopingspunten voor 
toekomstige onderzoeken, die de rol van deze hersengebieden in de ontstaanswijze van 
de ziekte verder kunnen ontrafelen. Ook wijzen onze resultaten op mogelijke nieuwe 
doelwitten voor interventies, waaronder de (visuo)spatiële vaardigheden, die echter 
eerst verdere bestudering behoeven in klinische studies.  
Daarnaast boden eerdere onderzoeken aanwijzingen voor een samenhang tussen 
klassieke galactosemie en verlaagde botmassa. Deze studies waren echter van beperkte 
grootte en de resultaten van de verschillende onderzoeken varieerden, waardoor de 
mate van botdichtheidsafname en de klinische relevantie nog altijd onduidelijk bleven. 
Wij voerden een systematische review en meta-analyse uit naar botdichtheid in volwas-
senen en kinderen met klassieke galactosemie om de botgezondheid in deze populatie 
te evalueren en de noodzaak tot monitoring en behandeling vast te stellen (hoofdstuk 
6). Wij toonden aan dat de botgezondheid over het algemeen mild is aangetast en dat 
naar schatting 10-25% van de patiënten risico loopt op een te lage botmassa. Derhalve 
zijn monitoring en behandeling van botdichtheid in deze groep gerechtvaardigd.  
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Een herziende strategie voor diagnostiek, behandeling en follow-up van verminderde 
botmassa in deze populatie wordt gepresenteerd in hoofdstuk 7. Wij adviseren regelmatige 
evaluatie van voedingsstatus en dieet, lichamelijke activiteit en, in vrouwelijke patiënten, 
eierstokfunctie. Herhaaldelijke botscans worden aanbevolen om de botdichtheid accuraat 
te monitoren. 
Ten slotte worden in hoofdstuk 8 alle resultaten bediscussieerd en worden sugges-
ties voor toekomstige vervolgonderzoeken gegeven. 
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The work presented in this dissertation aimed to further investigate the chronic im-
pairments of classic galactosemia using a combined approach that encompasses both 
basic and clinical research. In this addendum the valorization potential of this thesis is 
presented. 
Upon exposure to galactose in dairy milk, neonates with classic galactosemia devel-
op a potentially lethal syndrome that resolves when galactose-restriction is initiated 
timely. Notwithstanding its irrefutable life-saving role in the newborn phase, the current 
standard of therapy – a lifelong galactose-restricted diet – is unsatisfactory, since it fails 
to prevent damage to ovaries, brain and bones. Importantly, even those patients who 
were never exposed to galactose develop long-term impairments (1, 2), suggesting a 
more sophisticated therapy is needed to overcome the complex disease pathogenesis. 
The phenotypic spectrum is diverse, ranging from patients who are severely affected 
and unable to live independently to patients who experience only mild symptoms. In 
general, the chronic debilitations negatively influence quality of life in the galactosemia 
population, and they form a major concern for the patients’ parents as well (3). Fur-
thermore, educational levels and employment rates are lower in patients, leading to 
impaired societal functioning (4). Due to the high costs of disease monitoring and 
treatment, the complications of classic galactosemia also form a burden for the 
healthcare system. As a result, the ultimate aim of galactosemia research worldwide is 
the development of new therapies that can prevent these long-term impairments and 
their negative impacts on patients and their families, society and the healthcare system. 
Thus far, the timing of onset of organ damage in this disorder – more specifically the 
presence or absence of prenatal toxicity – remains to be elucidated. The existing dis-
ease models, the mouse and Drosophila melanogaster models (5, 6), showed their im-
portance for disease pathogenesis studies (7-11), yet fail to meet the features demand-
ed to evaluate whether damage has a prenatal and/or postnatal origin. Furthermore, 
these models are less amenable to testing pharmacologic compounds through a high-
throughput screening approach. Therefore, the first objective of this dissertation was to 
develop a novel disease model for classic galactosemia. For this purpose, we developed 
a galt knockout zebrafish model. The model mimics the human phenotype at both bio-
chemical and clinical levels, making it suitable to study the onset of organ damage and 
to develop new therapeutic strategies. 
Throughout the process of this thesis, we developed the galt knockout zebrafish 
model and crossed our model to reporter lines. Future studies in this disease model will 
focus on the organ-specific onset of damage (gonads and brain) and time-specific ex-
tent of damage, in order to answer the long-standing open question if, and to what 
extent, prenatal organ damage occurs in this disorder. The many advantageous features 
of the zebrafish allow the application of innovative study designs and analysis tech-
niques. Transgenic zebrafish lines that carry tissue-specific promoters driving green 
fluorescent protein (GFP) expression provide rapid, real-time in vivo developmental 
systems for analyzing tissue and organ development (12). Accordingly, to study damage 
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to gonads and brain, we crossed our galt knockout transgenic zebrafish line to two 
reporter lines: a reporter line with fluorescent primordial germ cells (PGCs) (vasa:GFP) 
(13), and a reporter line with fluorescent myelin (mbp:GFP) (14). By generating a galt 
knockout line with labeled PGCs and a galt knockout line with fluorescent myelin, we 
established two excellent models to study the damage to female gonads and brain from 
embryonic stage to adulthood.  
Secondly, our zebrafish model is amenable to a high-throughput screening ap-
proach, enabling rapid and efficient testing of pharmacologic compounds of interest. As 
a result, the zebrafish is increasingly used as a disease model in pharmacologic studies, 
with experience rapidly evolving (12). Hitherto, several potential therapeutic agents 
have been proposed for classic galactosemia treatment, including galactokinase inhibi-
tors and pharmacologic chaperones (15-18). Previous studies demonstrated that enzy-
matic impairment of the most important GALT variants results from altered protein 
folding, followed by aggregation and rapid destruction of the misfolded GALT protein 
(18-20). Pharmacologic chaperones - molecules that have the ability to stabilize (mis-
folded) proteins (21-23) - are therefore suggested as potential therapeutic agents for 
this disorder (18, 19). By changing protein conformation, the stability and activity of the 
protein is increased. Since individuals with a GALT activity of >10% are generally not 
considered patients (24), only a slight elevation of residual enzyme activity might be 
sufficient to prevent chronic impairments. One of the compounds of interest is arginine, 
an amino acid with high therapeutic potential as a pharmacologic chaperone and out-
standing in vitro results (15). Future studies are planned to assess arginine’s potential as 
a chaperone treatment for classic galactosemia in our zebrafish model. For this, a galt 
p.Q188R knock-in model will be developed.  
Since the establishment of well-validated therapies is a long-lasting process, it is 
highly important that current patient care is optimized and that interventions are de-
veloped to maximize patient functioning despite impairments. Previous research 
showed that many differences exist with regard to diagnosis, treatment and follow-up 
of patients with classic galactosemia (25). The second aim of this thesis was to further 
investigate the extent and clinical implications of the damage to ovaries, brain and 
bones, thereby providing recommendations for improvement of patient care.  
Ever since the report on a remarkably high prevalence of hypergonadotropic hy-
pogonadism in women with classic galactosemia in 1979 (26), female patients were 
counseled for infertility from an early age on. Current findings from our international, 
epidemiological study on pregnancy chance in women with classic galactosemia and 
primary ovarian insufficiency indicate this counseling approach is incorrect. We showed 
that, despite ovarian damage, these women have a considerable chance of spontaneous 
conception. This shifting paradigm has significant implications for fertility counseling 
and the potential application of fertility preservation techniques. In the future, female 
patients and their families/parents should be counseled for reduced fertility rather than 
for infertility, which is the current practice. 
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Physicians are often asked about possible options to preserve fertility in female pa-
tients. However, due to the lack of guidelines on fertility preservation in this population, 
there is a great diversity of approaches around the world. Therefore, we evaluated the 
risks and benefits of fertility preservation in females with this disorder and made rec-
ommendations on how to address this important matter. With the support of a multi-
disciplinary expert team, we suggested a conservative approach towards fertility 
preservation through invasive techniques, given the significant chance of spontaneous 
conception. If preservation of an individual’s fertility is truly wished for, ovarian tissue 
cryopreservation at an early age in a research setting seems the best option, due to the 
early depletion of the follicle pool.  
In addition, we were the first to investigate functional connectivity during rest in this 
population, using functional magnetic resonance imaging. We evaluated resting-state 
functional brain networks in patients and matched controls. Our results point towards 
several substantial group differences, with repeatedly altered connectivity of some 
brain regions across analyses. Importantly, the affected networks are known to be in-
volved in motor (speech) planning, visuospatial processing, working memory and lan-
guage processing, which is in line with the neurocognitive profile of these patients. 
These findings can form the basis for future in-depth studies and the development of 
new interventions, targeting the affected cognitive functions (speech and language, 
working memory, sensory-motor integration, visuospatial capacities). Our data suggest 
patients might benefit from visuospatial training, which has not yet been implicated 
before, but clinical studies are needed to further explore this hypothesis.  
Our meta-analysis on bone mineral density was the first study to provide adequate 
evidence for mild bone mass reduction in classic galactosemia. Previous studies were 
underpowered due to small sample sizes and results varied across studies (27-30), 
hampering solid conclusions on severity and clinical relevance of bone mass reduction 
in this disorder. Our findings warrant clinical awareness and monitoring of bone health, 
since 10-25% of patients are at risk of developing low bone mass. We also developed 
recommendations on diagnosis, treatment and follow-up of bone health in order to 
encourage consensual and accurate patient care worldwide. Implementation of these 
data on bone mass and bone health monitoring in future international guidelines is of 
importance.  
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Promoveren wordt gedefinieerd als de academische graad van doctor verwerven, maar 
ik zie het zelf meer als een traject van persoonlijke ontwikkeling op alle vlakken. Terug-
kijkend op mijn promotietraject denk ik vooral terug aan de successen, overwinningen 
en goede dingen die hieruit zijn voortgekomen. Ik ben trots op het eindresultaat! Ik had 
dit echter nooit kunnen bereiken zonder de fijne groep mensen om me heen. Graag wil 
ik iedereen bedanken die, op geheel eigen wijze, een bijdrage heeft geleverd aan de 
totstandkoming van dit proefschrift.  
Mijn eerste dank gaat uit naar mijn promotieteam. Estela, bedankt dat ik de kans heb 
gekregen om mezelf te kunnen ontwikkelen. Tijdens dit promotietraject heb ik kennis 
gemaakt met de vele aspecten van wetenschappelijk onderzoek. Het was een gevari-
eerd traject en de combinatie van klinisch en basaal onderzoek vond ik fantastisch. Met 
veel plezier kijk ik terug op onze Indiase diners, de gezamenlijke treinreizen door het 
hele land en je gastvrijheid. Ook heb ik er door jou een aantal geluksgetallen bijgekre-
gen. Het was een waardevolle en leerzame ervaring, niet alleen op wetenschappelijk 
niveau, maar ook voor mijn persoonlijke groei en ontwikkeling. Hiervoor ben ik je erg 
dankbaar.  
Connie, graag wil ik je bedanken voor de rust die je me hebt gegeven, het vertrouwen 
dat je in me had en de structuur die je mij hebt geboden op het moment dat ik dit nodig 
had. De deur stond altijd open, wat ik erg heb gewaardeerd. Ik vond het fijn dat je naast 
me stond en samen met mij naar oplossingen zocht of een plan opstelde. Bedankt dat je 
mijn promotor wilde zijn en zo betrokken bent geweest.  
Ontzettend dankbaar ben ik voor de inzet van alle deelnemers en hun families. Zonder 
jullie was dit proefschrift nooit tot stand gekomen. Telkens wisten jullie het enthousi-
asme en de moeite op te brengen om deel te nemen. Bedankt voor jullie onmisbare 
bijdrage! Tevens wil ik de Galactosemie Vereniging Nederland, en in het bijzonder 
Maaike van Kempen, bedanken voor de steun en hulp bij de organisatie van de pro-
jecten. Jullie betrokkenheid is enorm waardevol en inspirerend. Ik zal de jaarlijkse GVN 
dag, waar ik altijd warm werd ontvangen en met veel plezier onze nieuwste onder-
zoeken heb gepresenteerd, erg gaan missen!  
Daarnaast dank ik de leden van de beoordelingscommissie, Prof. Dr. Luc Zimmermann, 
Prof. Dr. Frans Ramaekers, Prof. Dr. Han Brunner, Prof. Dr. Jaak Jaeken en Dr. Stephanie 
Grunewald, voor het beoordelen van dit proefschrift op wetenschappelijke inhoud. 
Een groot deel van mijn promotietraject heb ik doorgebracht op het laboratorium van 
Clinical Genomics. Jo, veel dank voor de wijze waarop je me hebt begeleid in deze, voor 
mij, nieuwe wereld. We hebben vaak gelachen om mijn uitbarstingen van vreugde of 
irritatie wanneer een experiment wel of (alweer) niet was gelukt. Ik hoop dat je in de 
toekomst nog vele onderzoekers kunt aansteken met je enthousiasme over de zebravis. 
Ook wil ik Auke, Barbie, Bieke, Ellen, Erika, Iris, Ivo, Minh, Rick, Romy, Ruby en Tom 
Dankwoord 
167 
bedanken voor de hulp en vele gezellige momenten. Zonder jullie was mijn tijd op het 
lab nooit zo leuk geweest! 
Jörgen, ik heb veel bewondering voor je kennis en originele ideeën. Dank voor je op-
rechte interesse en kritische noten. Ook de andere collega’s van laboratorium Erfelijke 
Metabole Ziekten wil ik hartelijk danken, in het bijzonder Martijn Lindhout voor zijn hulp 
bij het zebravisproject. 
Speciale dank gaat uit naar de galactosemia girls. Ana, my colleague, roommate, and in 
the first place friend, thank you for looking after me. You supported me throughout this 
process and gave me good advises on so many things! Inge en Cynthia, mijn lieve voor-
gangsters, bedankt dat jullie me vanaf het eerste moment in de groep hebben opgeno-
men. Ik kon altijd bij jullie terecht, ook voor adviezen op niet-onderzoeksgebied. Ik vond 
het een eer om de zorg voor jullie “kindjes” over te nemen. Girls, I hope we’ll stay in 
touch and have many more gatherings with Indian food, Portuguese delicacies and 
Coffee-lovers cake in the future. 
Ik heb een heel prettige tijd gehad bij de afdeling Kindergeneeskunde en dat is mede te 
danken aan mijn lieve collega’s. Elke, het is ontzettend fijn om zo’n vrolijke, gezellige en 
betrokken collega te hebben. Dankjewel dat je mijn paranimf wilt zijn. Bob, Dillys, Ester, 
Gabrielle, Jesse, Kim, Kylie, Maartje, Marieke, Marlou, Sasha en Yvon, ook jullie ben ik 
dankbaar voor de gezellige lunches en mentale support! Linda, Dyonne en Tamara, dank 
voor de onmisbare secretariële ondersteuning. Jullie wisten de meest uiteenlopende 
zaken in goede banen te leiden.   
Dankbaar ben ik voor de samenwerking met collega’s in andere metabole centra, zowel 
in Nederland als in het buitenland, en de bijdrage die eenieder heeft geleverd. De on-
dersteuning van het Galactosemia Network was hierbij onmisbaar. Rein Vos, veel dank 
voor het advies op statistisch vlak. Eline, Kim, Minela, Myrna, Niels, Sarah, Sophia, Vivian 
en Walid, bedankt voor jullie inzet gedurende de wetenschapsstages. Minela, veel suc-
ces met je promotietraject! 
Tevens wil ik Martijn Brouwers bedanken voor de hulp die hij me heeft geboden bij het 
inslaan van een nieuwe weg: de weg van de interne geneeskunde. 
Ik wil mijn lieve vriendinnen en vrienden bedanken. Soms was het even druk en moest 
ik verjaardagen, feestjes en uitjes aan me voorbij laten gaan. Jullie begrepen dit en 
gaven me peptalks waar nodig, bedankt daarvoor. Lieve Lindsay, ik heb het enorm ge-
troffen met zo’n lieve vriendin als jij. Bij jou kan ik altijd terecht voor een luisterend oor, 
goede adviezen en veel eten. Je oprechte interesse in mijn werk betekent veel voor me. 
Daarnaast ben jij, in mijn ogen, professor in de innerlijke processen. Ik bewonder deze 
kwaliteiten van jou en ben dankbaar voor de hulp die je me biedt. Ik vind het ontzettend 
fijn om jou als paranimf aan mijn zijde te hebben.  
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Lieve papa en mama, zonder jullie onvoorwaardelijke steun en vertrouwen was ik nooit 
zo ver gekomen. Tijdens de ups en downs van dit traject had ik altijd een veilige en 
vertrouwde thuishaven om op terug te vallen. Het is moeilijk om in woorden uit te 
drukken wat jullie voor mij betekenen, maar weet dat ik heel dankbaar ben voor de hulp 
en liefde die jullie mij geven. Op momenten dat ik aan mezelf twijfelde, gaven jullie mij 
bemoedigende woorden, rust en vertrouwen waardoor ik weer verder kon. Jullie be-
trokkenheid bij mijn leven, mijn werk en alles wat belangrijk voor mij is, is voor mij on-
misbaar. 
Ook de rest van mijn familie is voor mij heel belangrijk. Bedankt voor jullie oprechte 
interesse en waardevolle adviezen.  
Lieve Ben, dankbaar ben ik voor jouw goede zorgen, de hulp die je me biedt wanneer ik 
het nodig heb en de rust die je me geeft. Soms heb ik enkel een luisterend oor of beves-
tiging nodig, dat voel je haarfijn aan. Je bent mijn rots in de branding en geeft me het 
(zelf)vertrouwen dat bij mij soms ontbreekt. Ik waardeer dat je nog steeds samen Frozen 
wilt kijken als ik een moeilijke dag achter de rug heb, ook al hebben we deze film al min-
stens tien keer gezien. Bij jou kan en mag ik altijd mezelf zijn, dat zal ik nooit vergeten. 
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